Document:

EX-10.1

 Exhibit 10.1 

COMMON STOCK PURCHASE AGREEMENT 

COMMON STOCK PURCHASE AGREEMENT (the “Agreement”), dated as of March 14, 2019, by and between
BIONANO GENOMICS, INC., a Delaware corporation (the “Company”), and ASPIRE CAPITAL FUND, LLC, an Illinois limited liability company (the “Buyer”). Capitalized terms used herein and not otherwise
defined herein are defined in Section 10 hereof. 
 WHEREAS: 

Subject to the terms and conditions set forth in this Agreement, the Company wishes to sell to the Buyer, and the Buyer wishes
to buy from the Company, up to Ten Million Dollars ($10,000,000) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”). The shares of Common Stock to be purchased hereunder are referred to herein as
the “Purchase Shares.” 
 NOW THEREFORE, the Company and the Buyer hereby agree as follows: 

 

	 	1.	 PURCHASE OF COMMON STOCK. 

Subject to the terms and conditions set forth in this Agreement, the Company has the right to sell to the Buyer, and the Buyer
has the obligation to purchase from the Company, Purchase Shares as follows: 
 (a)    Initial
Purchase; Commencement of Purchases of Common Stock. Immediately upon the execution of this Agreement, the Buyer shall purchase from the Company 272,479 Purchase Shares and upon receipt of such Purchase Shares shall pay to the Company as the
purchase price therefor, via wire transfer, One Million Dollars ($1,000,000) (such purchase the “Initial Purchase” and such Purchase Shares are referred to herein as “Initial Purchase Shares”). Upon issuance
and payment therefor as provided herein, such Initial Purchase Shares shall be validly issued and fully paid and non-assessable. The Initial Purchase Shares shall be issued to the Buyer bearing the restrictive
legend set forth in Section 4(e). Thereafter, the purchase and sale of Purchase Shares hereunder shall occur from time to time upon written notices by the Company to the Buyer on the terms and conditions as set forth herein following the
satisfaction of the conditions (the “Commencement”) as set forth in Sections 6 and 7 below (the date of satisfaction of such conditions, the “Commencement Date”). 

(b)    The Company’s Right to Require Regular Purchases. Subject to the terms
and conditions of this Agreement, on any given Business Day after the Commencement Date, the Company shall have the right but not the obligation to direct the Buyer by its delivery to the Buyer of a Purchase Notice from time to time, and the Buyer
thereupon shall have the obligation, to buy the number of Purchase Shares specified in such notice, up to 60,000 Purchase Shares, on such Business Day (as long as such notice is delivered on or before 5:00 p.m. Eastern time on such Business Day)
(each such purchase, a “Regular Purchase”) at the Purchase Price on the Purchase Date; however, in no event shall the Purchase Amount of a Regular Purchase exceed Three Hundred Thousand Dollars ($300,000) per Business Day. The
Company may deliver additional Purchase Notices to the Buyer from time to time so long as the most recent purchase has been completed. The share amounts in this Section 1(b) shall be appropriately adjusted for any reorganization,
recapitalization, non-cash dividend, stock split, reverse stock split or other similar transaction. 

 (c)    VWAP Purchases. Subject to the terms and
conditions of this Agreement, in addition to purchases of Purchase Shares as described in Section 1(b) above, with one Business Day’s prior written notice (as long as such notice is delivered on or before 5:00 p.m. Eastern time on the
Business Day immediately preceding the VWAP Purchase Date), the Company shall also have the right but not the obligation to direct the Buyer by the Company’s delivery to the Buyer of a VWAP Purchase Notice from time to time, and the Buyer
thereupon shall have the obligation, to buy the VWAP Purchase Share Percentage of the trading volume of the Common Stock on the VWAP Purchase Date up to the VWAP Purchase Share Volume Maximum on the VWAP Purchase Date (each such purchase, a
“VWAP Purchase”) at the VWAP Purchase Price. The Company may deliver a VWAP Purchase Notice to the Buyer on or before 5:00 p.m. Eastern time on a date on which the Company also submitted a Purchase Notice for a Regular Purchase of
60,000 Purchase Shares to the Buyer. The share amount in the prior sentence shall be appropriately adjusted for any reorganization, recapitalization, non-cash dividend, stock split, reverse stock split, or
other similar transaction. A VWAP Purchase shall automatically be deemed completed at such time on the VWAP Purchase Date that the Sale Price falls below the VWAP Minimum Price Threshold; in such circumstance, the VWAP Purchase Amount shall be
calculated using (i) the VWAP Purchase Share Percentage of the aggregate shares traded on the Principal Market for such portion of the VWAP Purchase Date prior to the time that the Sale Price fell below the VWAP Minimum Price Threshold and
(ii) a VWAP Purchase Price calculated using the volume weighted average price of Common Stock sold during such portion of the VWAP Purchase Date prior to the time that the Sale Price fell below the VWAP Minimum Price Threshold. Each VWAP
Purchase Notice must be accompanied by instructions to the Company’s Transfer Agent to immediately issue to the Buyer an amount of Common Stock equal to the VWAP Purchase Share Estimate, a good faith estimate by the Company of the number of
Purchase Shares that the Buyer shall have the obligation to buy pursuant to the VWAP Purchase Notice. In no event shall the Buyer, pursuant to any VWAP Purchase, purchase a number of Purchase Shares that exceeds the VWAP Purchase Share Estimate
issued on the VWAP Purchase Date in connection with such VWAP Purchase Notice; however, the Buyer will immediately return to the Company any amount of Common Stock issued pursuant to the VWAP Purchase Share Estimate that exceeds the number of
Purchase Shares the Buyer actually purchases in connection with such VWAP Purchase. Upon completion of each VWAP Purchase Date, the Buyer shall submit to the Company a confirmation of the VWAP Purchase in form and substance reasonably acceptable to
the Company. The Company may deliver additional VWAP Purchase Notices to the Buyer from time to time so long as the most recent purchase has been completed. 

(d)    Payment for Purchase Shares. For each Regular Purchase, the Buyer shall pay to the Company
an amount equal to the Purchase Amount as full payment for such Purchase Shares via wire transfer of immediately available funds on the same Business Day that the Buyer receives such Purchase Shares. For each VWAP Purchase, the Buyer shall pay to
the Company an amount equal to the VWAP Purchase Amount as full payment for such Purchase Shares via wire transfer of immediately available funds on the second Business Day following the VWAP Purchase Date. All payments made under this Agreement
shall be made in lawful money of the United States of America via wire transfer of immediately available funds to such account as the Company may from time to time designate by written notice in accordance with the provisions of this Agreement.
Whenever any amount expressed to be due by the terms of this Agreement is due on any day that is not a Business Day, the same shall instead be due on the next succeeding day that is a Business Day. 

(e)    Purchase Price Floor. The Company and the Buyer shall not effect any sales under this
Agreement on any Purchase Date where the Closing Sale Price is less than the Floor Price. “Floor Price” 

  
 -2- 

 
means $0.25 per share of Common Stock, which shall be appropriately adjusted for any reorganization, recapitalization, non-cash dividend, stock split,
reverse stock split or other similar transaction. 
 (f)    Records of Purchases. The Buyer and
the Company shall each maintain records showing the remaining Available Amount at any given time and the dates and Purchase Amounts for each purchase, or shall use such other method reasonably satisfactory to the Buyer and the Company to reconcile
the remaining Available Amount. 
 (g)    Taxes. The Company shall pay any and all transfer,
stamp or similar taxes that may be payable with respect to the issuance and delivery of any shares of Common Stock to the Buyer made under this Agreement. 

(h)    Compliance with Principal Market Rules. Notwithstanding anything in this Agreement to the
contrary, and in addition to the limitations set forth in Section 1(e), the total number of shares of Common Stock that may be issued under this Agreement, including the Commitment Shares (as defined in Section 4(e) hereof), shall be
limited to 2,018,271 shares of Common Stock (the “Exchange Cap”), which equals 19.99% of the Company’s outstanding shares of Common Stock as of the date hereof, unless stockholder approval is obtained to issue more than such
19.99%; provided, however, that the Exchange Cap percentage shall be reduced below 19.99% to the extent the Principal Market deems this transaction aggregated with any other transaction in which the Company issues equity securities. The Exchange Cap
shall be appropriately adjusted for any reorganization, recapitalization, non-cash dividend, stock split, reverse stock split or other similar transaction. The foregoing limitation shall not apply if
stockholder approval has not been obtained and at any time the Exchange Cap is reached and at all times thereafter the average price paid for all shares of Common Stock issued under this Agreement is equal to or greater than $4.32 (the
“Minimum Price”), a price equal to the lower of (1) the Closing Sale Price immediately preceding the execution of this Agreement or (2) the arithmetic average of the five (5) Closing Sale Prices for the Common Stock
immediately preceding the execution of this Agreement (in such circumstance, for purposes of the Principal Market, the transaction contemplated hereby would not be “below market” and the Exchange Cap would not apply). The Minimum Price
shall be appropriately adjusted for any reorganization, recapitalization, non-cash dividend, stock split, reverse stock split or other similar transaction. Notwithstanding the foregoing, the Company shall not
be required or permitted to issue, and the Buyer shall not be required to purchase, any shares of Common Stock under this Agreement if such issuance would violate the rules or regulations of the Principal Market. The Company may, in its sole
discretion, determine whether to obtain stockholder approval to issue more than 19.99% of its outstanding shares of Common Stock hereunder if such issuance would require stockholder approval under the rules or regulations of the Principal Market.

 (i)    Beneficial Ownership Limitation. The Company shall not issue and the Buyer shall not
purchase any shares of Common Stock under this Agreement if such shares proposed to be issued and sold, when aggregated with all other shares of Common Stock then owned beneficially (as calculated pursuant to Section 13(d) of the Securities
Exchange Act of 1934, as amended (the “1934 Act”) and Rule 13d-3 promulgated thereunder) by the Buyer and its affiliates would result in the beneficial ownership by the Buyer and its
affiliates of more than 19.99% of the then issued and outstanding shares of Common Stock. 
  

	 	2.	 BUYER’S REPRESENTATIONS AND WARRANTIES. 

The Buyer represents and warrants to the Company that as of the date hereof and as of the Commencement Date: 

  
 -3- 

 (a)    Investment Purpose. The Buyer is entering
into this Agreement and acquiring the Commitment Shares and the Purchase Shares (the Purchase Shares and the Commitment Shares are collectively referred to herein as the “Securities”), for its own account for investment only and not
with a view towards, or for resale in connection with, the public sale or distribution thereof; provided however, by making the representations herein, the Buyer does not agree to hold any of the Securities for any minimum or other specific term.

 (b)    Accredited Investor Status. The Buyer is an “accredited investor” as that
term is defined in Rule 501(a)(3) of Regulation D of the 1933 Act. 
 (c)    Reliance on
Exemptions. The Buyer understands that the Securities are being offered and sold to it in reliance on specific exemptions from the registration requirements of United States federal and state securities laws and that the Company is relying in
part upon the truth and accuracy of, and the Buyer’s compliance with, the representations, warranties, agreements, acknowledgments and understandings of the Buyer set forth herein in order to determine the availability of such exemptions and
the eligibility of the Buyer to acquire the Securities. 
 (d)    Information. The Buyer has been
furnished with all materials relating to the business, finances and operations of the Company and materials relating to the offer and sale of the Securities that have been reasonably requested by the Buyer, including, without limitation, the SEC
Documents (as defined in Section 3(f) hereof). The Buyer understands that its investment in the Securities involves a high degree of risk. The Buyer (i) is able to bear the economic risk of an investment in the Securities including a total
loss, (ii) has such knowledge and experience in financial and business matters that it is capable of evaluating the merits and risks of the proposed investment in the Securities and (iii) has had an opportunity to ask questions of and
receive answers from the officers of the Company concerning the financial condition and business of the Company and other matters related to an investment in the Securities. Neither such inquiries nor any other due diligence investigations conducted
by the Buyer or its representatives shall modify, amend or affect the Buyer’s right to rely on the Company’s representations and warranties contained in Section 3 below. The Buyer has sought such accounting, legal and tax advice as it
has considered necessary to make an informed investment decision with respect to its acquisition of the Securities. 

(e)    No Governmental Review. The Buyer understands that no United States federal or state agency
or any other government or governmental agency has passed on or made any recommendation or endorsement of the Securities or the fairness or suitability of the investment in the Securities nor have such authorities passed upon or endorsed the merits
of the offering of the Securities. 
 (f)    Transfer or Sale. The Buyer understands that except
as provided in the Registration Rights Agreement (as defined in Section 4(a) hereof): (i) the Securities have not been and are not being registered under the 1933 Act or any state securities laws, and may not be offered for sale, sold, assigned
or transferred unless (A) subsequently registered thereunder or (B) an exemption exists permitting such Securities to be sold, assigned or transferred without such registration; (ii) any sale of the Securities made in reliance on Rule
144 may be made only in accordance with the terms of Rule 144 and further, if Rule 144 is not applicable, any resale of the Securities under circumstances in which the seller (or the person through whom the sale is made) may be deemed to be an
underwriter (as that term is defined in the 1933 Act) may require compliance with some other exemption under the 1933 Act or the rules and regulations of the SEC thereunder; and (iii) neither the Company nor any other person is

  
 -4- 

 
under any obligation to register the Securities under the 1933 Act or any state securities laws or to comply with the terms and conditions of any exemption thereunder. 

(g)    Organization. The Buyer is a limited liability company duly organized and validly existing
in good standing under the laws of the jurisdiction in which it is organized, and has the requisite organizational power and authority to own its properties and to carry on its business as now being conducted. 

(h)    Validity; Enforcement. This Agreement has been duly and validly authorized, executed and
delivered on behalf of the Buyer and is a valid and binding agreement of the Buyer enforceable against the Buyer in accordance with its terms, subject as to enforceability to (i) general principles of equity and to applicable bankruptcy,
insolvency, reorganization, moratorium, liquidation and other similar laws relating to, or affecting generally, the enforcement of applicable creditors’ rights and remedies and (ii) public policy underlying any law, rule or regulation
(including any federal or state securities law, rule or regulation) with regards to indemnification, contribution or exculpation. The execution and delivery of the Transaction Documents (as defined in Section 3(b) hereof) by the Buyer and the
consummation by it of the transactions contemplated hereby and thereby do not conflict with the Buyer’s certificate of organization or operating agreement or similar documents, and do not require further consent or authorization by the Buyer,
its managers or its members. 
 (i)    Residency. The Buyer is a resident of the State of
Illinois. 
 (j)    No Prior Short Selling. The Buyer represents and warrants to the Company that
at no time prior to the date of this Agreement has any of the Buyer, its agents, representatives or affiliates engaged in or effected, in any manner whatsoever, directly or indirectly, any (i) “short sale” (as such term is defined in
Section 242.200 of Regulation SHO of the 1934 Act) of the Common Stock or (ii) hedging transaction, which establishes a net short position with respect to the Common Stock. 

 

	 	3.	 REPRESENTATIONS AND WARRANTIES OF THE COMPANY. 

The Company represents and warrants to the Buyer that as of the date hereof and as of the Commencement Date: 

(a)    Organization and Qualification. The Company and its “Subsidiaries” (which for
purposes of this Agreement means any entity in which the Company, directly or indirectly, owns more than 50% of the voting stock or capital stock or other similar equity interests) are corporations or limited liability companies duly organized and
validly existing in good standing under the laws of the jurisdiction in which they are incorporated or organized, and have the requisite corporate or organizational power and authority to own their properties and to carry on their business as now
being conducted. Each of the Company and its Subsidiaries is duly qualified as a foreign corporation or limited liability company to do business and is in good standing in every jurisdiction in which its ownership of property or the nature of the
business conducted by it makes such qualification necessary, except to the extent that the failure to be so qualified or be in good standing could not reasonably be expected to have a Material Adverse Effect. As used in this Agreement,
“Material Adverse Effect” means any material adverse effect on any of: (i) the business, properties, assets, operations, results of operations or financial condition of the Company and its Subsidiaries, if any, taken as a
whole, or (ii) the authority or ability of the Company to perform its obligations under the Transaction Documents. The Company has no material Subsidiaries except as set forth on Schedule 3(a). 

  
 -5- 

 (b)    Authorization; Enforcement; Validity.
(i) The Company has the requisite corporate power and authority to enter into and perform its obligations under this Agreement, the Registration Rights Agreement and each of the other agreements entered into by the parties on the Commencement
Date and attached hereto as exhibits to this Agreement (collectively, the “Transaction Documents”), and to issue the Securities in accordance with the terms hereof and thereof, (ii) the execution and delivery of the Transaction
Documents by the Company and the consummation by it of the transactions contemplated hereby and thereby, including without limitation, the issuance of the Commitment Shares and the reservation for issuance and the issuance of the Purchase Shares
issuable under this Agreement, have been duly authorized by the Company’s Board of Directors or duly authorized committee thereof, do not conflict with the Company’s Certificate of Incorporation or Bylaws (as defined below), and do not
require further consent or authorization by the Company, its Board of Directors, except as set forth in this Agreement, or its stockholders (other than as contemplated by Section 1(h) hereof), (iii) this Agreement has been, and each other
Transaction Document shall be on the Commencement Date, duly executed and delivered by the Company and (iv) this Agreement constitutes, and each other Transaction Document upon its execution on behalf of the Company, shall constitute, the valid
and binding obligations of the Company enforceable against the Company in accordance with their terms, except as such enforceability may be limited by (y) general principles of equity or applicable bankruptcy, insolvency, reorganization,
moratorium, liquidation or similar laws relating to, or affecting generally, the enforcement of creditors’ rights and remedies and (z) public policy underlying any law, rule or regulation (including any federal or state securities law,
rule or regulation) with regards to indemnification, contribution or exculpation. The Board of Directors of the Company or duly authorized committee thereof has approved resolutions (the “Signing Resolutions”) to authorize this
Agreement and the transactions contemplated hereby. The Signing Resolutions are valid, in full force and effect and have not been modified or supplemented in any material respect. The Company has delivered to the Buyer a true and correct copy of the
Signing Resolutions as approved by the Board of Directors of the Company or an appropriate Board committee. 

(c)    Capitalization. As of the date hereof, the authorized capital stock of the Company consists
of (i) 200,000,000 shares of Common Stock, par value $0.0001 per share, of which as of the date hereof, 10,096,407 shares are issued and outstanding, zero shares are held as treasury shares, 2,397,207 shares are reserved for future issuance pursuant
to the Company’s equity incentive plans, of which approximately 588,727 shares remain available for future option grants or stock awards, and 4,062,507 shares are issuable and reserved for issuance pursuant to securities (other than stock
options or equity based awards issued pursuant to the Company’s stock incentive plans) exercisable or exchangeable for, or convertible into, shares of Common Stock, and (ii) 10,000,000 shares of preferred stock, par value $0.0001 per share, of
which as of the date hereof zero shares are issued and outstanding. All of such outstanding shares have been, or upon issuance will be, validly issued and are fully paid and non-assessable. Except as disclosed
in Schedule 3(c), (i) no shares of the Company’s capital stock are subject to preemptive rights or any other similar rights or any liens or encumbrances suffered or permitted by the Company, (ii) there are no outstanding debt securities of
the Company or any of its Subsidiaries, (iii) other than issued pursuant to the Company’s equity incentive plans and employee stock purchase plan, there are no outstanding options, warrants, scrip, rights to subscribe to, calls or
commitments of any character whatsoever relating to, or securities or rights convertible into, any shares of capital stock of the Company or any of its Subsidiaries, or contracts, commitments, understandings or arrangements by which the Company or
any of its Subsidiaries is or may become bound to issue additional shares of capital stock of the Company or any of its Subsidiaries or options, warrants, scrip, rights to subscribe to, calls or commitments of any character whatsoever relating to,
or securities or rights convertible into, 

  
 -6- 

 
any shares of capital stock of the Company or any of its Subsidiaries, (iv) there are no material agreements or arrangements under which the Company or any of its Subsidiaries is obligated
to register the sale of any of their securities under the 1933 Act (except the Registration Rights Agreement), (v) there are no outstanding securities or instruments of the Company or any of its Subsidiaries which contain any redemption or similar
provisions, and there are no contracts, commitments, understandings or arrangements by which the Company or any of its Subsidiaries is or may become bound to redeem a security of the Company or any of its Subsidiaries, (vi) there are no
securities or instruments containing anti-dilution or similar provisions that will be triggered by the issuance of the Securities as described in this Agreement and (vii) the Company does not have any stock appreciation rights or “phantom
stock” plans or agreements or any similar plan or agreement. The Company has furnished or made available to the Buyer true and correct copies of the Company’s Certificate of Incorporation, as amended and as in effect on the date hereof
(the “Certificate of Incorporation”), and the Company’s Bylaws, as amended and as in effect on the date hereof (the “Bylaws”). 

(d)    Issuance of Securities. The Commitment Shares and the Initial Purchase Shares have been duly
authorized and, upon issuance in accordance with the terms hereof, the Commitment Shares and the Initial Purchase Shares shall be (i) validly issued, fully paid and non-assessable and (ii) free from
all taxes, liens and charges with respect to the issuance thereof. At least an additional 1,676,348 shares of Common Stock have been duly authorized and reserved for issuance upon future purchase as Purchase Shares under this Agreement. Upon
issuance and payment therefore in accordance with the terms and conditions of this Agreement, the Purchase Shares shall be validly issued, fully paid and non-assessable and free from all taxes, liens and
charges with respect to the issue thereof, with the holders being entitled to all rights accorded to a holder of Common Stock. 

(e)    No Conflicts. Except as disclosed in Schedule 3(e), the execution, delivery and performance
of the Transaction Documents by the Company and the consummation by the Company of the transactions contemplated hereby and thereby (including, without limitation, the reservation for issuance and issuance of the Purchase Shares) will not
(i) result in a violation of the Certificate of Incorporation, any Certificate of Designations, Preferences and Rights of any outstanding series of preferred stock of the Company or the Bylaws or (ii) conflict with, or constitute a default
(or an event which with notice or lapse of time or both would become a default) under, or give to others any rights of termination, amendment, acceleration or cancellation of, any agreement, indenture or instrument to which the Company or any of its
Subsidiaries is a party, or result, to the Company’s knowledge, in a violation of any law, rule, regulation, order, judgment or decree (including federal and state securities laws and regulations and the rules and regulations of the Principal
Market applicable to the Company or any of its Subsidiaries) or by which any property or asset of the Company or any of its Subsidiaries is bound or affected, except in the case of conflicts, defaults, terminations, amendments, accelerations,
cancellations and violations under clause (ii), which could not reasonably be expected to result in a Material Adverse Effect. Except as disclosed in Schedule 3(e), neither the Company nor its Subsidiaries is in violation of any term of or in
default under its Certificate of Incorporation, including any Certificate of Designation, Preferences and Rights of any outstanding series of preferred stock of the Company, or Bylaws or their organizational charter or bylaws, respectively. Except
as disclosed in Schedule 3(e), neither the Company nor any of its Subsidiaries is in violation of any term of or is in default under any material contract, agreement, mortgage, indebtedness, indenture, instrument, judgment, decree or order or any
statute, rule or regulation applicable to the Company or its Subsidiaries, except for possible violations, defaults, terminations or amendments that could not reasonably be expected to have a Material Adverse Effect. The business of the Company and
its Subsidiaries is not being conducted, and shall not be conducted, in violation of any law, ordinance, or regulation of any governmental entity, 

  
 -7- 

 
except for possible violations, the sanctions for which either individually or in the aggregate could not reasonably be expected to have a Material Adverse Effect. Except as specifically
contemplated by this Agreement, reporting obligations under the 1934 Act or as required under the 1933 Act or applicable state securities laws or the filing of a Listing of Additional Shares Notification Form with the Principal Market, the Company
is not required to obtain any consent, authorization or order of, or make any filing or registration with, any court or governmental agency or any regulatory or self-regulatory agency in order for it to execute, deliver or perform any of its
obligations under or contemplated by the Transaction Documents in accordance with the terms hereof or thereof. Except as disclosed in Schedule 3(e) and for reporting obligations under the 1934 Act, all consents, authorizations, orders, filings and
registrations which the Company is required to obtain pursuant to the preceding sentence shall be obtained or effected on or prior to the Commencement Date. Except as disclosed in Schedule 3(e), the Company is not subject to any notices or actions
from or to the Principal Market, other than routine matters incident to listing on the Principal Market and not involving a violation of the rules of the Principal Market. Except as disclosed in Schedule 3(e), to the Company’s knowledge, the
Principal Market has not commenced any delisting proceedings against the Company. 
 (f)    SEC
Documents; Financial Statements. Except as disclosed in Schedule 3(f), since December 31, 2017, the Company has filed all reports, schedules, forms, statements and other documents required to be filed by it with the SEC pursuant to the
reporting requirements of the 1934 Act (all of the foregoing filed prior to the date hereof and all exhibits included therein and financial statements and schedules thereto and documents incorporated by reference therein being hereinafter referred
to as the “SEC Documents”). As of their respective dates (except as they have been correctly amended), the SEC Documents complied in all material respects with the requirements of the 1934 Act and the rules and regulations of the
SEC promulgated thereunder applicable to the SEC Documents, and none of the SEC Documents, at the time they were filed with the SEC (except as they may have been properly amended), contained any untrue statement of a material fact or omitted to
state a material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading. As of their respective dates (except as they have been properly
amended), the financial statements of the Company included in the SEC Documents complied as to form in all material respects with applicable accounting requirements and the published rules and regulations of the SEC with respect thereto. Such
financial statements have been prepared in accordance with generally accepted accounting principles, consistently applied, during the periods involved (except (i) as may be otherwise indicated in such financial statements or the notes thereto
or (ii) in the case of unaudited interim statements, to the extent they may exclude footnotes or may be condensed or summary statements) and fairly present in all material respects the financial position of the Company as of the dates thereof
and the results of its operations and cash flows for the periods then ended (subject, in the case of unaudited statements, to normal year-end audit adjustments). Except as disclosed in Schedule 3(f) or routine
correspondence, such as comment letters and notices of effectiveness in connection with previously filed registration statements or periodic reports publicly available on EDGAR, to the Company’s knowledge, the Company or any of its Subsidiaries
are not on the date hereof the subject of any inquiry, investigation or action by the SEC. 

(g)    Absence of Certain Changes. Except as disclosed in Schedule 3(g), since December 31,
2018, there has been no material adverse change in the business, properties, operations, financial condition or results of operations of the Company or its Subsidiaries taken as a whole. For purposes of this Agreement, neither a decrease in cash or
cash equivalents or in the market price of the Common Stock nor losses incurred in the ordinary course of the Company’s business shall be deemed or considered a material adverse change. The Company has not taken any steps, and does not
currently 

  
 -8- 

 
expect to take any steps, to seek protection pursuant to any Bankruptcy Law nor does the Company or any of its Subsidiaries have any knowledge or reason to believe that its creditors intend to
initiate involuntary bankruptcy or insolvency proceedings. The Company is financially solvent and is generally able to pay its debts as they become due. 

(h)    Absence of Litigation. Except as disclosed in Schedule 3(h), to the Company’s
knowledge, there is no action, suit, proceeding, inquiry or investigation before or by any court, public board, government agency, self-regulatory organization or body pending or, to the knowledge of the Company or any of its Subsidiaries,
threatened against the Company, the Common Stock or any of the Company’s Subsidiaries or any of the Company’s or the Company’s Subsidiaries’ officers or directors in their capacities as such, which could reasonably be expected to
have a Material Adverse Effect (each, an “Action”). A description of each such Action, if any, is set forth in Schedule 3(h). 

(i)    Acknowledgment Regarding Buyer’s Status. The Company acknowledges and
agrees that the Buyer is acting solely in the capacity of arm’s length purchaser with respect to the Transaction Documents and the transactions contemplated hereby and thereby. The Company further acknowledges that the Buyer is not acting as a
financial advisor or fiduciary of the Company (or in any similar capacity) with respect to the Transaction Documents and the transactions contemplated hereby and thereby and any advice given by the Buyer or any of its representatives or agents in
connection with the Transaction Documents and the transactions contemplated hereby and thereby is merely incidental to the Buyer’s purchase of the Securities. The Company further represents to the Buyer that the Company’s decision to enter
into the Transaction Documents has been based solely on the independent evaluation by the Company and its representatives and advisors. 

(j)    Intellectual Property Rights. To the Company’s knowledge, the Company and its
Subsidiaries own or possess adequate rights or licenses to use all material trademarks, trade names, service marks, service mark registrations, service names, patents, patent rights, copyrights, inventions, licenses, approvals, governmental
authorizations, trade secrets and other intellectual property rights (collectively, “Intellectual Property”) necessary to conduct their respective businesses as now conducted, except as set forth in Schedule 3(j) or to the extent
that the failure to own, possess, license or otherwise hold adequate rights to use Intellectual Property would not, individually or in the aggregate, have a Material Adverse Effect. Except as disclosed in Schedule 3(j), to the Company’s
knowledge, none of the Company’s active and registered Intellectual Property have expired or terminated, or, by the terms and conditions thereof, will expire or terminate within two years from the date of this Agreement, except as would not
reasonably be expected to have a Material Adverse Effect. The Company and its Subsidiaries do not have any knowledge of any infringement by the Company or its Subsidiaries of any Intellectual Property of others and, except as set forth on Schedule
3(j), there is no claim, action or proceeding being made or brought against, or to the Company’s knowledge, being threatened against, the Company or its Subsidiaries regarding Intellectual Property, which could reasonably be expected to have a
Material Adverse Effect. 
 (k)    Environmental Laws. To the Company’s knowledge, the
Company and its Subsidiaries (i) are in material compliance with any and all applicable foreign, federal, state and local laws and regulations relating to the protection of human health and safety or the environment and with respect to
hazardous or toxic substances or wastes, pollutants or contaminants (“Environmental Laws”), (ii) have received all material permits, licenses or other approvals required of them under applicable Environmental Laws to conduct their
respective businesses and (iii) are in material compliance with all terms and conditions of any such permit, license or approval, except where, in each of the three 

  
 -9- 

 
foregoing clauses, the failure to so comply or receive such approvals could not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect. 

(l)    Title. The Company and its Subsidiaries have good and marketable title to all personal
property owned by them that is material to the business of the Company and its Subsidiaries, in each case free and clear of all liens, encumbrances and defects except such as are described in Schedule 3(l) or such as do not materially affect the
value of such property and do not interfere with the use made and proposed to be made of such property by the Company and any of its Subsidiaries or could not reasonably be expected to have, individually or in the aggregate, a Material Adverse
Effect. Any real property and facilities held under lease by the Company and any of its Subsidiaries, to the Company’s knowledge, are held by them under valid, subsisting and enforceable leases with such exceptions as are not material and do
not interfere with the use made and proposed to be made of such property and buildings by the Company and its Subsidiaries. 

(m)    Insurance. The Company and each of its Subsidiaries are insured by insurers of recognized
financial responsibility against such losses and risks and in such amounts as management of the Company believes to be reasonable and customary in the businesses in which the Company and its Subsidiaries are engaged. To the Company’s knowledge,
since January 1, 2017 neither the Company nor any such Subsidiary has been refused any insurance coverage sought or applied for and neither the Company nor any such Subsidiary, to the Company’s knowledge, will be unable to renew its
existing insurance coverage as and when such coverage expires or to obtain similar coverage from similar insurers as may be necessary to continue its business at a cost that would not reasonably be expected to have a Material Adverse Effect. 

(n)    Regulatory Permits. The Company and its Subsidiaries possess all material certificates,
authorizations and permits issued by the appropriate federal, state or foreign regulatory authorities necessary to conduct their respective businesses as currently conducted, except when the failure to so possess such certificates, authorizations or
permits could not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect, and neither the Company nor any such Subsidiary has received any written notice of proceedings relating to the revocation or modification
of any such material certificate, authorization or permit. 
 (o)    Tax Status. The Company and
each of its Subsidiaries has made or filed all federal and state income and all other material tax returns, reports and declarations required by any jurisdiction to which it is subject (unless and only to the extent that the Company and each of its
Subsidiaries has set aside on its books reserves reasonably adequate for the payment of all unpaid and unreported taxes or filed valid extensions) and has paid all taxes and other governmental assessments and charges that are material in amount,
shown or determined to be due on such returns, reports and declarations, except those being contested in good faith and has set aside on its books reserves reasonably adequate for the payment of all taxes for periods subsequent to the periods to
which such returns, reports or declarations apply. To the Company’s knowledge, there are no unpaid taxes in any material amount claimed to be due by the taxing authority of any jurisdiction. 

(p)    Transactions With Affiliates. Except as set forth on Schedule 3(p), and other than the grant
or exercise of stock options or any other equity securities offered pursuant to duly adopted stock or incentive compensation plans as disclosed on Schedule 3(c), none of the officers, directors or employees of the Company is on the date hereof a
party to any transaction with the Company or any of its Subsidiaries (other than for services as employees, officers and directors and reimbursement for 

  
 -10- 

 
expenses incurred on behalf of the Company), including any contract, agreement or other arrangement providing for the furnishing of services to or by, providing for rental of real or personal
property to or from, or otherwise requiring payments to or from any officer, director or such employee or, to the knowledge of the Company, any corporation, partnership, trust or other entity in which any officer, director, or any such employee has
a material interest or is an officer, director, trustee or general partner. 
 (q)    Application of
Takeover Protections. The Company and its board of directors have taken or will take prior to the Commencement Date all necessary action, if any, in order to render inapplicable any control share acquisition, business combination, poison pill
(including any distribution under a rights agreement) or other similar anti-takeover provision under the Certificate of Incorporation or the laws of the state of its incorporation, other than Section 203 of the Delaware General Corporation Law,
which is or could become applicable to the Buyer as a result of the transactions contemplated by this Agreement, including, without limitation, the Company’s issuance of the Securities and the Buyer’s ownership of the Securities. 

 

	 	4.	 COVENANTS. 

(a)    Filing of Form 8-K and Registration Statement. The
Company agrees that it shall, within the time required under the 1934 Act, file a Current Report on Form 8-K disclosing this Agreement and the transaction contemplated hereby. The Company shall also file
within fifteen (15) Business Days from the date hereof a new registration statement covering the sale of the Securities by the Buyer in accordance with the terms of the Registration Rights Agreement between the Company and the Buyer, dated as
of the date hereof (“Registration Rights Agreement”). 
 (b)    Blue Sky. The
Company shall take such action, if any, as is reasonably necessary in order to obtain an exemption for or to qualify (i) the initial issuance of the Securities to the Buyer under this Agreement and (ii) any subsequent sale of the
Securities by the Buyer, in each case, under applicable securities or “Blue Sky” laws of the states of the United States in such states as is reasonably requested by the Buyer from time to time, and shall provide evidence of any such
action so taken to the Buyer at its written request; provided, however, that the Company shall not be obligated to file any general consent to service of process or to qualify as a foreign corporation or as a dealer in securities in any jurisdiction
in which it is not so qualified or to subject itself to taxation in respect of doing business in any jurisdiction in which it is not otherwise so subject. 

(c)    Listing. The Company shall promptly secure the listing of all of the Securities upon each
national securities exchange and automated quotation system that requires an application by the Company for listing, if any, upon which shares of Common Stock are then listed (subject to official notice of issuance) and shall maintain such listing,
so long as any other shares of Common Stock shall be so listed. The Company shall use its reasonable best efforts to maintain the Common Stock’s listing on the Principal Market in accordance with the requirements of the Registration Rights
Agreement. Neither the Company nor any of its Subsidiaries shall take any action that would be reasonably expected to result in the delisting or suspension of the Common Stock on the Principal Market, unless the Common Stock is immediately
thereafter traded on the New York Stock Exchange, the NYSE American, the Nasdaq Global Select Market, the Nasdaq Global Market, or the Nasdaq Capital Market. The Company shall pay all fees and expenses in connection with satisfying its obligations
under this Section. 

  
 -11- 

 (d)    Limitation on Short Sales and Hedging
Transactions. The Buyer agrees that beginning on the date of this Agreement and ending on the date of termination of this Agreement as provided in Section 11(k), the Buyer and its agents, representatives and affiliates shall not in any
manner whatsoever enter into or effect, directly or indirectly, any (i) “short sale” (as such term is defined in Section 242.200 of Regulation SHO of the 1934 Act) of the Common Stock or (ii) hedging transaction, which
establishes a net short position with respect to the Common Stock. 
 (e)    Issuance of Commitment
Shares and Initial Purchase Shares. Immediately upon the execution of this Agreement, the Company shall issue to the Buyer as consideration for the Buyer entering into this Agreement 69,444 shares of Common Stock (the “Commitment
Shares”) and, pursuant to Section 1(a), the Buyer shall purchase the Initial Purchase Shares. The Commitment Shares and Initial Purchase Shares shall be issued in certificated or restricted book-entry form and (subject to
Section 5 hereof) shall bear a restrictive legend substantially similar to the following: 
 THE SECURITIES
REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR
ASSIGNED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS, UNLESS SOLD PURSUANT TO: (1) RULE 144 UNDER THE SECURITIES ACT OF 1933, AS
AMENDED, OR (2) AN OPINION OF HOLDER’S COUNSEL, IN A CUSTOMARY FORM, THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT OR APPLICABLE STATE SECURITIES LAWS. 

(f)    Due Diligence. The Buyer shall have the right, from time to time as the Buyer may reasonably
request, to perform reasonable due diligence on the Company during normal business hours and subject to reasonable prior notice to the Company. The Company and its officers and employees shall provide information and reasonably cooperate with the
Buyer in connection with any reasonable request by the Buyer related to the Buyer’s due diligence of the Company, including, but not limited to, any such request made by the Buyer in connection with (i) the filing of the registration
statement described in Section 4(a) hereof and (ii) the Commencement; provided, however, that at no time is the Company required to disclose material nonpublic information to the Buyer or breach any obligation of confidentiality or non-disclosure to a third party or make any disclosure that could cause a waiver of attorney-client privilege. Except as may be required by law, court order or governmental authority, each party hereto agrees not to
disclose any Confidential Information of the other party to any third party and shall not use the Confidential Information of such other party for any purpose other than in connection with, or in furtherance of, the transactions contemplated hereby;
provided, that to the extent such disclosure is required by law, court order or governmental authority, the receiving party shall provide the disclosing party with reasonable prior written notice of such disclosure and make a reasonable effort to
assist the disclosing party in obtaining a protective order preventing or limiting the disclosure and/or requiring that the Confidential Information so disclosed be used only for the purposes for which the law, court order or governmental authority
requires. Each party hereto acknowledges that the Confidential Information shall remain the property of the disclosing party and agrees that it shall take all reasonable measures to protect the secrecy of any Confidential Information disclosed by
the other party. 

  
 -12- 

 (g)    Disposition of Securities. The Buyer shall
not sell any Securities except as provided in this Agreement, the Registration Rights Agreement and the “Plan of Distribution” section of the prospectus included in the Registration Statement (as defined in the Registration Rights
Agreement). The Buyer shall not transfer any Securities except pursuant to sales described in the “Plan of Distribution” section of the prospectus included in the Registration Statement or pursuant to Rule 144 under the 1933 Act. In the
event of any sales of Securities pursuant to the Registration Statement, the Buyer will (i) effect such sales pursuant to the “Plan of Distribution” section of the prospectus included in the Registration Statement, and (ii) will
comply with all applicable prospectus delivery requirements. 
  

	 	5.	 TRANSFER AGENT INSTRUCTIONS. 

Immediately upon the execution of this Agreement, the Company shall deliver to the Transfer Agent a letter in the form as set
forth as Exhibit C attached hereto with respect to the issuance of the Initial Purchase Shares and the Commitment Shares. On the Commencement Date, the Company shall cause any restrictive legend on the Initial Purchase Shares
and the Commitment Shares to be removed upon surrender of the originally issued certificate(s) for such shares. So long as the Buyer complies with its obligations in Section 4(g), all of the additional Purchase Shares to be issued under this
Agreement shall be issued without any restrictive legend unless the Buyer expressly consents otherwise. The Company shall issue irrevocable instructions to the Transfer Agent, and any subsequent transfer agent, to issue Common Stock in the name of
the Buyer for the Purchase Shares (the “Irrevocable Transfer Agent Instructions”). The Company warrants to the Buyer that, so long as the Buyer complies with its obligations in Section 4(g), no instruction other than the
Irrevocable Transfer Agent Instructions referred to in this Section 5, will be given by the Company to the Transfer Agent with respect to the Purchase Shares and that the Commitment Shares, Initial Purchase Shares and the Purchase Shares
shall otherwise be freely transferable on the books and records of the Company as and to the extent provided in this Agreement and the Registration Rights Agreement, subject to the provisions of Section 4(e) in the case of the Commitment Shares
and the Initial Purchase Shares. 
  

	 	6.	 CONDITIONS TO THE COMPANY’S RIGHT TO COMMENCE SALES OF SHARES OF COMMON STOCK UNDER THIS AGREEMENT.

 The right of the Company hereunder to commence sales of the Purchase Shares (other than the Initial
Purchase Shares) is subject to the satisfaction of each of the following conditions on or before the Commencement Date (the date that the Company may begin sales of Purchase Shares (other than the Initial Purchase Shares)): 

(a)    The Buyer shall have executed each of the Transaction Documents and delivered the same to the
Company; 
 (b)    The representations and warranties of the Buyer shall be true and correct as of the
Commencement Date as though made at that time (except for representations and warranties that speak as of a specific date, which shall be true and correct in all material respects as of such specific date) and the Buyer shall have performed,
satisfied and complied in all material respects with the covenants and agreements required by this Agreement to be performed, satisfied or complied with by the Buyer at or prior to the Commencement Date; and 

  
 -13- 

 (c)    A registration statement covering the sale of the
Securities by the Buyer shall have been declared effective under the 1933 Act by the SEC and no stop order with respect to the registration statement shall be pending or threatened by the SEC. 

 

	 	7.	 CONDITIONS TO THE BUYER’S OBLIGATION TO MAKE PURCHASES OF SHARES OF COMMON STOCK.

 The obligation of the Buyer to buy Purchase Shares (other than the Initial Purchase Shares) under
this Agreement is subject to the satisfaction of each of the following conditions on or before the Commencement Date (the date that the Company may begin sales of Purchase Shares (other than the Initial Purchase Shares)) and once such conditions
have been initially satisfied, there shall not be any ongoing obligation to satisfy such conditions after the Commencement has occurred: 

(a)    The Company shall have executed each of the Transaction Documents and delivered the same to the
Buyer; 
 (b)    The Company shall have issued to the Buyer the Commitment Shares and, in the event that
the Buyer shall have surrendered the originally issued certificate(s), shall have removed the restrictive transfer legend from the certificate representing the Commitment Shares; 

(c)    The Common Stock shall be authorized for quotation on the Principal Market, trading in the Common
Stock shall not have been within the last 365 days suspended by the SEC or the Principal Market, other than a general halt in trading in the Common Stock by the Principal Market under halt codes indicating pending or released material news, and the
Securities shall be approved for listing upon the Principal Market; 
 (d)    The Buyer shall have
received the opinion of the Company’s legal counsel dated as of the Commencement Date in customary form and substance; 

(e)    The representations and warranties of the Company shall be true and correct in all material
respects (except to the extent that any of such representations and warranties is already qualified as to materiality in Section 3 above, in which case, such representations and warranties shall be true and correct without further
qualification) as of the date of this Agreement and as of the Commencement Date as though made at that time (except for representations and warranties that speak as of a specific date, which shall be true and correct in all material respects as of
such specific date) and the Company shall have performed, satisfied and complied in all material respects with the covenants, agreements and conditions required by the Transaction Documents to be performed, satisfied or complied with by the Company
at or prior to the Commencement Date. The Buyer shall have received a certificate, executed by the CEO, President or CFO of the Company, dated as of the Commencement Date, to the foregoing effect in the form attached hereto as Exhibit A; 

(f)    The Board of Directors of the Company or a duly authorized committee thereof shall have adopted the
Signing Resolutions, which shall be in full force and effect without any amendment or supplement thereto as of the Commencement Date; 

(g)    As of the Commencement Date, the Company shall have reserved out of its authorized and unissued
Common Stock, solely for the purpose of effecting future purchases of Purchase Shares hereunder, 1,676,348 shares of Common Stock; 

  
 -14- 

 (h)    The Irrevocable Transfer Agent Instructions, in
form acceptable to the Buyer, shall have been signed by the Company and the Buyer and shall have been delivered to the Transfer Agent; 

(i)    The Company shall have delivered to the Buyer a certificate evidencing the incorporation and good
standing of the Company in the State of Delaware issued by the Secretary of State of the State of Delaware as of a date within ten (10) Business Days of the Commencement Date; 

(j)    [Intentionally Omitted.]; 

(k)    The Company shall have delivered to the Buyer a secretary’s certificate executed by the
Secretary of the Company, dated as of the Commencement Date, in the form attached hereto as Exhibit B; 

(l)    A registration statement covering the sale of (i) all of the Commitment Shares and the Initial
Purchase Shares and (ii) such number of additional Purchase Shares as reasonably determined by the Company shall have been declared effective under the 1933 Act by the SEC and no stop order with respect thereto shall be pending or threatened by
the SEC. The Company shall have prepared and delivered to the Buyer a final and complete form of prospectus, dated and current as of the Commencement Date, to be used by the Buyer in connection with any sales of any Securities, and to be filed by
the Company one (1) Business Day after the Commencement Date pursuant to Rule 424(b). The Company shall have made all filings under all applicable federal and state securities laws necessary to consummate the issuance of the Commitment Shares
and the Purchase Shares pursuant to this Agreement in compliance with such laws; 
 (m)    No Event of
Default has occurred and is continuing, or any event which, after notice and/or lapse of time, would become an Event of Default has occurred; 

(n)    On or prior to the Commencement Date, the Company shall take all necessary action, if any, and such
actions as reasonably requested by the Buyer, in order to render inapplicable any control share acquisition, business combination, stockholder rights plan or poison pill (including any distribution under a rights agreement) or other similar
anti-takeover provision under the Certificate of Incorporation or the laws of the state of its incorporation, other than Section 203 of the Delaware General Corporation Law, that is or could become applicable to the Buyer as a result of the
transactions contemplated by this Agreement, including, without limitation, the Company’s issuance of the Securities and the Buyer’s ownership of the Securities; and 

(o)    The Company shall have provided the Buyer with the information reasonably requested by the Buyer in
connection with its due diligence requests made prior to, or in connection with, the Commencement, in accordance with the terms of Section 4(f) hereof. 
  

	 	8.	 INDEMNIFICATION. 

In consideration of the Buyer’s execution and delivery of the Transaction Documents and acquiring the Securities hereunder
and in addition to all of the Company’s other obligations under the Transaction Documents, the Company shall defend, protect, indemnify and hold harmless the Buyer and all of its affiliates, members, officers, directors, and employees, and any
of the foregoing person’s agents or other representatives (including, without limitation, those retained in connection with the 

  
 -15- 

 
transactions contemplated by this Agreement) (collectively, the “Indemnitees”) from and against any and all third party actions, causes of action, suits, claims, losses, costs,
penalties, fees, liabilities and damages, and expenses in connection therewith (irrespective of whether any such Indemnitee is a party to the action for which indemnification hereunder is sought), and including reasonable attorneys’ fees and
disbursements (the “Indemnified Liabilities”), incurred by any Indemnitee as a result of, or arising out of, or relating to (a) any misrepresentation or breach of any representation or warranty made by the Company in the
Transaction Documents or any other certificate, instrument or document contemplated hereby or thereby, (b) any breach of any covenant, agreement or obligation of the Company contained in the Transaction Documents or any other certificate,
instrument or document contemplated hereby or thereby, or (c) any cause of action, suit or claim brought or made against such Indemnitee and arising out of or resulting from the execution, delivery, performance or enforcement of the Transaction
Documents or any other certificate, instrument or document contemplated hereby or thereby, other than with respect to Indemnified Liabilities which directly and primarily result from (A) a breach of any of the Buyer’s representations and
warranties, covenants or agreements contained in this Agreement, or (B) the gross negligence, bad faith or willful misconduct of the Buyer or any other Indemnitee. To the extent that the foregoing undertaking by the Company may be unenforceable
for any reason, the Company shall make the maximum contribution to the payment and satisfaction of each of the Indemnified Liabilities which is permissible under applicable law. 

 

	 	9.	 EVENTS OF DEFAULT. 

An “Event of Default” shall be deemed to have occurred at any time as any of the following events occurs: 

(a)    during any period in which the effectiveness of any registration statement is required to be
maintained pursuant to the terms of the Registration Rights Agreement, the effectiveness of such registration statement lapses for any reason (including, without limitation, the issuance of a stop order) or is unavailable to the Buyer for the sale
of all of the Registrable Securities (as defined in the Registration Rights Agreement), and such lapse or unavailability continues for a period of ten (10) consecutive Business Days or for more than an aggregate of thirty (30) Business
Days in any 365-day period, which is not in connection with a Permitted Delay (as defined in the Registration Rights Agreement), post-effective amendment to any such registration statement or the filing of a
new registration statement; provided, however, that in connection with any post-effective amendment to such registration statement or filing of a new registration statement that is required to be declared effective by the SEC, such lapse or
unavailability may continue for a period of no more than thirty (30) consecutive Business Days, which such period shall be extended for an additional thirty (30) Business Days if the Company receives a comment letter from the SEC in
connection therewith; 
 (b)    the suspension from trading or failure of the Common Stock to be listed
on a Principal Market for a period of three (3) consecutive Business Days; 
 (c)    the delisting
of the Common Stock from the Principal Market, and the Common Stock is not immediately thereafter trading on the New York Stock Exchange, the NYSE American, the Nasdaq Global Select Market, the Nasdaq Global Market, or the Nasdaq Capital Market;

 (d)    the failure for any reason by the Transfer Agent to issue Purchase Shares to the Buyer within
five (5) Business Days after the applicable Purchase Date that the Buyer is entitled to receive; 

  
 -16- 

 (e)    the Company’s breach of any representation
or warranty (as of the dates made), covenant or other term or condition under any Transaction Document if such breach could reasonably be expected to have a Material Adverse Effect and except, in the case of a breach of a covenant which is
reasonably curable, only if such breach continues uncured for a period of at least five (5) Business Days; 

(f)    if any Person commences a proceeding against the Company pursuant to or within the meaning of any
Bankruptcy Law; 
 (g)    if the Company pursuant to or within the meaning of any Bankruptcy Law;
(A) commences a voluntary case, (B) consents to the entry of an order for relief against it in an involuntary case, (C) consents to the appointment of a Custodian of it or for all or substantially all of its property, (D) makes a
general assignment for the benefit of its creditors or (E) becomes insolvent; 
 (h)    a court of
competent jurisdiction enters an order or decree under any Bankruptcy Law that (A) is for relief against the Company in an involuntary case, (B) appoints a Custodian of the Company or for all or substantially all of its property, or
(C) orders the liquidation of the Company or any Subsidiary; or 
 (i)    if at any time after the
Commencement Date, the Exchange Cap is reached unless and until stockholder approval has been obtained pursuant to Section 1(h) hereof. The Exchange Cap shall be deemed to be reached at such time if, upon submission of a Purchase Notice or VWAP
Purchase Notice under this Agreement, the issuance of such shares of Common Stock would exceed the number of shares of Common Stock which the Company may issue under this Agreement without breaching the Company’s obligations under the rules or
regulations of the Principal Market. 
 So long as an Event of Default has occurred and is continuing, or if any event which, after notice
and/or lapse of time, would become an Event of Default, has occurred and is continuing, or so long as the Closing Sale Price is below the Floor Price, the Company may not require and the Buyer shall not be obligated or permitted to purchase any
shares of Common Stock under this Agreement. If pursuant to or within the meaning of any Bankruptcy Law, the Company commences a voluntary case or any Person commences a proceeding against the Company, a Custodian is appointed for the Company or for
all or substantially all of its property, or the Company makes a general assignment for the benefit of its creditors, (any of which would be an Event of Default as described in Sections 9(f), 9(g) and 9(h) hereof) this Agreement shall
automatically terminate without any liability or payment to the Company without further action or notice by any Person. No such termination of this Agreement under Section 11(k)(i) shall affect the Company’s or the Buyer’s obligations
under this Agreement with respect to pending purchases and the Company and the Buyer shall complete their respective obligations with respect to any pending purchases under this Agreement. 

 

	 	10.	 CERTAIN DEFINED TERMS. 

For purposes of this Agreement, the following terms shall have the following meanings: 

(a)    “1933 Act” means the Securities Act of 1933, as amended. 

(b)    “Available Amount” means initially Ten Million Dollars ($10,000,000) in the
aggregate which amount shall be reduced by the Purchase Amount (including the Initial Purchase) each 

  
 -17- 

 
time the Buyer purchases shares of Common Stock pursuant to Section 1 hereof including the purchase of the Initial Purchase Shares under Section 1(a) hereof. 

(c)    “Bankruptcy Law” means Title 11, U.S. Code, or any similar federal or state law
for the relief of debtors. 
 (d)    “Business Day” means any day on which the
Principal Market is open for trading during normal trading hours (i.e., 9:30 a.m. to 4:00 p.m. Eastern Time), including any day on which the Principal Market is open for trading for a period of time less than the customary time. 

(e)    “Closing Sale Price” means the last closing trade price for the Common Stock on
the Principal Market as reported by the Principal Market. 
 (f)    “Confidential
Information” means any information disclosed by either party to the other party, either directly or indirectly, in writing, orally or by inspection of tangible objects (including, without limitation, documents, prototypes, samples, plant
and equipment), which is designated as “Confidential,” “Proprietary” or some similar designation. Information communicated orally shall be considered Confidential Information if such information is expressly identified as
Confidential Information at the time of such initial disclosure and confirmed in writing as being Confidential Information within ten (10) Business Days after the initial disclosure. Confidential Information may also include information
disclosed to a disclosing party by third parties. Confidential Information shall not, however, include any information which (i) was publicly known and made generally available in the public domain prior to the time of disclosure by the
disclosing party; (ii) becomes publicly known and made generally available after disclosure by the disclosing party to the receiving party through no action or inaction of the receiving party or its affiliates; (iii) is already in the
possession of the receiving party at the time of disclosure by the disclosing party as shown by the receiving party’s files and records immediately prior to the time of disclosure; (iv) is obtained by the receiving party from a third party
without a breach of such third party’s obligations of confidentiality; or (v) is independently developed by the receiving party without use of or reference to the disclosing party’s Confidential Information, as shown by documents and
other competent evidence in the receiving party’s possession. 

(g)    “Custodian” means any receiver, trustee, assignee, liquidator or similar official
under any Bankruptcy Law. 
 (h)    “Maturity Date” means the date that is thirty
(30) months from the Commencement Date. 
 (i)    “Person” means an individual or
entity including any limited liability company, a partnership, a joint venture, a corporation, a trust, an unincorporated organization and a government or any department or agency thereof. 

(j)    “Principal Market” means the Nasdaq Capital Market; provided however, that in the
event the Company’s Common Stock is ever listed or traded on the New York Stock Exchange, the NYSE American, the Nasdaq Global Select Market, the Nasdaq Global Market, or the Nasdaq Capital Market, then the “Principal Market” shall
mean such other market or exchange on which the Company’s Common Stock is then listed or traded. 

  
 -18- 

 (k)    “Purchase Amount” means, with
respect to any particular purchase made hereunder, the portion of the Available Amount to be purchased by the Buyer pursuant to Section 1 hereof as set forth in a valid Purchase Notice or VWAP Purchase Notice which the Company delivers to the
Buyer. 
 (l)    “Purchase Date” means, with respect to any Regular Purchase made
hereunder, the Business Day of receipt by the Buyer of a valid Purchase Notice that the Buyer is to buy Purchase Shares pursuant to Section 1(b) hereof. 

(m)     “Purchase Notice” shall mean an irrevocable written notice from the Company to
the Buyer directing the Buyer to buy Purchase Shares pursuant to Section 1(b) hereof as specified by the Company therein at the applicable Purchase Price on the Purchase Date. 

(n)     “Purchase Price” means the lesser of (i) the lowest Sale Price of the Common
Stock on the Purchase Date or (ii) the arithmetic average of the three (3) lowest Closing Sale Prices for the Common Stock during the ten (10) consecutive Business Days ending on the Business Day immediately preceding such Purchase
Date (to be appropriately adjusted for any reorganization, recapitalization, non-cash dividend, stock split, reverse stock split or other similar transaction). 

(o)    “Sale Price” means any trade price for the shares of Common Stock on the Principal
Market during normal trading hours, as reported by the Principal Market. 

(p)    “SEC” means the U.S. Securities and Exchange Commission. 

(q)    “Transfer Agent” means the transfer agent of the Company as set forth in
Section 11(f) hereof or such other person who is then serving as the transfer agent for the Company in respect of the Common Stock. 

(r)    “VWAP Minimum Price Threshold” means, with respect to any particular VWAP Purchase
Notice, the Sale Price on the VWAP Purchase Date equal to the greater of (i) 80% of the Closing Sale Price on the Business Day immediately preceding the VWAP Purchase Date or (ii) such higher price as set forth by the Company in the VWAP
Purchase Notice. 
 (s)    “VWAP Purchase Amount” means, with respect to any particular
VWAP Purchase Notice, the portion of the Available Amount to be purchased by the Buyer pursuant to Section 1(c) hereof pursuant to a valid VWAP Purchase Notice which requires the Buyer to buy the VWAP Purchase Share Percentage of the aggregate
shares traded on the Principal Market during normal trading hours on the VWAP Purchase Date up to the VWAP Purchase Share Volume Maximum, subject to the VWAP Minimum Price Threshold. 

(t)    “VWAP Purchase Date” means, with respect to any VWAP Purchase made
hereunder, the Business Day following the receipt by the Buyer of a valid VWAP Purchase Notice that the Buyer is to buy Purchase Shares pursuant to Section 1(c) hereof. 

(u)    “VWAP Purchase Notice” shall mean an irrevocable written notice from the Company
to the Buyer directing the Buyer to buy Purchase Shares on the VWAP Purchase Date pursuant to Section 1(c) hereof as specified by the Company therein at the applicable VWAP Purchase Price with the applicable VWAP Purchase Share Percentage
specified therein. 

  
 -19- 

 (v)    “VWAP Purchase Share Percentage”
means, with respect to any particular VWAP Purchase Notice pursuant to Section 1(c) hereof, the percentage set forth in the VWAP Purchase Notice which the Buyer will be required to buy as a specified percentage of the aggregate shares traded on
the Principal Market during normal trading hours up to the VWAP Purchase Share Volume Maximum on the VWAP Purchase Date subject to Section 1(c) hereof but in no event shall this percentage exceed thirty percent (30%) of such VWAP Purchase
Date’s share trading volume of the Common Stock on the Principal Market during normal trading hours. 

(w)     “VWAP Purchase Price” means the lesser of (i) the Closing Sale Price on the
VWAP Purchase Date; or (ii) ninety-seven percent (97%) of volume weighted average price for the Common Stock traded on the Principal Market during normal trading hours on (A) the VWAP Purchase Date if the aggregate shares traded on the
Principal Market on the VWAP Purchase Date have not exceeded the VWAP Purchase Share Volume Maximum and the Sale Price of Common Stock has not fallen below the VWAP Minimum Price Threshold (to be appropriately adjusted for any reorganization,
recapitalization, non-cash dividend, stock split, reverse stock split or other similar transaction), or (B) the portion of the VWAP Purchase Date until such time as the sooner to occur of (1) the
time at which the aggregate shares traded on the Principal Market has exceeded the VWAP Purchase Share Volume Maximum, or (2) the time at which the Sale Price of Common Stock falls below the VWAP Minimum Price Threshold (to be appropriately
adjusted for any reorganization, recapitalization, non-cash dividend, stock split, reverse stock split or other similar transaction). 

(x)     “VWAP Purchase Share Estimate” means the number of shares of Common Stock that
the Company has in its sole discretion irrevocably instructed its Transfer Agent to issue to the Buyer via the Depository Trust Company (“DTC”) Fast Automated Securities Transfer Program in connection with a VWAP Purchase Notice
pursuant to Section 1(c) hereof and issued to the Buyer’s or its designee’s balance account with DTC through its Deposit Withdrawal At Custodian (DWAC) system on the VWAP Purchase Date (to be appropriately adjusted for any
reorganization, recapitalization, non-cash dividend, stock split, reverse stock split or other similar transaction). 

(y)     “VWAP Purchase Share Volume Maximum” means a number of shares of Common Stock
traded on the Principal Market during normal trading hours on the VWAP Purchase Date equal to: (i) the VWAP Purchase Share Estimate, divided by (ii) the VWAP Purchase Share Percentage (to be appropriately adjusted for any reorganization,
recapitalization, non-cash dividend, stock split, reverse stock split or other similar transaction). 
  

	 	11.	 MISCELLANEOUS. 

(a)    Governing Law; Jurisdiction; Jury Trial. The corporate laws of the State of Delaware shall
govern all issues concerning the relative rights of the Company and its stockholders. All other questions concerning the construction, validity, enforcement and interpretation of this Agreement and the other Transaction Documents shall be governed
by the internal laws of the State of Illinois, without giving effect to any choice of law or conflict of law provision or rule (whether of the State of Illinois or any other jurisdictions) that would cause the application of the laws of any
jurisdictions other than the State of Illinois. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City of Chicago, for the adjudication of any dispute hereunder or under the other
Transaction Documents or in connection herewith or therewith, or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not
personally subject to the jurisdiction of any such court, that such suit, 

  
 -20- 

 
action or proceeding is brought in an inconvenient forum or that the venue of such suit, action or proceeding is improper. Each party hereby irrevocably waives personal service of process and
consents to process being served in any such suit, action or proceeding by mailing a copy thereof to such party at the address for such notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of
process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any manner permitted by law. EACH PARTY HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE, AND AGREES NOT TO REQUEST, A JURY
TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION HEREWITH OR ARISING OUT OF THIS AGREEMENT OR ANY TRANSACTION CONTEMPLATED HEREBY. 

(b)    Counterparts. This Agreement may be executed in two or more identical counterparts, all of
which shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to the other party; provided that a facsimile or pdf (or other electronic reproduction) signature shall be
considered due execution and shall be binding upon the signatory thereto with the same force and effect as if the signature were an original, not a facsimile or PDF (or other electronic reproduction) signature. 

(c)    Headings. The headings of this Agreement are for convenience of reference and shall not form
part of, or affect the interpretation of, this Agreement. 
 (d)    Severability. If any
provision of this Agreement shall be invalid or unenforceable in any jurisdiction, such invalidity or unenforceability shall not affect the validity or enforceability of the remainder of this Agreement in that jurisdiction or the validity or
enforceability of any provision of this Agreement in any other jurisdiction. 
 (e)    Entire
Agreement. This Agreement and the Registration Rights Agreement supersede all other prior oral or written agreements between the Buyer, the Company, their affiliates and persons acting on their behalf with respect to the matters discussed
herein, and this Agreement, the other Transaction Documents and the instruments referenced herein contain the entire understanding of the parties with respect to the matters covered herein and therein and, except as specifically set forth herein or
therein, neither the Company nor the Buyer makes any representation, warranty, covenant or undertaking with respect to such matters. Each of the Company and the Buyer acknowledges and agrees that it has not relied on, in any manner whatsoever, any
representations or statements, written or oral, other than as expressly set forth in this Agreement. 

(f)    Notices. Any notices, consents or other communications required or permitted to be given
under the terms of this Agreement must be in writing and will be deemed to have been delivered: (i) upon receipt, when delivered personally; (ii) upon receipt, when sent by facsimile (provided confirmation of transmission is mechanically
or electronically generated and kept on file by the sending party); (iii) upon receipt, when sent by electronic message (provided the recipient responds to the message and confirmation of both electronic messages are kept on file by the sending
party); or (iv) one (1) Business Day after timely deposit with a nationally recognized overnight delivery service, in each case properly addressed to the party to receive the same. The addresses and facsimile numbers for such communications
shall be: 
 If to the Company: 

  
 -21- 

			
	 Bionano Genomics, Inc.

	 9640 Towne Centre Drive, Suite 100

	 San Diego, CA 92121

	 Telephone:
	 	
	 Facsimile:
	 	
	 Attention:
	 	 Mike Ward

	 Email:
	 	
	
	 With a copy (which shall not constitute notice) to:

	
	 Cooley LLP

	 4401 Eastgate Mall

	 San Diego, CA 92121

	 Telephone:
	 	
	 Facsimile:
	 	
	 Attention:
	 	 James C. Pennington

	 Email:
	 	
	
	 If to the Buyer:

	
	 Aspire Capital Fund, LLC

	 155 North Wacker Drive, Suite 1600

	 Chicago, IL 60606

	 Telephone:
	 	
	 Facsimile:
	 	
	 Attention:
	 	 Steven G. Martin

	 Email:
	 	
	
	 With a copy to (which shall not constitute delivery to the Buyer):

	
	 Morrison & Foerster LLP

	 2000 Pennsylvania Avenue, NW, Suite 6000

	 Washington, DC 20006

	 Telephone:
	 	
	 Facsimile:
	 	
	 Attention:
	 	 Martin P. Dunn, Esq.

	 Email:
	 	
	
	 If to the Transfer Agent:

	
	 American Stock Transfer & Trust Company, LLC

	 6201 15th Avenue

	 Brooklyn, NY 11219

	 Telephone:
	 	
	 Facsimile:
	 	
	 Attention:
	 	 Jacqueline I. Kretzu

	 Email:
	 	

  
 -22- 

 or at such other address and/or facsimile number and/or to the attention of such other
person as the recipient party has specified by written notice given to each other party at least one (1) Business Day prior to the effectiveness of such change. Written confirmation of receipt (A) given by the recipient of such notice,
consent or other communication, (B) mechanically or electronically generated by the sender’s facsimile machine containing the time, date, and recipient facsimile number, (C) electronically generated by the sender’s electronic
mail containing the time, date and recipient email address or (D) provided by a nationally recognized overnight delivery service, shall be rebuttable evidence of receipt in accordance with clause (i), (ii), (iii) or (iv) above,
respectively. 
 (g)    Successors and Assigns. This Agreement shall be binding upon and inure to
the benefit of the parties and their respective successors and assigns. The Company shall not assign this Agreement or any rights or obligations hereunder without the prior written consent of the Buyer, including by merger or consolidation;
provided, however, that any transaction, whether by merger, reorganization, restructuring, consolidation, financing or otherwise, whereby the Company remains the surviving entity immediately after such transaction shall not be deemed a succession or
assignment. The Buyer may not assign its rights or obligations under this Agreement. 
 (h)    No
Third Party Beneficiaries. This Agreement is intended for the benefit of the parties hereto and their respective permitted successors and assigns, and is not for the benefit of, nor may any provision hereof be enforced by, any other person. 

(i)    Publicity. The Buyer shall have the right to approve before issuance any press release, SEC
filing or any other public disclosure made by or on behalf of the Company whatsoever with respect to, in any manner, the Buyer, its purchases hereunder or any aspect of this Agreement or the transactions contemplated hereby; provided, however, that
the Company shall be entitled, without the prior approval of the Buyer, to make any press release or other public disclosure (including any filings with the SEC) with respect to such transactions as is required by applicable law and regulations so
long as the Company and its counsel consult with the Buyer in connection with any such press release or other public disclosure at least one (1) Business Day prior to its release; provided, however, that the Company’s obligations pursuant
to this Section 11(i) shall not apply if the material provisions of such press release, SEC filing, or other public disclosure previously has been publicly disclosed by the Company in accordance with this Section 11(i). The Buyer must be
provided with a copy thereof at least one (1) Business Day prior to any release or use by the Company thereof.  

(j)    Further Assurances. Each party shall do and perform, or cause to be done and performed, all
such further acts and things, and shall execute and deliver all such other agreements, certificates, instruments and documents, as the other party may reasonably request in order to carry out the intent and accomplish the purposes of this Agreement
and the consummation of the transactions contemplated hereby. 
 (k)    Termination. This
Agreement may be terminated only as follows: 
 (i)    If pursuant to or within the
meaning of any Bankruptcy Law, the Company commences a voluntary case or any Person commences a proceeding against the Company, a Custodian is appointed for the Company or for all or substantially all of its property, or the Company makes a general
assignment for the benefit of its creditors, (any of which would be an Event of Default as described in Sections 9(f), 9(g) and 9(h) hereof) this Agreement shall automatically terminate without any liability or payment to the Company without further
action 

  
 -23- 

 
or notice by any Person. No such termination of this Agreement under this Section 11(k)(i) shall affect the Company’s or the Buyer’s obligations under this Agreement with respect
to pending purchases and the Company and the Buyer shall complete their respective obligations with respect to any pending purchases under this Agreement. 

(ii)    In the event that the Commencement shall not have occurred the Company shall have
the option to terminate this Agreement for any reason or for no reason without any liability whatsoever of either party to the other party under this Agreement except as set forth in Section 11(k)(viii) hereof. 

(iii)    In the event that the Commencement shall not have occurred on or before the one
year anniversary of the date of this Agreement, due to the failure to satisfy any of the conditions set forth in Sections 6 and 7 above with respect to the Commencement, this Agreement shall automatically terminate without any liability or payment
to the Company without further action or notice by any Person. 
 (iv)     At any time
after the Commencement Date, the Company shall have the option to terminate this Agreement for any reason or for no reason by delivering notice (a “Company Termination Notice”) to the Buyer electing to terminate this Agreement
without any liability whatsoever of either party to the other party under this Agreement except as set forth in Section 11(k)(viii) hereof. The Company Termination Notice shall not be effective until one (1) Business Day after it has been
received by the Buyer. 
 (v)    This Agreement shall automatically terminate on the date
that the Company sells and the Buyer purchases the full Available Amount as provided herein, without any action or notice on the part of any party and without any liability whatsoever of any party to any other party under this Agreement except as
set forth in Section 11(k)(viii) hereof. 
 (vi)    If by the Maturity Date for any
reason or for no reason the full Available Amount under this Agreement has not been purchased as provided for in Section 1 of this Agreement, this Agreement shall automatically terminate on the Maturity Date, without any action or notice on the
part of any party and without any liability whatsoever of any party to any other party under this Agreement except as set forth in Section 11(k)(viii) hereof. 

(vii)    Except as set forth in Sections 11(k)(i) (in respect of an Event of Default under
Sections 9(f), 9(g) and 9(h)), 11(k)(v) and 11(k)(vi), any termination of this Agreement pursuant to this Section 11(k) shall be effected by written notice from the Company to the Buyer setting forth the basis for the termination hereof. 

(viii)    The representations and warranties of the Company and the Buyer contained in
Sections 2, 3 and 5 hereof, the indemnification provisions set forth in Section 8 hereof and the agreements and covenants set forth in Sections 4(e), 4(g) and 11, shall survive the Commencement and any termination of this Agreement. No
termination of this Agreement shall affect the Company’s or the Buyer’s rights or obligations (i) under the Registration Rights Agreement, which shall survive any such termination in accordance with its terms, or (ii) under this
Agreement with respect to pending purchases and the Company and the Buyer shall complete their respective obligations with respect to any pending purchases under this Agreement. 

  
 -24- 

 (l)    No Financial Advisor, Placement Agent, Broker
or Finder. The Company represents and warrants to the Buyer that it has not engaged any financial advisor, placement agent, broker or finder in connection with the transactions contemplated hereby. The Buyer represents and warrants to the
Company that it has not engaged any financial advisor, placement agent, broker or finder in connection with the transactions contemplated hereby. Each party shall be responsible for the payment of any fees or commissions, if any, of any financial
advisor, placement agent, broker or finder engaged by such party relating to or arising out of the transactions contemplated hereby. Each party shall pay, and hold the other party harmless against, any liability, loss or expense (including, without
limitation, attorneys’ fees and out of pocket expenses) arising in connection with any such claim. 

(m)    No Strict Construction. The language used in this Agreement will be deemed to be the
language chosen by the parties to express their mutual intent, and no rules of strict construction will be applied against any party. 

(n)    Failure or Indulgence Not Waiver. No failure or delay in the exercise of any power, right or
privilege hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of any such power, right or privilege preclude other or further exercise thereof or of any other right, power or privilege. 

*    *    *    *    * 

  
 -25- 

 IN WITNESS WHEREOF, the Buyer and the Company have caused this Common
Stock Purchase Agreement to be duly executed as of the date first written above. 
  

			
	THE COMPANY:
	
	BIONANO GENOMICS, INC.
		
	 By:
	 	 /s/ R. Erik Holmlin, Ph.D.

	 Name:
	 	 R. Erik Holmlin, Ph.D.

	 Title:
	 	 Chief Executive Officer

	
	BUYER:
	
	ASPIRE CAPITAL FUND, LLC
	 BY:
	 	 ASPIRE CAPITAL PARTNERS, LLC

	 BY:
	 	 SGM HOLDINGS CORP.

		
	 By:
	 	 /s/ Steven G. Martin

	 Name:
	 	 Steven G. Martin

	 Title:
	 	 President

  
 -26- 

 SCHEDULES 
  

			
	 Schedule 3(a)
	  	 Subsidiaries

	 Schedule 3(c)
	  	 Capitalization

	 Schedule 3(e)
	  	 Conflicts

	 Schedule 3(f)
	  	 1934 Act Filings

	 Schedule 3(g)
	  	 Material Changes

	 Schedule 3(h)
	  	 Litigation

	 Schedule 3(j)
	  	 Intellectual Property

	 Schedule 3(l)
	  	 Title

	 Schedule 3(p)
	  	 Transactions with Affiliates

	
	EXHIBITS
		
	 Exhibit A
	  	 Form of Officer’s Certificate

	 Exhibit B
	  	 Form of Secretary’s Certificate

	 Exhibit C
	  	 Form of Letter to Transfer Agent

 DISCLOSURE SCHEDULES 

Schedule 3(a) – Subsidiaries 
  

	 	•	 	 BioNano Genomics UK, Ltd., a private limited company organized under the laws of the United Kingdom

  

	 	•	 	 BioNano Genomics (Shanghai) Trading Co., Ltd., a private limited company organized under the laws of the
China 

 Schedule 3(c) – Capitalization 

 

	 	•	 	 Fifth Amended and Restated Investors’ Rights Agreement, dated August 5, 2016 as amended (the
“Investors Rights Agreement”). 

  

	 	•	 	 Warrant to Purchase Common Stock, dated July 3, 2012, originally issued by Bionano Genomics, Inc. to Square
1 Bank and subsequently transferred to PacWest Bancorp (f/k/a Square 1 Financial, Inc.) on October 6, 2015. 

  

	 	•	 	 Warrant to Purchase Common Stock, dated December 11, 2013, originally issued by Bionano Genomics, Inc. to
Square 1 Bank and subsequently transferred to PacWest Bancorp (f/k/a Square 1 Financial, Inc.) on October 6, 2015. 

  

	 	•	 	 Warrant to Purchase Common Stock, dated March 8, 2016, issued by Bionano Genomics, Inc. to Western Alliance
Bank 

  

	 	•	 	 Warrant to Purchase Common Stock, dated December 9, 2016, issued by Bionano Genomics, Inc. to Western
Alliance Bank 

  

	 	•	 	 Warrant to Purchase Common Stock, dated June 29, 2018, issued by Bionano Genomics, Inc. to Midcap Financial
Trust 

  

	 	•	 	 Warrant to Purchase Common Stock, dated August 23, 2018, issued by Bionano Genomics, Inc. to Roth Capital
Partners. 

  

	 	•	 	 Warrant to Purchase Common Stock, dated August 23, 2018, issued by Bionano Genomics, Inc. to Maxim Partners
LLC. 

  

	 	•	 	 Warrant to Purchase Common Stock, dated August 23, 2018, issued by Bionano Genomics, Inc. to LifeSci
Capital, LLC. 

  

	 	•	 	 Warrant to Purchase Common Stock, dated August 30, 2018, issued by Bionano Genomics, Inc. to Roth Capital
Partners. 

  

	 	•	 	 Warrant to Purchase Common Stock, dated August 30, 2018, issued by Bionano Genomics, Inc. to Maxim Partners
LLC. 

  

	 	•	 	 Warrant to Purchase Common Stock, dated August 30, 2018, issued by Bionano Genomics, Inc. to LifeSci
Capital, LLC. 

  

	 	•	 	 Warrant to Purchase Common Stock, dated November 19, 2018, issued by Bionano Genomics, Inc. to Russell
Creative. 

  

	 	•	 	 Warrant to Purchase Common Stock, dated November 19, 2018, issued by Bionano Genomics, Inc. to LifeSci
Capital, LLC. 

  

	 	•	 	 On August 21, 2018, the Company completed its initial public offering (the “IPO”), pursuant
to which the Company sold an aggregate of 3,864,000 units (each unit consisting of one share of Common Stock and one warrant to purchase one share of Common Stock). As of the commencement of trading on September 21, 2018, the units sold in the
IPO separated in accordance with their terms and the Common Stock and warrants began trading separately on 

	 	 
the Nasdaq Capital Market (“Nasdaq”). Currently, there are outstanding warrants to purchase 3,864,000 shares of Common Stock listed on Nasdaq under the symbol “BNGOW”.

 Schedule 3(e) – Conflicts 

None. 
 Schedule 3(f) –
1934 Act Filings 
 None. 

Schedule 3(g) – Material Changes 

None. 
 Schedule 3(h) –
Litigation 
 None. 

Schedule 3(j) – Intellectual Property 
  

	 	•	 	 Employee Inventions 

The Company’s core intellectual property, licensed exclusively from Princeton University, was
co-invented by the Company’s founder, Han Cao, while he was employed by Princeton University. Dr. Cao assigned all rights to the intellectual property to Princeton University but retains 10% net
revenue sharing rights payable to him by Princeton University under the university’s standard agreements (the “Han Cao Rights”). 

Schedule 3(l) – Title 
  

	 	•	 	 MidCap Financial Trust 

Pursuant to that certain Credit Security Agreement by and between the Company and Midcap Financial Trust, dated June 29, 2018, (the “Credit
Security Agreement”), the Company has granted to Midcap Financial Trust a first ranking security interest in substantially all of its assets, including, without limitation, the Company’s Intellectual Property. 

 

	 	•	 	 Union Bank 

A lien on cash collateral ($100,000) of Company securing reimbursement obligations under a letter of credit issued by Union Bank. 

 

	 	•	 	 Western Alliance Bank 

 A lien on cash collateral ($150,000) of Company securing reimbursement obligations under a letter of credit
issued by Western Alliance Bank. 
  

	 	•	 	 The Han Cao Rights 

Schedule 3(p) – Transactions with Affiliates 
  

	•	 	 The Investors Rights Agreement 

 EXHIBIT A 

FORM OF OFFICER’S CERTIFICATE 

This Officer’s Certificate (“Certificate”) is being delivered pursuant to Section 7(e) of that
certain Common Stock Purchase Agreement dated as of March 14, 2019 (the “Common Stock Purchase Agreement”), by and between BIONANO GENOMICS, INC., a Delaware corporation (the “Company”), and ASPIRE CAPITAL
FUND, LLC, an Illinois limited liability company (the “Buyer”). Terms used herein and not otherwise defined shall have the meanings ascribed to them in the Common Stock Purchase Agreement. 

The undersigned,
                    , in his capacity as
                     of the Company, and not individually, hereby certifies as follows: 

1.    I am the
                     of the Company and make the statements contained in this Certificate in my capacity as
                     of the Company; 

2.    The representations and warranties of the Company are true and correct in all
material respects (except to the extent that any of such representations and warranties is already qualified as to materiality in Section 3 of the Common Stock Purchase Agreement, in which case, such representations and warranties are true and
correct without further qualification) as of the date when made and as of the Commencement Date as though made at that time (except for representations and warranties that speak as of a specific date); 

3.    The Company has performed, satisfied and complied in all material respects with
covenants, agreements and conditions required by the Transaction Documents to be performed, satisfied or complied with by the Company at or prior to the Commencement Date. 

4.    The Company has not taken any steps, and does not currently expect to take any steps,
to seek protection pursuant to any Bankruptcy Law nor does the Company or any of its Subsidiaries have any knowledge or reason to believe that its creditors intend to initiate involuntary bankruptcy or insolvency proceedings. The Company is
financially solvent and is generally able to pay its debts as they become due. 
 IN WITNESS WHEREOF, I have hereunder
signed my name on this      day of                     . 

 

	
	  

	 Name:

	 Title:

 The undersigned as Secretary of the Company hereby certifies that
                     is the duly elected, appointed, qualified and acting
                     of the Company and that the signature appearing above is his genuine signature. 

 

	
	  

	                    , Secretary

 EXHIBIT B 

FORM OF SECRETARY’S CERTIFICATE 

This Secretary’s Certificate (the “Certificate”) is being delivered pursuant to Section 7(k) of that certain Common
Stock Purchase Agreement dated as of March 14, 2019 (the “Common Stock Purchase Agreement”), by and between BIONANO GENOMICS, INC., a Delaware corporation (the “Company”) and ASPIRE CAPITAL FUND,
LLC, an Illinois limited liability company (the “Buyer”), pursuant to which the Company may sell to the Buyer up to Ten Million Dollars ($10,000,000) of the Company’s Common Stock, par value $0.0001 (the “Common
Stock”). Terms used herein and not otherwise defined shall have the meanings ascribed to them in the Common Stock Purchase Agreement. 

The undersigned,
                    , in her capacity as Secretary of the Company, and not individually, hereby certifies as follows: 

1.    I am the Secretary of the Company and make the statements contained in this
Secretary’s Certificate in my capacity as the Secretary of the Company. 

2.    Attached hereto as Exhibit A and Exhibit B are true, correct and complete copies of
the Company’s bylaws (“Bylaws”) and Certificate of Incorporation (“Certificate of Incorporation”), respectively, in each case, as amended through the date hereof, and no action has been taken by the Company,
its directors, officers or stockholders, in contemplation of the filing of any further amendment relating to or affecting the Bylaws or Articles. 

3.    Attached hereto as Exhibit C are true, correct and complete copies of the Signing
Resolutions duly adopted by the Board of Directors of the Company. Such resolutions have not been amended, modified or rescinded and remain in full force and effect and such resolutions are the only resolutions adopted by the Company’s Board of
Directors, or any committee thereof, or the stockholders of the Company relating to or affecting (i) the entering into and performance of the Common Stock Purchase Agreement, or the issuance, offering and sale of the Purchase Shares and the
Commitment Shares and (ii) and the performance of the Company of its obligation under the Transaction Documents as contemplated therein. 

4.    As of the date hereof, the authorized, issued and reserved capital stock of the
Company is as set forth on Exhibit D hereto. 
 IN WITNESS WHEREOF, I have hereunder signed my name on this
     day of                     . 

 

	
	  

	                    , Secretary

 The undersigned, as
                     of the Company, hereby certifies that
                     is the duly elected, appointed, qualified and acting Secretary of the Company and that the signature appearing above is
her genuine signature. 
  

	
	
                  
   

	  

 EXHIBIT C 

FORM OF LETTER TO THE TRANSFER AGENT FOR THE ISSUANCE OF THE COMMITMENT SHARES AND INITIAL PURCHASE SHARES AT SIGNING OF THE PURCHASE
AGREEMENT 
 [COMPANY LETTERHEAD] 

            , 201   

[Transfer Agent] 
 [Address] 

[Address] 
 Attention: 

Re: Issuance of Common Stock to Aspire Capital Fund, LLC 

Ladies and Gentlemen: 
 On behalf of BIONANO
GENOMICS, INC., (the “Company”), you are hereby instructed to issue as soon as possible
                     shares of our common stock in the name of ASPIRE CAPITAL FUND, LLC. The share certificate should be dated March
    , 2019. I have included a true and correct copy of adopted resolutions of the Board of Directors of the Company approving the issuance of these shares. The shares should be issued subject to the following restrictive
legend: 
 THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE
SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS, UNLESS SOLD PURSUANT TO: (1) RULE 144 UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR (2) AN OPINION OF HOLDER’S COUNSEL, IN A CUSTOMARY FORM, THAT REGISTRATION
IS NOT REQUIRED UNDER SAID ACT OR APPLICABLE STATE SECURITIES LAWS. 

 The share certificate should be sent as soon as possible via overnight mail to the
following address: 
 Aspire Capital Fund, LLC 

155 North Wacker Drive, Suite 1600 

Chicago, IL 60606 

Attention: Steven G. Martin 

Thank you very much for your help. Please call
                    , at
                     if you have any questions or need anything further. 

 

			
	BIONANO GENOMICS, INC.
		
	 BY:
	 	
                  
                                         
          

	 Name:
	 	
                    

	 Title:EX-10.2

 Exhibit 10.2 

LOAN AND SECURITY AGREEMENT 

THIS LOAN AND SECURITY AGREEMENT (as the same may be amended, restated, modified, or supplemented from time to time,
this “Agreement”) dated as of March 14, 2019 (the “Effective Date”) among INNOVATUS LIFE SCIENCES LENDING FUND I, LP, a Delaware limited partnership, as collateral agent (in such capacity, together with its
successors and assigns in such capacity, “Collateral Agent”), and the Lenders listed on Schedule 1.1 hereof or otherwise a party hereto from time to time including EAST WEST BANK in its capacity as a Lender
(“Bank”), and BIONANO GENOMICS, INC., a Delaware corporation (“Borrower”), provides the terms on which the Lenders shall lend to Borrower and Borrower shall repay the Lenders. The parties agree as follows: 

 

	1.	 DEFINITIONS, ACCOUNTING AND OTHER TERMS 

1.1    Capitalized terms used herein shall have the meanings set forth in Section 13 to
the extent defined therein. All other capitalized terms used but not defined herein shall have the meaning given to such terms in the Code. Any accounting term used but not defined herein shall be construed in accordance with GAAP and all
calculations shall be made in accordance with GAAP. The term “financial statements” shall include the accompanying notes and schedules. Any section, subsection, schedule or exhibit references are to this Agreement unless otherwise
specified. 
  

	2.	 LOANS AND TERMS OF PAYMENT 

2.1    Promise to Pay. Borrower hereby unconditionally promises to pay each Lender the
outstanding principal amount of the Term Loan advanced to Borrower by such Lender and accrued and unpaid interest thereon and any other amounts due hereunder as and when due in accordance with this Agreement. 

2.2    Term Loans. 

(a)    Availability. 

(i)    Subject to the terms and conditions of this Agreement, the Lenders agree, severally and not
jointly, to make a term loan to Borrower during the Term A-1 Draw Period in an aggregate principal amount of Seventeen Million Five Hundred Thousand Dollars ($17,500,000.00) according to each Lender’s
Term Loan Commitment as set forth on Schedule 1.1 hereto (the “Term A-1 Loan”). After repayment, the Term A-1 Loan may not be re-borrowed. 
 (ii)    Subject to the terms and conditions of this
Agreement, the Lenders agree, severally and not jointly, to make a term loan to Borrower during the Term A-2 Draw Period in an aggregate principal amount of Two Million Five Hundred Thousand Dollars
($2,500,000.00) according to each Lender’s Term Loan Commitment as set forth on Schedule 1.1 hereto (the “Term A-2 Loan;” each Term A-1 Loan
and Term A-2 Loan is referred to singly as a “Term A Loan” and Term A-1 Loan and Term A-2 Loan are referred to
collectively as “Term A Loans”). After repayment, the Term A-2 Loan may not be re-borrowed. 

(iii)    Subject to the terms and conditions of this Agreement, the Lenders agree, severally and not
jointly, to make a term loan to Borrower during the Term B Draw Period in an aggregate principal amount of Five Million Dollars ($5,000,000.00) according to each Lender’s Term Loan Commitment as set forth on Schedule 1.1 hereto (the
“Term B Loan;” each Term A Loan and Term B Loan is referred to singly as a “Term Loan” and the Term A Loan and the Term B Loan are referred to collectively as the “Term Loans”). After repayment, the
Term B Loan may not be re-borrowed. 
 (b)    Repayment.
Borrower shall make monthly payments of interest only commencing on the second (2nd) Payment Date following the Funding Date of the Term Loan, and continuing on the Payment Date of each successive month thereafter through and including the Payment
Date immediately preceding the Amortization Date. Borrower agrees to pay, on the Funding Date of the Term Loan, any initial partial monthly interest payment otherwise due for the period between the Funding Date of such Term Loan and the first
Payment Date after such Funding Date. Commencing on the Amortization Date, and continuing on the Payment Date of each month thereafter, 

 
Borrower shall make consecutive equal monthly payments of principal and interest, in arrears, to each Lender, as calculated by Collateral Agent (which calculations shall be deemed correct absent
manifest error) based upon: (1) the amount of such Lender’s Term Loan, (2) the effective rate of interest, as determined in Section 2.5(a), and (3) a repayment schedule equal to twenty-four (24) months. All unpaid
principal and accrued and unpaid interest with respect to the Term Loan is due and payable in full on the Maturity Date. The Term Loan may only be prepaid in accordance with Sections 2.2(c) and 2.2(d). 

(c)    Mandatory Prepayments. If an event described in Section 7.2(c)(ii) occurs or the Term
Loan is accelerated following the occurrence of an Event of Default, Borrower shall immediately pay to Lenders, payable to each Lender in accordance with its respective Pro Rata Share, an amount equal to the sum of: (i) all outstanding
principal of the Term Loan plus accrued and unpaid interest thereon through the prepayment date, (ii) the Final Fee, (iii) the Prepayment Fee, plus (iv) all other Obligations that are due and payable, including, without limitation,
Lenders’ Expenses and interest at the Default Rate with respect to any past due amounts. Notwithstanding (but without duplication with) the foregoing, on the Maturity Date, if the Final Fee had not previously been paid in full in connection
with the prepayment of the Term Loan in full, Borrower shall pay to each Lender in accordance with its respective Pro Rata Share, the Final Fee in respect of the Term Loan. 

(d)    Permitted Prepayment of Term Loan. After the date that is the first anniversary of the
Effective Date, Borrower shall have the option to prepay all, but not less than all, of the Term Loan advanced by the Lenders under this Agreement, provided Borrower (i) provides written notice to Collateral Agent of its election to prepay the
Term Loan at least seven (7) Business Days prior to such prepayment, and (ii) pays to the Lenders on the date of such prepayment, payable to each Lender in accordance with its respective Pro Rata Share, an amount equal to the sum of
(A) all outstanding principal of the Term Loan plus accrued and unpaid interest thereon through the prepayment date, (B) the Final Fee, (C) the Prepayment Fee, plus (D) all other Obligations that are due and payable, including,
without limitation, Lenders’ Expenses and interest at the Default Rate with respect to any past due amounts. 

2.3    Advances Under Revolving Line. 

(a)    Amount. Subject to and upon the terms and conditions of this Agreement, including
Borrower’s compliance with Section 6.6(d) of this Agreement, Borrower may request Advances from Bank in an aggregate outstanding amount not to exceed the lesser of (A) the Revolving Line or (B) the Borrowing Base. Amounts
borrowed pursuant to this Section 2.3(a) may be repaid and reborrowed at any time without penalty or premium prior to the Maturity Date, at which time all Advances under this Section 2.3(b) shall be immediately due and payable; provided
that, in the event of a mandatory or permitted prepayment of the Term Loan in accordance with Section 2.2(c) or (d) above, Borrower shall, at the same time as such prepayment, satisfy in full the Obligations owing with respect to the
Revolving Line. 
 (b)    Form of Request. Whenever Borrower desires an Advance, Borrower will
notify Bank by facsimile transmission or telephone no later than 12:00 p.m. Pacific time on the Business Day that the Advance is to be made. Each such notification shall be promptly confirmed by a Payment/Advance Form in substantially the form of
Exhibit B-1; provided that, Borrower shall deliver to Bank, no less than five (5) Business Days prior to the first request for an Advance hereunder, a completed Borrowing Base Certificate, together with
detailed aged listings by invoice date of accounts receivable and accounts payable for Bank’s review and approval in its sole reasonable discretion. Bank is authorized to make Advances under this Agreement, based upon instructions received from
a Responsible Officer or a designee of a Responsible Officer, or without instructions if in Bank’s discretion such Advances are necessary to meet Obligations which have become due and remain unpaid. Bank shall be entitled to rely on any
facsimile or telephonic notice given by a person who Bank reasonably believes to be a Responsible Officer or a designee thereof, and Borrower shall indemnify and hold Bank harmless for any damages or loss suffered by Bank

  
 2 

 
as a result of such reliance. Bank will credit the amount of Advances made under this Section 2.3(b) to Borrower’s deposit account. 

2.4    Overadvances. If the aggregate amount of the outstanding Advances exceeds the lesser
of the Revolving Line or the Borrowing Base at any time, Borrower shall immediately pay to Bank, in cash, the amount of such excess. 

2.5    Payment of Interest. 

(a)    Interest Rates, Payments, and Calculations. 

(i)    Term Loans. Subject to Section 2.3(b), the principal amount outstanding under the Term
Loan shall accrue interest at a floating per annum rate equal to the Term Loan Basic Rate, determined by Collateral Agent on the Funding Date of the Term Loan and monthly thereafter, which interest shall be payable monthly in arrears in accordance
with Sections 2.2(b) and 2.3(e); provided that at the election of Borrower (which shall be considered elected on the Funding Date of the applicable Term Loan) with no less than five (5) Business Days’ written notice to Collateral
Agent prior to the Funding Date of the applicable Term Loan, 3.00% of such Term Loan Basic Rate may be payable in-kind by adding an amount equal to such 3.00% of the outstanding principal amount to the then
outstanding principal balance on a monthly basis until the second anniversary of the Effective Date so as to increase the outstanding principal balance of the applicable Term Loan on each Payment Date and which amount shall be payable when the
principal amount of the applicable Term Loan is payable in accordance with Sections 2.2(b) and 2.3(e) and on which principal amount interest shall be owed pursuant to Section 2.3(a). 

Interest shall accrue on the Term Loan commencing on, and including, the Funding Date of the Term Loan, and shall accrue on the principal
amount outstanding under the Term Loan through and including the day on which the Term Loan is paid in full. 

(ii)    Advances. Subject to Section 2.5(b), the Advances shall bear interest, on the
outstanding daily balance thereof, at a rate equal to two percent (2.00%) above the Prime Rate. 

(b)    Late Fee; Default Rate. If any payment is not made within ten (10) days after the date
such payment is due, Borrower shall pay Collateral Agent, for the ratable benefit of the Lenders, a late fee equal to the greater of (i) five percent (5.00%) of the amount of such unpaid amount or (ii) the maximum amount permitted to be
charged under applicable law, but not less than Five Dollars ($5.00). Immediately upon the occurrence and during the continuance of an Event of Default, Obligations shall accrue interest at a fixed per annum rate equal to the rate that is otherwise
applicable thereto plus five percentage points (5.00%) (the “Default Rate”). Payment or acceptance of the increased interest rate provided in this Section 2.5(b) is not a permitted alternative to timely payment and shall not
constitute a waiver of any Event of Default or otherwise prejudice or limit any rights or remedies of Collateral Agent. 

(c)    365-Day Year. Interest shall be computed on the
basis of a three hundred sixty-five (365) day year and the actual number of days elapsed. 

(d)    Debit of Accounts. Collateral Agent and each Lender may debit (or ACH) any deposit accounts
maintained by Borrower or any of its Subsidiaries for principal and interest payments or any other amounts Borrower owes the Lenders under the Loan Documents when due. Any such debits (or ACH activity) shall not constitute a set-off. 
 (e)    Payments. Except as otherwise expressly
provided herein, all payments by Borrower under the Loan Documents shall be made to Collateral Agent in immediately available funds on the date specified herein. Unless otherwise provided, interest is payable monthly on the Payment Date of each
month. Payments of principal and/or interest received after 12:00 noon Eastern time are considered received at the opening of business on the next Business Day. When a payment is due on a day that is not a Business Day, the payment is due the next
Business Day and additional fees or interest, as applicable, shall continue to accrue until paid. All payments to be made by Borrower hereunder or under any other Loan Document, including payments of principal and interest, and all fees, expenses,
indemnities and reimbursements, shall be made without set-off, recoupment or counterclaim, in lawful money of the 

  
 3 

 
United States and in immediately available funds. Collateral Agent shall, within one (1) Business Day of receipt thereof, remit to the respective Lender to which such payments are owed, at
such Lender’s office, all amounts of principal, interest, fees and/or expenses due to such Lender. 

(f)    Application of Payments. Unless otherwise agreed or required by applicable law, payments
will be applied first to any accrued unpaid interest as shown on the most recent statement or bill provided to Borrower (if no statement or bill has been provided for any reason, it shall be applied to the unpaid interest accrued since the last
payment); then to principal; then to any late charges; and then to any unpaid collection costs. Borrower will pay Collateral Agent at Collateral Agent’s address shown above or at such other place as Collateral Agent may designate in writing.

 (g)    Changes in Prime Rate. In the event the Prime Rate is changed from time to time
hereafter, the applicable rate of interest hereunder shall be increased or decreased, effective as of the day the Prime Rate is changed, by an amount equal to such change in the Prime Rate. 

2.6    Fees. Borrower shall pay to Collateral Agent: 

(a)    Term Loan Facility Fee. The Term Loan Facility Fee, which shall be due on the Funding Date
of the Term A-1 Loan with respect to the Term A-1 Loan, on the Funding Date of the Term A-2 Loan with respect to the Term A-2 Loan and the Funding Date of the Term B Loan with respect to the Term Loan, to be shared among the Lenders in accordance with their respective Pro Rata Shares; 

(b)    Revolving Facility Fee. The Revolving Facility Fee, which shall be due on the Effective Date
with respect to the Revolving Line, payable solely for the account of Bank; 
 (c)    Unused Facility
Fee. On April 1, 2019 and the first day of each month thereafter prior to the Maturity Date, and on the Maturity Date, a fee (the “Unused Facility Fee”) equal to seventy-five hundredths percent (0.75%) per annum of the
average daily unused portion of the Revolving Line, as reasonably determined by Bank, solely for the account of Bank, and which shall be nonrefundable; 

(d)    Final Fee. The Final Fee, when due hereunder, to be shared among the Lenders in accordance
with their fee letter; 
 (e)    Prepayment Fee. The Prepayment Fee, when due hereunder, to be
shared among the Lenders in accordance with their fee letter; and 
 (f)    Lenders’
Expenses. All Lenders’ Expenses incurred through and after the Effective Date, when due; provided that all such Lenders’ Expenses incurred up to and including the Effective Date shall not exceed One Hundred Fifty Thousand
Dollars ($150,000.00) in the aggregate for the account of Borrower. 
 2.7    Withholding.
Payments received by the Collateral Agent or the Lenders from Borrower hereunder will be made free and clear of and without deduction for any and all present or future taxes, levies, imposts, duties, deductions, withholdings, assessments, fees or
other charges imposed by any governmental authority (including any interest, additions to tax or penalties applicable thereto). Specifically, however, if at any time any Governmental Authority, applicable law, regulation or international agreement
requires Borrower to make any withholding or deduction from any such payment or other sum payable hereunder to the Lenders, Borrower hereby covenants and agrees that the amount due from Borrower with respect to such payment or other sum payable
hereunder will be increased to the extent necessary to ensure that, after the making of such required withholding or deduction, each Lender receives a net sum equal to the sum which it would have received had no withholding or deduction been
required and Borrower shall pay the full amount withheld or deducted to the relevant Governmental Authority. Borrower will, upon request, furnish the Lenders with proof reasonably satisfactory to the Lenders indicating that Borrower has made such
withholding payment; provided, however, that Borrower need not make any withholding payment if the amount or validity of such withholding payment is contested in good faith by appropriate and timely 

  
 4 

 
proceedings and as to which payment in full is bonded or reserved against by Borrower. The agreements and obligations of Borrower contained in this Section 2.7 shall survive the termination
of this Agreement. 
 2.8    Secured Promissory Notes. The Term Loan and the Revolving
Line shall be evidenced by a Secured Promissory Note or Notes in the form attached as Exhibit E hereto (each a “Secured Promissory Note”), and shall be repayable as set forth in this Agreement. Borrower irrevocably authorizes
each Lender to make or cause to be made, on or about the Funding Date of any Credit Extension or at the time of receipt of any payment of principal on such Lender’s Secured Promissory Note, an appropriate notation on such Lender’s Secured
Promissory Note Record reflecting the making of such Credit Extension or (as the case may be) the receipt of such payment. The outstanding amount of each Credit Extension set forth on such Lender’s Secured Promissory Note Record shall, absent
manifest error, be prima facie evidence of the principal amount thereof owing and unpaid to such Lender, but the failure to record, or any error in so recording, any such amount on such Lender’s Secured Promissory Note Record shall not limit or
otherwise affect the obligations of Borrower under any Secured Promissory Note or any other Loan Document to make payments of principal of or interest on any Secured Promissory Note when due. Upon receipt of an affidavit of an officer of a Lender as
to the loss, theft, destruction, or mutilation of its Secured Promissory Note, Borrower shall issue, in lieu thereof, a replacement Secured Promissory Note in the same principal amount thereof and of like tenor. 

 

	3.	 CONDITIONS OF LOANS 

3.1    Conditions Precedent to Initial Credit Extension. Each Lender’s obligation to
make the initial Credit Extension is subject to the condition precedent that Collateral Agent and each Lender shall consent to or shall have received, in form and substance satisfactory to Collateral Agent and each Lender, such documents, and
completion of such other matters, as Collateral Agent and each Lender may reasonably deem necessary or appropriate, including, without limitation: 

(a)    original Loan Documents, each duly executed by Borrower and each Subsidiary, as applicable; 

(b)    a completed Perfection Certificate for Borrower and each of its Subsidiaries, which must be
received on the Effective Date; 
 (c)    duly executed original Control Agreements with respect to any
Collateral Accounts maintained by Borrower or any of its Subsidiaries; 
 (d)    the Operating Documents
and good standing certificates of Borrower and its Subsidiaries certified by the Secretary of State (or equivalent agency) of Borrower’s and such Subsidiaries’ jurisdiction of organization or formation and each jurisdiction in which
Borrower and each Subsidiary is qualified to conduct business, each as of a date no earlier than thirty (30) days prior to the Effective Date; 

(e)    a copy of resolutions of the governing body for Borrower evidencing approval of the Term Loan and
other transactions evidenced by the Loan Documents; 
 (f)    duly executed original officer’s
certificates for Borrower and each Subsidiary that is a party to the Loan Documents certifying as to (i) the incumbency of each Responsible Officer executing each Loan Document and (ii) the documents delivered pursuant to
Section 3.1(d) and 3.1(e), in a form acceptable to Collateral Agent and the Lenders; 

(g)    certified copies, dated as of date no earlier than thirty (30) days prior to the Effective
Date, of financing statement searches, as Collateral Agent shall request, accompanied by written evidence (including any 

  
 5 

 
UCC termination statements) that the Liens indicated in any such financing statements either constitute Permitted Liens or have been or, in connection with the initial Term Loan, will be
terminated or released; 
 (h)    a duly executed legal opinion of counsel to Borrower dated as of the
Funding Date of the initial Credit Extension; 
 (i)    evidence satisfactory to Collateral Agent and
the Lenders that the insurance policies required by Section 6.5 hereof are in full force and effect, together with appropriate evidence showing loss payable and/or additional insured clauses or endorsements in favor of Collateral Agent, for the
ratable benefit of the Lenders; 
 (j)    payment of the Term Loan Facility Fee, Revolving Facility Fee
and Lenders’ Expenses then due as specified in Section 2.6 hereof; 
 (k)    a landlord’s
consent executed in favor of Collateral Agent in respect of all of Borrower’s and each Subsidiaries’ leased locations; 

(l)    a bailee waiver executed in favor of Collateral Agent in respect of each third party bailee where
Borrower or any Subsidiary maintains Collateral having a book value in excess of Two Hundred Fifty Thousand Dollars ($250,000.00); 

(m)    a payoff letter from MidCap Financial Trust in respect of the Existing Indebtedness; 

(n)    evidence that (i) the Liens securing the Existing Indebtedness will be terminated and
(ii) the documents and/or filings evidencing the perfection of such Liens, including without limitation any financing statements and/or control agreements, have or will, concurrently with the initial Credit Extension, be terminated; and 

(o)    an Automatic Debit Authorization. 

3.2    Conditions Precedent to all Credit Extensions. The obligation of each Lender to
extend each Credit Extension, including the Term A-1 Loan, is subject to the following conditions precedent: 

(a)    receipt by Collateral Agent of (i) an executed Loan Payment Request Form in the form of
EXHIBIT B-1 attached hereto and (ii) an executed Disbursement Letter in the form of EXHIBIT B-2 attached hereto; 

(b)    the representations and warranties in Section 5 hereof shall be true, accurate and complete in
all material respects on the date of each Loan Payment Request Form and the date of each Disbursement Letter and the Funding Date of each Term Loan; provided, however, that such materiality qualifier shall not be applicable to any representations
and warranties that already are qualified or modified by materiality in the text thereof; and provided, further that those representations and warranties expressly referring to a specific date shall be true, accurate and complete in all material
respects as of such date, and no Event of Default shall have occurred and be continuing or result from the funding of such Term Loan; 

(c)    if such Credit Extension is the initial Advance, an audit of Borrower’s accounts, the results
of which must be satisfactory to Bank and which must have been completed prior to the making of the initial Advance and, regardless of the initial Advance, no later than the date that is 180 days after the Effective Date (it being agreed and
understood that Bank may in its sole discretion terminate its commitment under this Agreement to make Advances if the results of such audit are not satisfactory to Bank); 

(d)    if such Credit Extension is the initial Advance, Borrower must be in compliance with its
obligations under 6.6(d), (ii) the full amount of Term A-1 Loan must have been drawn by Borrower and (iii) the security interest granted under this Agreement to Collateral Agent for the ratable benefit of the Lenders must already be effective and
constitute a first priority perfected security interest in the Collateral, subject only to Permitted Liens that are permitted by the terms of this Agreement to have priority to Collateral Agent’s Lien; 

(e)    in such Lender’s reasonable discretion, there has not been any Material Adverse Change; 

(f)    no Event of Default or an event that with the passage of time could result in an Event of Default,
shall exist; 

  
 6 

 (g)    to the extent not delivered at the Effective
Date, duly executed original Secured Promissory Notes and Warrants, in number, form and content acceptable to each Lender, and in favor of each Lender according to its Commitment Percentage, with respect to each Credit Extension made by such Lender
after the Effective Date; 
 (h)    if such Credit Extension is the Term
A-2 Loan, the Term A-1 Loan must already have been drawn or should be drawn contemporaneously with the Term A-2 Loan; 

(i)    if such Credit Extension is the Term B Loan, the Term A-1
Loan and the Term A-2 Loan must already have been drawn; and 

(j)    payment of the fees and Lenders’ Expenses then due as specified in Section 2.5 hereof.

 3.3    Covenant to Deliver. Borrower agrees to deliver to Collateral Agent and the
Lenders each item required to be delivered to Collateral Agent under this Agreement as a condition precedent to any Term Loan. Borrower expressly agrees that the Term Loan made prior to the receipt by Collateral Agent or any Lender of any such item
shall not constitute a waiver by Collateral Agent or any Lender of Borrower’s obligation to deliver such item, and any such Term Loan in the absence of a required item shall be made in each Lender’s sole discretion. 

3.4    Procedures for Borrowing. Subject to the prior satisfaction of all other applicable
conditions to the making of the Credit Extensions set forth in this Agreement, to obtain each Credit Extension, Borrower shall notify the Collateral Agent, with respect to the Term Loans, and the Bank, with respect to the Revolving Line, (each of
which notices shall be irrevocable) by electronic mail, facsimile, or telephone by 12:00 noon New York City time twelve (12) Business Days prior to the date the Credit Extension is to be made (unless a shorter period for such notice is agreed
to by Collateral Agent or Bank, as applicable). Together with any such electronic, facsimile or telephonic notification, Borrower shall deliver to Collateral Agent by electronic mail or facsimile a completed Disbursement Letter and Loan
Advance/Payment Authorization executed by a Responsible Officer or his or her designee. The Collateral Agent may rely on any telephone notice given by a person whom Collateral Agent reasonably believes is a Responsible Officer or designee.
Notwithstanding anything herein or in any other Loan Document to the contrary, the parties agree that Borrower is by its execution hereof hereby requesting the Term A-1 Loan and the Term A-2 Loan to be funded upon the earliest date when they become available, subject to the prior satisfaction of all other applicable conditions, and is accordingly notifying the Collateral Agent. 

 

	4.	 CREATION OF SECURITY INTEREST 

4.1    Grant of Security Interest. Borrower hereby grants Collateral Agent, effective as of
the Funding Date of the first Credit Extension made hereunder, for the ratable benefit of the Lenders, to secure the payment and performance in full of all of the Obligations, a continuing security interest in, and pledges to Collateral Agent, for
the ratable benefit of the Lenders, the Collateral, wherever located, whether now owned or hereafter acquired or arising, and all proceeds and products thereof. If Borrower shall acquire a commercial tort claim (as defined in the Code), Borrower
shall grant to Collateral Agent, for the ratable benefit of the Lenders, a security interest therein and in the proceeds thereof, all upon the terms of this Agreement, with such writing to be in form and substance reasonably satisfactory to
Collateral Agent. 
 If this Agreement is terminated, Collateral Agent’s Lien in the Collateral shall continue until the Obligations
(other than inchoate indemnity obligations) are repaid in full in cash. Upon payment in full in cash of the Obligations (other than inchoate indemnity obligations) and at such time as the Lenders’ obligation to extend the Term Loan has
terminated, Collateral Agent shall, at the sole cost and expense of Borrower, release its Liens in the Collateral and all rights therein shall revert to Borrower. 

4.2    Authorization to File Financing Statements. Borrower hereby authorizes Collateral
Agent, from and after the Funding Date of the first Credit Extension made hereunder, to file financing statements or take any other action required to perfect Collateral Agent’s security interests in the Collateral,

  
 7 

 
without notice to Borrower, with all appropriate jurisdictions to perfect or protect Collateral Agent’s interest or rights under the Loan Documents. 

 

	5.	 REPRESENTATIONS AND WARRANTIES 

Borrower represents and warrants to Collateral Agent and the Lenders as follows: 

5.1    Due Organization, Authorization: Power and Authority. Borrower and each of its
Subsidiaries is duly existing and in good standing as a Registered Organization in its jurisdictions of organization or formation and Borrower and each of its Subsidiaries is qualified and licensed to do business and is in good standing in any
jurisdiction in which the conduct of its businesses or its ownership of property requires that it be qualified except where the failure to do so could not reasonably be expected to have a Material Adverse Change. In connection with this Agreement,
Borrower and each of its Subsidiaries has delivered to Collateral Agent a completed perfection certificate and any updates or supplements thereto on or before the Effective Date (each a “Perfection Certificate” and collectively, the
“Perfection Certificates”). Borrower represents and warrants that all the information set forth on the Perfection Certificates pertaining to Borrower and each of its Subsidiaries is accurate and complete as of the Effective Date or
as of the date of the most recently delivered update or supplement delivered by Borrower to Collateral Agent in accordance with the terms hereof. 

The execution, delivery and performance by Borrower and each of its Subsidiaries of the Loan Documents to which it is a party have been duly
authorized, and do not (i) conflict with any of Borrower’s or such Subsidiaries’ organizational documents, including its respective Operating Documents, (ii) contravene, conflict with, constitute a default under or violate any
material Requirement of Law applicable thereto, (iii) contravene, conflict or violate any applicable order, writ, judgment, injunction, decree, determination or award of any Governmental Authority by which Borrower or such Subsidiary, or any of
their property or assets may be bound or affected, (iv) require any action by, filing, registration, or qualification with, or Governmental Approval from, any Governmental Authority (except such Governmental Approvals which have already been
obtained and are in full force and effect) or are being obtained pursuant to Section 6.1(b), or (v) constitute an event of default under any material agreement by which Borrower or any of such Subsidiaries, or their respective properties,
is bound. Neither Borrower nor any of its Subsidiaries is in default under any agreement to which it is a party or by which it or any of its assets is bound in which such default could reasonably be expected to have a Material Adverse Change. 

5.2    Collateral. 

(a)    Borrower and each its Subsidiaries have good title to, have rights in, and the power to transfer
each item of the Collateral upon which it purports to grant a Lien under the Loan Documents, free and clear of any and all Liens except Permitted Liens and, prior to the Funding Date of the initial Credit Extension, Liens securing Existing
Indebtedness, and neither Borrower nor any of its Subsidiaries have any Deposit Accounts, Securities Accounts, Commodity Accounts or other investment accounts other than the Collateral Accounts or the other investment accounts, if any, described in
the Perfection Certificates delivered to Collateral Agent in connection herewith with respect of which Borrower or such Subsidiary has given Collateral Agent notice and taken such actions as are necessary to give Collateral Agent a perfected
security interest therein. The Accounts are bona fide, existing obligations of the Account Debtors. 

(b)    The Eligible Accounts are bona fide existing obligations. The property or services giving rise to
such Eligible Accounts has been delivered or rendered to the Account Debtor or its agent for immediate shipment to and unconditional acceptance by the Account Debtor. Borrower has not received notice of an actual or imminent Insolvency Proceeding of
any Account Debtor whose accounts are included in any Borrowing Base Certificate as an Eligible Account. No licenses or agreements giving rise to such Eligible Accounts is with any Prohibited Territory or with any Person organized under or doing
business in a Prohibited Territory. All Inventory is in all material respects of good and merchantable quality, free from all material defects, except for Inventory for which adequate reserves have been made. 

(c)    The security interest granted herein, which shall become effective as of the Funding Date of the
first Credit Extension made under this Agreement, once effective shall at all times continue to be a first priority perfected security interest in the Collateral, subject only to Permitted Liens that are permitted by the terms of this Agreement to
have priority to Collateral Agent’s Lien. 

  
 8 

 (d)    On the Effective Date, and except as disclosed on
the Perfection Certificate (i) the Collateral is not in the possession of any third party bailee, and (ii) no such third party bailee possesses components of the Collateral in excess of Two Hundred Fifty Thousand Dollars ($250,000.00).

 (e)    All Inventory and Equipment is in all material respects of good and marketable quality, free
from material defects. 
 (f)    Borrower and each of its Subsidiaries is the sole owner of the
Intellectual Property each respectively purports to own, free and clear of all Liens other than Permitted Liens and, prior to the Funding Date of the initial Credit Extension, Liens securing Existing Indebtedness. Except as noted on the Perfection
Certificates delivered to Collateral Agent as of the Effective Date, and as updated from time to time with respect hereto in accordance with the terms hereof, neither Borrower nor any of its Subsidiaries is a party to, nor is bound by, any material
license or other Material Agreement. 
 5.3    Litigation. Except as disclosed on the
Perfection Certificate, there are no actions, suits, investigations, or proceedings pending or, to the Knowledge of the Responsible Officers, threatened in writing by or against Borrower or any of its Subsidiaries involving more than Two Hundred
Fifty Thousand Dollars ($250,000.00) or a claim for infringement of any intellectual property. Except as disclosed on the Perfection Certificate, there are no actions, suits, investigations or proceedings pending or, to the Knowledge of the
Responsible Officers, threatened in writing by or against Borrower or any Subsidiaries involving challenges to the validity of the Intellectual Property. 

5.4    No Material Adverse Change; Financial Statements. All consolidated financial
statements for Borrower and its Subsidiaries, delivered to Collateral Agent fairly present, in conformity with GAAP, in all material respects the consolidated financial condition of Borrower and its Subsidiaries, and the consolidated results of
operations of Borrower and its Subsidiaries. Since the date of the most recent financial statements submitted to any Lender, there has not been a Material Adverse Change. 

5.5    Solvency. Borrower and each of its Subsidiaries, when taken as a whole, is Solvent.

 5.6    Regulatory Compliance. Neither Borrower nor any of its Subsidiaries is an
“investment company” or a company “controlled” by an “investment company” under the Investment Company Act of 1940, as amended. Neither Borrower nor any of its Subsidiaries is engaged as one of its important activities
in extending credit for margin stock (under Regulations X, T and U of the Federal Reserve Board of Governors). Borrower and each of its Subsidiaries has complied in all material respects with the Federal Fair Labor Standards Act. Neither Borrower
nor any of its Subsidiaries is a “holding company” or an “affiliate” of a “holding company” or a “subsidiary company” of a “holding company” as each term is defined and used in the Public Utility
Holding Company Act of 2005. Neither Borrower nor any of its Subsidiaries has violated any laws, ordinances or rules, the violation of which could reasonably be expected to have a Material Adverse Change. Neither Borrower’s nor any of its
Subsidiaries’ properties or assets has been used by Borrower or such Subsidiary or, to Borrower’s Knowledge, by previous Persons, in disposing, producing, storing, treating, or transporting any hazardous substance other than in material
compliance with applicable laws. Borrower and each of its Subsidiaries has obtained all consents, approvals and authorizations of, made all declarations or filings with, and given all notices to, all Governmental Authorities that are necessary to
continue their respective businesses as currently conducted. 
 None of Borrower, any of its Subsidiaries, or any of
Borrower’s or its Subsidiaries’ Affiliates or any of their respective agents acting or benefiting in any capacity in connection with the transactions contemplated by this Agreement is (i) in violation of any Anti-Terrorism Law,
(ii) engaging in or conspiring to engage in any transaction that evades or avoids, or has the purpose of evading or avoiding or attempts to violate, any of the prohibitions set forth in any Anti-Terrorism Law, or (iii) is a Blocked Person.
None of Borrower, any of its Subsidiaries, or to the Knowledge of Borrower and any of their Affiliates or agents, acting or benefiting in any capacity in connection with the transactions contemplated by this Agreement, (x) conducts any business
or engages in making or receiving any contribution of funds, goods or services to or for the benefit of any Blocked Person, or (y) deals in, or otherwise engages in any transaction relating to, any property or interest in property blocked
pursuant to Executive Order No. 13224, any similar executive order or other Anti-Terrorism Law. 

5.7    Investments. Neither Borrower nor any of its Subsidiaries owns any stock, shares,
partnership interests or other equity securities except for Permitted Investments. 

  
 9 

 5.8    Tax Returns and Payments; Pension
Contributions. Borrower and each of its Subsidiaries has (i) timely filed all required tax returns and reports, and Borrower and each of its Subsidiaries, and (ii) has timely paid all foreign, federal, state, and material local taxes,
assessments, deposits and contributions owed by Borrower and such Subsidiaries, in each case of (i) and (ii), in an amount greater than Twenty-Five Thousand Dollars ($25,000.00), in all jurisdictions in which Borrower or any such Subsidiary is
subject to taxes, including the United States, unless such taxes are being contested in accordance with the next sentence. Borrower and each of its Subsidiaries, may defer payment of any contested taxes, provided that Borrower or such Subsidiary in
good faith contests its obligation to pay the taxes by appropriate proceedings promptly and diligently instituted and conducted. Neither Borrower nor any of its Subsidiaries is aware of any claims or adjustments proposed for any of Borrower’s
or such Subsidiaries’ prior tax years which could result in additional taxes (in an amount greater than Twenty-Five Thousand Dollars ($25,000.00)) becoming due and payable by Borrower or its Subsidiaries. Borrower and each of its Subsidiaries
have paid all amounts necessary to fund all present pension, profit sharing and deferred compensation plans in accordance with their terms, and neither Borrower nor any of its Subsidiaries have, withdrawn from participation in, and have not
permitted partial or complete termination of, or permitted the occurrence of any other event with respect to, any such plan which could reasonably be expected to result in any liability of Borrower or its Subsidiaries, including any liability to the
Pension Benefit Guaranty Corporation or its successors or any other Governmental Authority.  

5.9    Use of Proceeds. Borrower shall use the proceeds of the Term Loan solely as working
capital and to fund its general business requirements in accordance with the provisions of this Agreement, and not for personal, family, household or agricultural purposes. A portion of the proceeds of the Term
A-1 Loans shall be used by Borrower to repay the Existing Indebtedness in full on the Funding Date of the Term A-1 Loans. 

5.10    Full Disclosure. No written representation, warranty or other statement of Borrower
or any of its Subsidiaries in any certificate or written statement given to Collateral Agent or any Lender, as of the date such representation, warranty, or other statement was made, taken together with all such written certificates and written
statements given to Collateral Agent or any Lender, contains any untrue statement of a material fact or omits to state a material fact necessary to make the statements contained in the certificates or statements not misleading (it being recognized
that projections and forecasts provided by Borrower in good faith and based upon reasonable assumptions are not viewed as facts and that actual results during the period or periods covered by such projections and forecasts may differ from the
projected or forecasted results). 
  

	6.	 AFFIRMATIVE COVENANTS 

Borrower shall, and shall cause each of its Subsidiaries to, do all of the following:  

6.1    Government Compliance. 

(a)    Maintain its and all its Subsidiaries’ legal existence and good standing in their respective
jurisdictions of organization and maintain qualification in each jurisdiction in which the failure to so qualify could reasonably be expected to have a Material Adverse Change. Comply with all laws, ordinances and regulations to which Borrower or
any of its Subsidiaries is subject, the noncompliance with which could reasonably be expected to have a Material Adverse Change. 

(b)    Obtain and keep in full force and effect, all of the material Governmental Approvals necessary for
the performance by Borrower and its Subsidiaries of their respective businesses and obligations under the Loan Documents and the grant of a security interest to Collateral Agent for the ratable benefit of the Lenders, in all of the Collateral. 

6.2    Financial Statements, Reports, Certificates; Notices. 

(a)    Deliver to Collateral Agent and each Lender: 

(i)    (A) as soon as available, but no later than thirty (30) days after the last day of each
month, a company prepared income statement and cash burn statement covering the consolidated operations of Borrower and its Subsidiaries for such month certified by a Responsible Officer and in a form reasonably acceptable

  
 10 

 
to Collateral Agent and (B) as soon as available, but no later than forty-five (45) days after the last day of each quarter a company prepared consolidated and consolidating balance
sheet, income statement and cash flow statement covering the consolidated operations of Borrower and its Subsidiaries for such quarter certified by a Responsible Officer and in a form reasonably acceptable to Collateral Agent; 

(ii)    as soon as available, but no later than one hundred twenty (120) days after the last day of
Borrower’s fiscal year or within five (5) days of filing with the Securities and Exchange Commission, audited consolidated financial statements prepared under GAAP, consistently applied, together with an unqualified opinion on the
financial statements from an independent certified public accounting firm acceptable to Collateral Agent in its reasonable discretion; 

(iii)    as soon as available after approval thereof by Borrower’s board of directors, but no later
than the earlier of ten (10) days after such approval and forty-five (45) days after the last day of Borrower’s fiscal year, Borrower’s annual (A) financial projections and (B) budget, in each case, for the entire
current fiscal year as approved by Borrower’s board of directors; provided that, any board approved revisions to such projections and/or budget approved by Borrower’s board of directors shall be delivered to Collateral Agent and the
Lenders no later than seven (7) days after such approval; 
 (iv)    within five (5) days of
delivery, copies of all non-ministerial statements, reports and notices made available to Borrower’s board of directors, security holders or holders of Subordinated Debt; 

(v)    in the event that Borrower becomes subject to the reporting requirements under the Securities
Exchange Act of 1934, as amended, within five (5) days of filing, all reports on Form 10-K, 10-Q and 8-K filed with the
Securities and Exchange Commission; 
 (vi)    prompt notice of any amendments of or other changes to
the capitalization table of Borrower and to the Operating Documents of Borrower or any of its Subsidiaries, together with any copies reflecting such amendments or changes with respect thereto; 

(vii)    as soon as available, but no later than thirty (30) days after the last day of each month,
copies of the month-end account statements for each Collateral Account maintained by Borrower or its Subsidiaries, provided that (x) Borrower shall cause such statements to be provided to Collateral Agent
and each Lender by the applicable institution(s), by virtue of the inclusion of the same in any control agreement(s) delivered by such institution(s); 

(viii)    prompt delivery of (and in any event within five (5) days after the same are sent or
received) copies of all material correspondence, reports, documents and other filings with any Governmental Authority that could reasonably be expected to have a material adverse effect on any of the Governmental Approvals material to
Borrower’s business or otherwise could reasonably be expected to have a Material Adverse Change; 

(ix)    prompt notice of any event that (A) could reasonably be expected to materially and adversely
affect the Borrower’s Intellectual Property and (B) could reasonably be expected to result in a Material Adverse Change; 

(x)    written notice at least (10) days’ prior to Borrower’s creation of a New Subsidiary
in accordance with the terms of Section 6.10; 
 (xi)    prompt written notice upon
Borrower’s (A) adding any new offices or business locations, including warehouses (unless such new offices or business locations contain less than Two Hundred and Fifty Thousand Dollars ($250,000.00) in assets or property of Borrower or
any of its Subsidiaries), (B) changing its jurisdiction of organization, (C) changing its organizational structure or type, (D) changing its legal name, or (E) changing any organizational number (if any) assigned by its jurisdiction
of organization; 
 (xii)    upon Borrower becoming aware of the existence of any Event of Default or
event which, with the giving of notice or passage of time, or both, would constitute an Event of Default, prompt (and in any 

  
 11 

 
event within three (3) Business Days) written notice of such occurrence, which such notice shall include a reasonably detailed description of such Event of Default or event which, with the
giving of notice or passage of time, or both, would constitute an Event of Default; 

(xiii)    immediate notice if Borrower or such Subsidiary has Knowledge that Borrower, or any Subsidiary
or Affiliate of Borrower, is listed on the OFAC Lists or (a) is convicted on, (b) pleads nolo contendere to, (c) is indicted on, or (d) is arraigned and held over on charges involving money laundering or predicate crimes
to money laundering; 
 (xiv)    notice of any commercial tort claim which could result in proceeds to
the Borrower in excess of Two Hundred and Fifty Thousand Dollars ($250,000.00) and of the general details thereof; 

(xv)    if Borrower or any of its Subsidiaries is not now a Registered Organization but later becomes
one, written notice of such occurrence and information regarding such Person’s organizational identification number within seven (7) Business Days of receiving such organizational identification number; and 

(xvi)    other information as reasonably requested by Collateral Agent or any Lender. 

Notwithstanding the foregoing, documents required to be delivered pursuant to the terms hereof (to the extent any such documents are included
in materials otherwise filed with the Securities and Exchange Commission) may be delivered electronically and if so delivered, shall be deemed to have been delivered on the date on which Borrower posts such documents, or provides a link thereto, on
Borrower’s website on the internet at Borrower’s website address. 
 (b)    Concurrently with
the delivery of the financial statements specified in Section 6.2(a)(i)(A), deliver to Collateral Agent and each Lender: 

(i)    a duly completed Compliance Certificate signed by a Responsible Officer; 

(ii)    after the first Advance hereunder has been made, a Borrowing Base Certificate signed by a
Responsible Officer, together with detailed aged listings by invoice date of accounts receivable and accounts payable; provided, however, such a Borrowing Base Certificate along with detailed aged listings by invoice date of accounts receivable and
accounts payable shall also be delivered five (5) Business Days in advance of first Advance made hereunder; 

(iii)    copies of any material Governmental Approvals obtained by Borrower or any of its Subsidiaries;

 (iv)    written notice of the commencement of, and any material development in, the proceedings
contemplated by Section 5.8 hereof; 
 (v)    written notice of any litigation or governmental
proceedings pending or threatened (in writing) against Borrower or any of its Subsidiaries, which could reasonably be expected to result in damages or costs to Borrower or any of its Subsidiaries of more than Two Hundred and Fifty Thousand Dollars
($250,000.00); and 
 (vi)    written notice of all returns, recoveries, disputes and claims regarding
Inventory that involve more than Two Hundred and Fifty Thousand Dollars ($250,000.00) individually or in the aggregate in any calendar year. 

(c)    Keep proper, complete and true books of record and account in accordance with GAAP in all material
respects. Borrower shall, and shall cause each of its Subsidiaries to, allow, at the sole cost of Borrower, Collateral Agent or any Lender, during regular business hours upon reasonable prior notice (provided that no notice shall be required when an
Event of Default has occurred and is continuing), to visit and inspect any of its properties, to examine and make abstracts or copies from any of its books and records, and to conduct a collateral audit and analysis of its operations and the
Collateral. Such audits shall be conducted no more often than once every year unless 

  
 12 

 
(and more frequently if) an Event of Default has occurred and is continuing. Notwithstanding the foregoing, upon request of any Lender, but not more frequently than annually, unless an Event of
Default has occurred and is continuing, Borrower agrees to permit Collateral Agent or such Lender to communicate with Borrower’s accounting firm with respect to the consolidated financial statements delivered pursuant to this Section 6.2.

 (d)    Concurrently with the delivery of the financial statements specified in
Section 6.2(a)(i)(B), deliver to Collateral Agent and each Lender, an updated Perfection Certificate to reflect any amendments, modifications and updates to certain information in the Perfection Certificate after the Effective Date to the
extent such amendments, modifications and updates are permitted by one or more specific provisions in this Agreement; in each case, subject to the review and approval of Collateral Agent and each Lender. 

(e)    Concurrently with the delivery of the financial statements specified in Section 6.2(a)(ii),
deliver to Bank a detailed listing of each Account Debtor and each such Account Debtor’s contact information 

6.3    Inventory; Returns. Keep all Inventory in good and marketable condition, free from
material defects. Returns and allowances between Borrower, or any of its Subsidiaries, and their respective Account Debtors shall follow Borrower’s, or such Subsidiary’s, customary practices as they exist at the Effective Date. 

6.4    Taxes; Pensions. Timely file and require each of its Subsidiaries to timely file, all
required tax returns and reports and timely pay, and require each of its Subsidiaries to timely pay, all federal, state and material foreign and local taxes, assessments, deposits and contributions owed by Borrower or its Subsidiaries, except as
otherwise permitted pursuant to the terms of Section 5.8 hereof, and shall deliver to Collateral Agent and each Lender, on demand, appropriate certificates attesting to such payments, and pay all amounts necessary to fund all present pension,
profit sharing and deferred compensation plans in accordance with the terms of such plans. 

6.5    Insurance. Keep Borrower’s and its Subsidiaries’ business and the
Collateral insured for risks and in amounts standard for companies in Borrower’s and its Subsidiaries’ industry and location and as Collateral Agent may reasonably request, including, but not limited to, D&O insurance reasonably
satisfactory to Collateral Agent. Insurance policies shall be in a form, with companies, and in amounts that are reasonably satisfactory to Collateral Agent and Lenders. All property policies shall have a lender’s loss payable endorsement
showing Collateral Agent as lender loss payee and waive subrogation against Collateral Agent, and all liability policies shall show, or have endorsements showing, Collateral Agent, as additional insured. Effective as of the Funding Date of the first
Credit Extension made under this Agreement, the Collateral Agent shall be named as lender loss payee and/or additional insured with respect to any such insurance providing coverage in respect of any Collateral, and each provider of any such
insurance shall agree, by endorsement upon the policy or policies issued by it or by independent instruments furnished to the Collateral Agent, that it will give the Collateral Agent thirty (30) days’ prior written notice before any such
policy or policies shall be materially altered or canceled (other than cancellation for non-payment of premiums, for which ten (10) days’ prior written notice shall be required). At Collateral
Agent’s request, Borrower shall deliver certified copies of policies and evidence of all premium payments. Proceeds payable under any policy shall, at Collateral Agent’s option, be payable to Collateral Agent, for the ratable benefit of
the Lenders, on account of the Obligations. Notwithstanding the foregoing, (a) so long as no Event of Default has occurred and is continuing, Borrower shall have the option of applying the proceeds of any casualty policy within 180 days of
receipt thereof up to Two Hundred Fifty Thousand Dollars ($250,000.00) with respect to any loss, but not exceeding Three Hundred Thousand Dollars ($300,000.00), in the aggregate for all losses under all casualty policies in any one year, toward the
replacement or repair of destroyed or damaged property; provided that any such replaced or repaired property (i) shall be of equal or like value as the replaced or repaired Collateral and (ii) shall be deemed Collateral in which Collateral
Agent has been granted a first priority security interest, and (b) after the occurrence and during the continuance of an Event of Default, all proceeds payable under such casualty policy shall, at the option of Collateral Agent, be payable to
Collateral Agent, for the ratable benefit of the Lenders, on account of the Obligations. If Borrower or any of its Subsidiaries fails to obtain insurance as required under this Section 6.5 or to pay any amount or furnish any required proof of
payment to third persons, Collateral Agent and/or any Lender may make (but has no 

  
 13 

 
obligation to do so), at Borrower’s expense, all or part of such payment or obtain such insurance policies required in this Section 6.5, and take any action under the policies
Collateral Agent or such Lender deems prudent. 
 6.6    Operating Accounts. 

(a)    From and after the date ninety (90) days from the Effective Date, Borrower shall maintain its,
and its Domestic Subsidiaries’, domestic depository and operating accounts with Bank, subject to a Control Agreement in favor of, and in form and content acceptable to, Collateral Agent; provided, however, that during such ninety (90) day
period, all Collateral Accounts maintained with any bank or financial institution shall be subject to one or more Control Agreements in favor of Collateral Agent that are in such form and substance as are acceptable to Collateral Agent. 

(b)    Borrower shall provide Collateral Agent ten (10) days’ prior written notice before
Borrower or any of its Subsidiaries establishes any Collateral Account. In addition, for each Collateral Account that Borrower or any of its Subsidiaries at any time maintains, commencing with the Funding Date of the first Credit Extension made
hereunder, Borrower or such Subsidiary shall cause the applicable bank or financial institution at or with which such Collateral Account is maintained to execute and deliver a Control Agreement or other appropriate instrument with respect to such
Collateral Account to perfect Collateral Agent’s Lien in such Collateral Account in accordance with the terms hereunder prior to the establishment of such Collateral Account, which Control Agreement may not be terminated without prior written
consent of Collateral Agent. The provisions of the previous sentence shall not apply to deposit accounts exclusively used for payroll, payroll taxes and other employee wage and benefit payments to or for the benefit of Borrower’s, or any of its
Subsidiaries’, employees and identified to Collateral Agent by Borrower as such in the Perfection Certificate. 

(c)    Neither Borrower nor any of its Subsidiaries shall maintain any Collateral Accounts except
Collateral Accounts maintained in accordance with Section 6.6. 
 (d)    Lock Box; Dominion of
Funds. Without liming any of the foregoing: 
 (i)    Borrower agrees that the Obligations with
respect to the Revolving Line shall be on a “remittance basis.” Borrower shall at its sole expense establish and maintain (and Bank, at Bank’s option, may establish and maintain at Borrower’s expense), prior to the Funding Date
of the initial Advance and no later than ninety (90) days from the Effective Date: 

(1)    A United States Post Office lock box (the “Lock Box”), to which Bank shall
have exclusive access and control. Borrower expressly authorizes Bank, from time to time, to remove the contents from the Lock Box, for disposition in accordance with this Agreement. Borrower shall notify all account debtors and other parties
obligated to Borrower that all payments made to Borrower (other than payments by electronic funds transfer) shall be remitted, for the credit of Borrower, to the Lock Box, and Borrower shall include a like statement on all invoices; and 

(2)    A non-interest bearing deposit account with Bank
which shall be titled as designated by Bank (the “Dominion of Funds Account”) to which Bank shall have exclusive access and control. Borrower shall notify all account debtors and other parties obligated to Borrower that all payments made
to Borrower by electronic funds transfer shall be remitted to the Dominion of Funds Account, and Borrower, at Bank’s request, shall include a like statement on all invoices. Borrower shall execute all documents and authorizations as required by
Bank to establish and maintain the Lock Box and the Dominion of Funds Account. 
 (ii)    Borrower
shall hold in trust for Bank all amounts that Borrower receives despite the directions to make payments to the Lock Box or Dominion of Funds Account, and immediately deliver such payments to Bank in their original form as received from the account
debtor, with proper endorsements for deposit into the Lock Box or Dominion of Funds Account, as applicable; 

(iii)    All items or amounts which are remitted to the Dominion of Funds Account, or otherwise delivered
by or for the benefit of Borrower to Bank on account of partial or full payment of, or with respect to, any Collateral shall, on a daily basis, be applied to the payment of outstanding Advances, whether then due or not,

  
 14 

 
with the balance, if any, deposited to Borrower’s operating account maintained at Bank. After the occurrence and during the continuance of an Event of Default, all items or amounts remitted
to the Lock Box, the Dominion of Funds Account or that Bank has otherwise received shall, in Bank’s sole discretion, be applied to the payment of any Obligations, whether then due or not, in such order or at such time of application as Bank may
determine in its sole discretion. Bank shall not be liable for any loss or damage which Borrower may suffer as a result of Bank’s processing of items or its exercise of any other rights or remedies under this Agreement, including without
limitation indirect, special or consequential damages, loss of revenues or profits, or any claim, demand or action by any third party arising out of or in connection with the processing of items or the exercise of any other rights or remedies under
this Agreement. Borrower shall indemnify and hold Bank harmless from and against all such third party claims, demands or actions, and all related expenses or liabilities, including, without limitation, attorney’s fees and including claims,
damages, fines, expenses, liabilities or causes of action of whatever kind resulting from bank’s own negligence except to the extent (but only to the extent) caused by Bank’s gross negligence or willful misconduct. 

6.7    Protection of Intellectual Property Rights. Borrower and each of its Subsidiaries
shall: (a) protect, defend and maintain the validity and enforceability of its Intellectual Property that is material to its business; (b) promptly advise Collateral Agent in writing of a challenge to the validity, or material infringement
by a third party of its Intellectual Property; and (c) not allow any Intellectual Property material to its business to be abandoned, forfeited or dedicated to the public without Collateral Agent’s prior written consent, not to be
unreasonably withheld. If Borrower or any of its Subsidiaries (i) obtains any patent, registered trademark or servicemark, registered copyright, registered mask work, or any pending application for any of the foregoing, whether as owner,
licensee or otherwise, or (ii) applies for any patent or the registration of any trademark or servicemark, then Borrower or such Subsidiary shall substantially contemporaneously provide written notice thereof to Collateral Agent and each Lender
and shall execute such intellectual property security agreements and other documents and take such other actions as Collateral Agent shall reasonably request in its good faith business judgment to perfect and maintain a first priority perfected
security interest in favor of Collateral Agent, for the ratable benefit of the Lenders, in such property. If Borrower or any of its Subsidiaries decides to register any copyrights or mask works in the United States Copyright Office, Borrower or such
Subsidiary shall: (x) provide Collateral Agent and each Lender with at least ten (10) days prior written notice of Borrower’s or such Subsidiary’s intent to register such copyrights or mask works together with a copy of the
application it intends to file with the United States Copyright Office (excluding exhibits thereto); (y) execute an intellectual property security agreement and such other documents and take such other actions as Collateral Agent may reasonably
request in its good faith business judgment to perfect and maintain a first priority perfected security interest in favor of Collateral Agent, for the ratable benefit of the Lenders, in the copyrights or mask works intended to be registered with the
United States Copyright Office; and (z) record such intellectual property security agreement with the United States Copyright Office contemporaneously with filing the copyright or mask work application(s) with the United States Copyright
Office. Borrower or such Subsidiary shall promptly provide to Collateral Agent and each Lender with evidence of the recording of the intellectual property security agreement necessary for Collateral Agent to perfect and maintain a first priority
perfected security interest in such property. 
 6.8    Litigation Cooperation. Commencing
on the Effective Date and continuing through the termination of this Agreement, make available to Collateral Agent and the Lenders, without expense to Collateral Agent or the Lenders, Borrower and each of Borrower’s officers, employees and
agents and Borrower’s Books, to the extent that Collateral Agent or any Lender may reasonably deem them necessary to prosecute or defend any third-party suit or proceeding instituted by or against Collateral Agent or any Lender with respect to
any Collateral or relating to Borrower. 
 6.9    Landlord Waivers; Bailee Waivers. In the
event that Borrower or any of its Subsidiaries, after the Funding Date of the first Credit Extension made under this Agreement, intends to add any new offices or business locations, including warehouses, or otherwise store any portion of the
Collateral with, or deliver any portion of the Collateral to, a bailee, in each case pursuant to Section 7.2, then Borrower or such Subsidiary will first receive the written consent of Collateral Agent and, in the event that the Collateral at
any new location is valued in excess of Two Hundred Fifty Thousand Dollars ($250,000.00) in the aggregate, at Collateral Agent’s election, Borrower shall cause such bailee or landlord, as applicable, to execute and deliver a bailee waiver or
landlord waiver, as applicable, in form and substance reasonably satisfactory to Collateral Agent no later than fifteen (15) days after the addition of any new offices or business locations, or any such storage with or delivery to any such
bailee, as the case may be. 

  
 15 

 6.10    Creation/Acquisition of
Subsidiaries. In the event any Borrower or any Subsidiary of any Borrower creates or acquires any Subsidiary after the Effective Date, Borrower or such Subsidiary shall promptly notify Collateral Agent of such creation or acquisition, and
Borrower or such Guarantor shall take all actions reasonably requested by Collateral Agent to achieve any of the following with respect to such “New Subsidiary” (defined as a Subsidiary formed after the date hereof during the term
of this Agreement): (i) to cause such New Subsidiary to become either a co-Borrower hereunder or a secured guarantor with respect to the Obligations, if such New Subsidiary is organized under the laws of the
United States; and (ii) to grant and pledge to Collateral Agent a perfected security interest in the Shares of such New Subsidiary. 

6.11    Financial Covenant. Borrower shall achieve the following TTM Revenue, as determined
by Collateral Agent: 
 (a)    As tested on June 30, 2019, September 30, 2019 and
December 31, 2019, actual TTM Revenue for the 12-month period then ended in an amount not less than eighty-five percent (85.00%) of the projections for the same
12-month period as then ended as set forth in the Management Plan; and 

(b)    As tested on the last date of each quarter starting with the quarter ending March 31, 2020,
actual TTM Revenue for the 12-month period then ended in an amount not less than seventy-five percent (75.00%) of the projections for the same 12-month period as then
ended as set forth in the Management Plan. 
 6.12    Liquidity Covenant. Effective as of
the Funding Date of the first Credit Extension made under this Agreement, Borrower shall at all times maintain in a Collateral Account subject to a Control Agreement in favor of Collateral Agent a cash balance of not less than an amount equal to:
(i) the greater of (A) Three Million Dollars ($3,000,000.00) or (B) the Cash Burn of Borrower in the immediately preceding three months, minus (ii) such amount of Revolving Line (if any) as is then available to Borrower but has
not been drawn by the Borrower; provided, however, the cash balance in such aforementioned Collateral Account shall not be less than Two Million Dollars ($2,000,000.00) at any given time. 

6.13    Further Assurances. Execute any further instruments and take further action as
Collateral Agent or any Lender reasonably requests to perfect or continue Collateral Agent’s Lien in the Collateral or to effect the purposes of this Agreement, including without limitation, permit Collateral Agent or any Lender to discuss
Borrower’s financial condition with Borrower’s accountants. 
  

	7.	 NEGATIVE COVENANTS 

Borrower shall not, and shall not permit any of its Subsidiaries to, do any of the following without the prior written consent of the Required
Lenders:  
 7.1    Dispositions. From and after the Funding Date of the first
Credit Extension made under this Agreement, convey, sell, lease, transfer, assign, dispose of (collectively, “Transfer”), or permit any of its Subsidiaries to Transfer, all or any part of its business or property (including
Intellectual Property), except for Transfers (a) of Inventory in the ordinary course of business; (b) of worn-out, surplus or obsolete Equipment; (c) in connection with Permitted Liens,
Permitted Investments and Permitted Licenses and (d) other assets of Borrower and its Subsidiaries the book value of which does not in the aggregate exceed Two Hundred Fifty Thousand Dollars ($250,000.00) per fiscal year. 

7.2    Changes in Business, Management, Ownership, or Business Locations. (a) Engage in
or permit any of its Subsidiaries to engage in any business other than the businesses engaged in by Borrower as of the Effective Date or reasonably related thereto; (b) liquidate or dissolve; or (c) (i) any Key Person shall cease to be
actively engaged in the management of Borrower unless written notice thereof is provided to Collateral Agent and each Lender within ten (10) days of such, or (ii) enter into any transaction or series of related transactions in which
(A) the stockholders of Borrower who were not stockholders immediately prior to the first such transaction own more than 50% of the voting stock of Borrower immediately after giving effect to such transaction or related series of such
transactions and (B) Borrower ceases to own 100% of the ownership interests of a Subsidiary of Borrower. Borrower shall not, without at least ten (10) days’ prior written notice to Collateral Agent: (A) add any new offices or
business locations, including warehouses (unless such new offices or business locations contain less than Two Hundred Fifty Thousand Dollars ($250,000.00)in assets or property of Borrower or any of its Subsidiaries); (B) change its jurisdiction of
organization, 

  
 16 

 
(C) change its organizational structure or type, (D) change its legal name, or (E) change any organizational number (if any) assigned by its jurisdiction of organization. 

7.3    Mergers or Acquisitions. Merge or consolidate, or permit any of its Subsidiaries to
merge or consolidate, with any other Person, or acquire, or permit any of its Subsidiaries to acquire, all or substantially all of the capital stock, shares or property of another Person. A Subsidiary may merge or consolidate into another Subsidiary
(provided such surviving Subsidiary is a “co-borrower” hereunder or has provided a secured Guaranty of Borrower’s Obligations hereunder) or with (or into) Borrower provided Borrower is the
surviving legal entity, and as long as no Event of Default is occurring prior thereto or arises as a result therefrom. 

7.4    Indebtedness. From and after the Funding Date of the first Credit Extension made
under this Agreement, create, incur, assume, or be liable for any Indebtedness, or permit any Subsidiary to do so, other than Permitted Indebtedness. 

7.5    Encumbrance. From and after the Funding Date of the first Credit Extension made under
this Agreement, create, incur, allow, or suffer any Lien on any of its property, or assign or convey any right to receive income, including the sale of any Accounts, or permit any of its Subsidiaries to do so, except for Permitted Liens, or permit
any Collateral not to be subject to the first priority security interest granted herein (except for Permitted Liens), or enter into any agreement, document, instrument or other arrangement (except with or in favor of Collateral Agent, for the
ratable benefit of the Lenders) with any Person which directly or indirectly prohibits or has the effect of prohibiting Borrower, or any of its Subsidiaries, from assigning, mortgaging, pledging, granting a security interest in or upon, or
encumbering any of Borrower’s or such Subsidiary’s Intellectual Property, except as is otherwise permitted in Section 7.1 hereof and the definition of “Permitted Liens”. 

7.6    Maintenance of Collateral Accounts. Maintain any Collateral Account except pursuant
to the terms of Section 6.6 hereof. 
 7.7    Restricted Payments. From and after the
Funding Date of the first Credit Extension made under this Agreement, pay any dividends (other than dividends payable solely in capital stock) or make any distribution or payment in respect of or redeem, retire or purchase any capital stock (other
than repurchases pursuant to the terms of employee stock purchase plans, employee restricted stock agreements, stockholder rights plans, director or consultant stock option plans, or similar plans, provided such repurchases (i) do not exceed
One Hundred Fifty Thousand Dollars ($150,000.00) in the aggregate per fiscal year or (ii) are transactions for which the consideration is limited to the cancellation of indebtedness owed by such employee, director or consultant to Borrower,
provided further that the aggregate amount of such cancelled indebtedness does not exceed Five Hundred Thousand Dollars ($500,000.00) in any given year, unless consented to by the Required Lenders, which consent shall not be unreasonably withheld.

 7.8    Investments. Directly or indirectly make any Investment other than Permitted
Investments, or permit any of its Subsidiaries to do so. 
 7.9    Transactions with
Affiliates. Directly or indirectly enter into or permit to exist any material transaction with any Affiliate of Borrower or any of its Subsidiaries, except for (a) transactions that are in the ordinary course of Borrower’s or such
Subsidiary’s business, upon fair and reasonable terms that are no less favorable to Borrower or such Subsidiary than would be obtained in an arm’s length transaction with a non-affiliated Person, and
(b) Subordinated Debt or equity investments by Borrower’s investors in Borrower or its Subsidiaries. 

7.10    Subordinated Debt. (a) Make or permit any payment on any Subordinated Debt,
except under the terms of the subordination, intercreditor, or other similar agreement to which such Subordinated Debt is subject, or (b) amend any provision in any document relating to the Subordinated Debt which would increase the amount
thereof or adversely affect the subordination thereof to Obligations owed to the Lenders. 

7.11    Compliance. Become an “investment company” or a company controlled by an
“investment company”, under the Investment Company Act of 1940, as amended, or undertake as one of its important activities extending credit to purchase or carry margin stock (as defined in Regulation U of the Board of Governors of the
Federal Reserve System), or use the proceeds of any Term Loan for that purpose; fail to meet the minimum funding 

  
 17 

 
requirements of ERISA, permit a Reportable Event or Prohibited Transaction, as defined in ERISA, to occur; fail to comply with the Federal Fair Labor Standards Act or violate any other law or
regulation, if the failure to comply or violation could reasonably be expected to have a Material Adverse Change, or permit any of its Subsidiaries to do so; withdraw or permit any Subsidiary to withdraw from participation in, permit partial or
complete termination of, or permit the occurrence of any other event with respect to, any present pension, profit sharing and deferred compensation plan which could reasonably be expected to result in any liability of Borrower or any of its
Subsidiaries, including any liability to the Pension Benefit Guaranty Corporation or its successors or any other Governmental Authority. 

7.12    Compliance with Anti-Terrorism Laws. Neither Borrower nor any of its Subsidiaries
shall, nor shall Borrower or any of its Subsidiaries permit any Affiliate to, directly or indirectly, knowingly enter into any documents, instruments, agreements or contracts with any Person listed on the OFAC Lists. Neither Borrower nor any of its
Subsidiaries shall, nor shall Borrower or any of its Subsidiaries, permit any Affiliate to, directly or indirectly, (i) conduct any business or engage in any transaction or dealing with any Blocked Person, including, without limitation, the
making or receiving of any contribution of funds, goods or services to or for the benefit of any Blocked Person, (ii) deal in, or otherwise engage in any transaction relating to, any property or interests in property blocked pursuant to
Executive Order No. 13224 or any similar executive order or other Anti-Terrorism Law, or (iii) engage in or conspire to engage in any transaction that evades or avoids, or has the purpose of evading or avoiding, or attempts to violate, any
of the prohibitions set forth in Executive Order No. 13224 or other Anti-Terrorism Law. 

7.13    Material Agreements. Borrower shall provide Collateral Agent no less than ten
(10) days’ notice after the termination of any Material Agreement. 
  

	8.	 EVENTS OF DEFAULT 

Any one of the following shall constitute an event of default (an “Event of Default”) under this Agreement: 

8.1     Payment Default. Borrower fails to (a) make any payment of principal or
interest on any Term Loan on its due date, or (b) pay any other Obligations within three (3) Business Days after such Obligations are due and payable (which three (3) Business Day grace period shall not apply to payments due on the
Maturity Date or the date or acceleration pursuant to Section 9.1 (a) hereof); 

8.2    Covenant Default. 

(a)    Borrower or any of its Subsidiaries fails or neglects to perform any obligation in Sections 6.2
(Financial Statements, Reports, Certificates), 6.4 (Taxes), 6.5 (Insurance), 6.6 (Operating Accounts), 6.10 (Creation/Acquisition of Subsidiaries), 6.7 (Protection of Intellectual Property Rights), 6.11 (Financial Covenant) or 6.12 (Minimum
Liquidity) or Borrower violates any provision in Section 7; provided, however, in the event that the Borrower fails to comply with the requirements of the financial covenant set forth in Section 6.11, Collateral Agent may, in its sole
discretion, allow Borrower to cure such breach by means of raising such amount of capital from the sale and issuance of its equity securities during such period of time as Collateral Agent may permit in its sole discretion; or 

(b)    Borrower, or any of its Subsidiaries, fails or neglects to perform, keep, or observe any other
term, provision, condition, covenant or agreement contained in this Agreement or any Loan Documents, and as to any default (other than those specified in this Section 8) under such other term, provision, condition, covenant or agreement that
can be cured, has failed to cure the default within ten (10) days after the occurrence thereof; provided, however, that if the default cannot by its nature be cured within the ten (10) day period or cannot after diligent attempts by
Borrower be cured within such ten (10) day period, and such default is likely to be cured within a reasonable time, then Borrower shall have an additional period (which shall not in any case exceed thirty (30) days) to attempt to cure such
default, and within such reasonable time period the failure to cure the default shall not be deemed an Event of Default (but no Term Loan shall be made during such cure period). 

8.3    Material Adverse Change. A Material Adverse Change has occurred; 

8.4    Attachment; Levy; Restraint on Business. 

  
 18 

 (a)    (i) The service of process seeking to attach, by
trustee or similar process, any funds of Borrower or any of its Subsidiaries or of any entity under control of Borrower or its Subsidiaries on deposit with any institution at which Borrower or any of its Subsidiaries maintains a Collateral Account,
or (ii) a notice of lien, levy, or assessment is filed against Borrower or any of its Subsidiaries or their respective assets by any government agency, and the same under subclauses (i) and (ii) hereof are not, within ten (10) days
after the occurrence thereof, discharged or stayed (whether through the posting of a bond or otherwise); and 

(b)    (i) any material portion of Borrower’s or any of its Subsidiaries’ assets is attached,
seized, levied on, or comes into possession of a trustee or receiver, or (ii) any court order enjoins, restrains, or prevents Borrower or any of its Subsidiaries from conducting any part of its business; 

8.5    Insolvency. (a) Borrower or any of its Subsidiaries is or becomes Insolvent;
(b) Borrower or any of its Subsidiaries begins an Insolvency Proceeding; or (c) an Insolvency Proceeding is begun against Borrower or any of its Subsidiaries and not dismissed or stayed within forty-five (45) days (but no Term Loan
shall be extended while Borrower or any Subsidiary is Insolvent and/or until any Insolvency Proceeding is dismissed); 

8.6    Other Agreements. There is (a) a default in any agreement to which Borrower or
any of its Subsidiaries is a party with a third party or parties resulting in a right by such third party or parties, whether or not exercised, to accelerate the maturity of any Indebtedness in an amount in excess of Two Hundred Fifty Thousand
Dollars ($250,000.00) or could reasonably be expected to have a Material Adverse Change; or (b) any default under a Material Agreement that permits the counterparty thereto to accelerate the payments owed thereunder; 

8.7    Judgments. (a) One or more judgments, orders, or decrees for the payment of
money in an amount, individually or in the aggregate, of at least Two Hundred Fifty Thousand Dollars ($250,000.00) (not covered by independent third-party insurance) shall be rendered against Borrower or any of its Subsidiaries and shall remain
unsatisfied, unvacated, or unstayed for a period of ten (10) days after the entry thereof; or (b) any judgment, orders or decrees rendered against Borrower that could reasonably be expected to result in a Material Adverse Change; 

8.8    Misrepresentations. Borrower or any of its Subsidiaries or any Person acting for
Borrower or any of its Subsidiaries makes any representation, warranty, or other statement now or later in this Agreement, any Loan Document or in any writing delivered to Collateral Agent and/or Lenders or to induce Collateral Agent and/or the
Lenders to enter this Agreement or any Loan Document, and such representation, warranty, or other statement, when taken as a whole, is incorrect in any material respect when made; 

8.9    Subordinated Debt. A default or breach occurs under any agreement between Borrower or
any of its Subsidiaries and any creditor of Borrower or any of its Subsidiaries that signed a subordination, intercreditor, or other similar agreement with Collateral Agent or the Lenders, or any creditor that has signed such an agreement with
Collateral Agent or the Lenders breaches any terms of such agreement; 
 8.10    Guaranty.
(a) Any Guaranty terminates or ceases for any reason to be in full force and effect; (b) any Guarantor does not perform any obligation or covenant under any Guaranty; (c) any circumstance described in Section 8 occurs with
respect to any Guarantor; or (d) a Material Adverse Change with respect to any Guarantor; 

8.11    Governmental Approvals; FDA Action. (a) Any Governmental Approval shall have
been revoked, rescinded, suspended, modified in an adverse manner, or not renewed in the ordinary course for a full term and such revocation, rescission, suspension, modification or non-renewal has resulted in
or could reasonably be expected to result in a Material Adverse Change; or (b) (i) the FDA, DOJ, or other Governmental Authority initiates a Regulatory Action or any other enforcement action against Borrower or any of its Subsidiaries or any
supplier of Borrower or any of its Subsidiaries that causes Borrower or any of its Subsidiaries to recall, withdraw, remove or discontinue manufacturing, distributing, and/or marketing any of its products, even if such action is based on previously
disclosed conduct; (ii) the FDA issues a warning letter or Regulatory Action to Borrower or any of its Subsidiaries with respect to any of its activities or products which could reasonably be expected to result in a Material Adverse Change;
(iii) Borrower or any of its Subsidiaries conducts a mandatory or voluntary recall which could reasonably be expected to result in liability and expense to Borrower or any of its Subsidiaries of Two Hundred Fifty Thousand Dollars ($250,000.00)
or more; (iv) Borrower or any of its Subsidiaries enters into a settlement agreement with the FDA, DOJ, or other Governmental Authority that results in aggregate liability as to any single or related

  
 19 

 
series of transactions, incidents or conditions, of Two Hundred Fifty Thousand Dollars ($250,000.00) or more, or that could reasonably be expected to result in a Material Adverse Change even if
such settlement agreement is based on previously disclosed conduct; or (v) Borrower or any of its Subsidiaries fails to remediate observations identified in an FDA Form 483 notice of inspection observation to Collateral Agent’s reasonable
satisfaction within six months of receipt; or (vi) the FDA revokes any authorization or permission granted under any Registration, or Borrower or any of its Subsidiaries withdraws any Registration, that could reasonably be expected to result in
a Material Adverse Change. 
 8.12    Lien Priority; Intellectual Property. Any Lien
created hereunder or by any other Loan Document shall at any time fail to constitute a valid and perfected Lien on any of the Collateral purported to be secured thereby, subject to no prior or equal Lien, other than Permitted Liens arising as a
matter of applicable law. Any Intellectual Property material to Borrower’s business shall cease to be validly owned or licensed by Borrower free and clear of any Liens other than Permitted Liens. 

 

	9.	 RIGHTS AND REMEDIES 

9.1    Rights and Remedies. 

(a)    From and after the Funding Date of the first Credit Extension made under this Agreement, upon the
occurrence and during the continuance of an Event of Default, Collateral Agent may, without notice or demand, do any or all of the following: (i) deliver notice of the Event of Default to Borrower, (ii) by notice to Borrower declare all
Obligations immediately due and payable (but if an Event of Default described in Section 8.5 occurs all Obligations shall be immediately due and payable without any action by Collateral Agent or the Lenders) or (iii) by notice to Borrower
suspend or terminate the obligations, if any, of the Lenders to advance money or extend credit for Borrower’s benefit under this Agreement or under any other agreement between Borrower and Collateral Agent and/or the Lenders (but if an Event of
Default described in Section 8.5 occurs all obligations, if any, of the Lenders to advance money or extend credit for Borrower’s benefit under this Agreement or under any other agreement between Borrower and Collateral Agent and/or the
Lenders shall be immediately terminated without any action by Collateral Agent or the Lenders). 

(b)    Without limiting the rights of Collateral Agent and the Lenders set forth in Section 9.1(a)
above, from and after the Funding Date of the first Credit Extension made under this Agreement, upon the occurrence and during the continuance of an Event of Default, Collateral Agent shall have the right, without notice or demand, to do any or all
of the following: 
 (i)    foreclose upon and/or sell or otherwise liquidate, the Collateral; 

(ii)    apply to the Obligations any (a) balances and deposits of Borrower that Collateral Agent or
any Lender holds or controls, or (b) any amount held or controlled by Collateral Agent or any Lender owing to or for the credit or the account of Borrower; and/or 

(iii)    commence and prosecute an Insolvency Proceeding or consent to Borrower commencing any Insolvency
Proceeding. 
 (c)    Without limiting the rights of Collateral Agent and the Lenders set forth in
Sections 9.1(a) and (b) above, upon the occurrence and during the continuance of an Event of Default, Collateral Agent shall have the right, without notice or demand, to do any or all of the following: 

(i)    settle or adjust disputes and claims directly with Account Debtors for amounts on terms and in any
order that Collateral Agent considers advisable, notify any Person owing Borrower money of Collateral Agent’s security interest in such funds, and verify the amount of such account; 

(ii)    make any payments and do any acts it considers necessary or reasonable to protect the Collateral
and/or its security interest in the Collateral. Borrower shall assemble the Collateral if Collateral Agent requests and make it available in a location as Collateral Agent reasonably designates. Collateral Agent may enter premises where the
Collateral is located, take and maintain possession of any part of the Collateral, and pay, purchase, contest, or compromise any Lien which appears to be prior or superior to its security interest and pay all expenses

  
 20 

 
incurred. Borrower grants Collateral Agent a license to enter and occupy any of its premises, without charge, to exercise any of Collateral Agent’s rights or remedies; 

(iii)    ship, reclaim, recover, store, finish, maintain, repair, prepare for sale, and/or advertise for
sale, the Collateral. Collateral Agent is hereby granted a non-exclusive, royalty-free license or other right to use, without charge, Borrower’s and each of its Subsidiaries’ labels, Patents,
Copyrights, mask works, rights of use of any name, trade secrets, trade names, Trademarks, service marks, and advertising matter, or any similar property as it pertains to the Collateral, in completing production of, advertising for sale, and
selling any Collateral and, in connection with Collateral Agent’s exercise of its rights under this Section 9.1, Borrower’s and each of its Subsidiaries’ rights under all licenses and all franchise agreements inure to Collateral
Agent, for the benefit of the Lenders; 
 (iv)    place a “hold” on any account maintained
with Collateral Agent or the Lenders and/or deliver a notice of exclusive control, any entitlement order, or other directions or instructions pursuant to any Control Agreement or similar agreements providing control of any Collateral; 

(v)    demand and receive possession of Borrower’s Books; 

(vi)    appoint a receiver to seize, manage and realize any of the Collateral, and such receiver shall
have any right and authority as any competent court will grant or authorize in accordance with any applicable law, including any power or authority to manage the business of Borrower or any of its Subsidiaries; and 

(vii)    subject to clauses 9.1(a) and (b), exercise all rights and remedies available to Collateral
Agent and each Lender under the Loan Documents or at law or equity, including all remedies provided under the Code (including disposal of the Collateral pursuant to the terms thereof). 

Notwithstanding any provision of this Section 9.1 to the contrary, upon the occurrence of any Event of Default, Collateral Agent shall
have the right to exercise any and all remedies referenced in this Section 9.1 without the written consent of Required Lenders following the occurrence of an Exigent Circumstance. 

9.2    Power of Attorney. Effective as of the Funding Date of the first Credit Extension
made under this Agreement, Borrower hereby irrevocably appoints Collateral Agent as its lawful attorney-in-fact, exercisable upon the occurrence and during the
continuance of an Event of Default, to: (a) endorse Borrower’s or any of its Subsidiaries’ name on any checks or other forms of payment or security; (b) sign Borrower’s or any of its Subsidiaries’ name on any invoice or
bill of lading for any Account or drafts against Account Debtors; (c) settle and adjust disputes and claims about the Accounts directly with Account Debtors, for amounts and on terms Collateral Agent determines reasonable; (d) make,
settle, and adjust all claims under Borrower’s insurance policies; (e) pay, contest or settle any Lien, charge, encumbrance, security interest, and adverse claim in or to the Collateral, or any judgment based thereon, or otherwise take any
action to terminate or discharge the same; and (f) transfer the Collateral into the name of Collateral Agent or a third party as the Code or any applicable law permits. Borrower hereby appoints Collateral Agent as its lawful attorney-in-fact to sign Borrower’s or any of its Subsidiaries’ name on any documents necessary to perfect or continue the perfection of Collateral Agent’s
security interest in the Collateral regardless of whether an Event of Default has occurred until all Obligations (other than inchoate indemnity obligations) have been satisfied in full and Collateral Agent and the Lenders are under no further
obligation to extend the Credit Extensions hereunder. Collateral Agent’s foregoing appointment as Borrower’s or any of its Subsidiaries’ attorney in fact, and all of Collateral Agent’s rights and powers, coupled with an interest,
are irrevocable until all Obligations (other than inchoate indemnity obligations) have been fully repaid and performed and Collateral Agent’s and the Lenders’ obligation to provide the Credit Extensions terminates. 

9.3    Protective Payments. If Borrower or any of its Subsidiaries fail to obtain the
insurance called for by Section 6.5 or fails to pay any premium thereon or fails to pay any other amount which Borrower or any of its Subsidiaries is obligated to pay under this Agreement or any other Loan Document, Collateral Agent may obtain
such insurance or make such payment, and all amounts so paid by Collateral Agent are Lenders’ Expenses and immediately due and payable, bearing interest at the Default Rate, and secured by the Collateral. Collateral Agent will make reasonable
efforts to provide Borrower with notice of Collateral Agent obtaining such insurance or making such payment at the time it is obtained or paid or within a reasonable time thereafter. No such payments by Collateral

  
 21 

 
Agent are deemed an agreement to make similar payments in the future or Collateral Agent’s waiver of any Event of Default. 

9.4    Application of Payments and Proceeds. Notwithstanding anything to the contrary
contained in this Agreement, upon the occurrence and during the continuance of an Event of Default, (a) Borrower irrevocably waives the right to direct the application of any and all payments at any time or times thereafter received by
Collateral Agent from or on behalf of Borrower or any of its Subsidiaries of all or any part of the Obligations, and, as between Borrower on the one hand and Collateral Agent and Lenders on the other, Collateral Agent shall have the continuing and
exclusive right to apply and to reapply any and all payments received against the Obligations in such manner as Collateral Agent may deem advisable notwithstanding any previous application by Collateral Agent, and (b) the proceeds of any sale
of, or other realization upon all or any part of the Collateral shall be applied: first, to the Lenders’ Expenses; second, to accrued and unpaid interest on the Obligations (including any interest which, but for the provisions of the United
States Bankruptcy Code, would have accrued on such amounts); third, to the principal amount of the Obligations outstanding; and fourth, to any other indebtedness or obligations of Borrower owing to Collateral Agent or any Lender under the Loan
Documents. Any balance remaining shall be delivered to Borrower or to whoever may be lawfully entitled to receive such balance or as a court of competent jurisdiction may direct. In carrying out the foregoing, (x) amounts received shall be
applied in the numerical order provided until exhausted prior to the application to the next succeeding category, and (y) each of the Persons entitled to receive a payment in any particular category shall receive an amount equal to its pro rata
share of amounts available to be applied pursuant thereto for such category. Any reference in this Agreement to an allocation between or sharing by the Lenders of any right, interest or obligation “ratably,” “proportionally” or
in similar terms shall refer to Pro Rata Share unless expressly provided otherwise. Collateral Agent, or if applicable, each Lender, shall promptly remit to the other Lenders such sums as may be necessary to ensure the ratable repayment of each
Lender’s portion of any Credit Extension and the ratable distribution of interest, fees and reimbursements paid or made by Borrower. Notwithstanding the foregoing, a Lender receiving a scheduled payment shall not be responsible for determining
whether the other Lenders also received their scheduled payment on such date; provided, however, if it is later determined that a Lender received more than its ratable share of scheduled payments made on any date or dates, then such Lender shall
remit to Collateral Agent or other Lenders such sums as may be necessary to ensure the ratable payment of such scheduled payments, as instructed by Collateral Agent. If any payment or distribution of any kind or character, whether in cash,
properties or securities, shall be received by a Lender in excess of its ratable share, then the portion of such payment or distribution in excess of such Lender’s ratable share shall be received by such Lender in trust for and shall be
promptly paid over to the other Lender for application to the payments of amounts due on the other Lenders’ claims. To the extent any payment for the account of Borrower is required to be returned as a voidable transfer or otherwise, the
Lenders shall contribute to one another as is necessary to ensure that such return of payment is on a pro rata basis. If any Lender shall obtain possession of any Collateral, it shall hold such Collateral for itself and as agent and bailee for
Collateral Agent and other Lenders for purposes of perfecting Collateral Agent’s security interest therein. 

9.5     Liability for Collateral. So long as Collateral Agent and the Lenders comply with
reasonable banking practices regarding the safekeeping of the Collateral in the possession or under the control of Collateral Agent and the Lenders, Collateral Agent and the Lenders shall not be liable or responsible for: (a) the safekeeping of
the Collateral; (b) any loss or damage to the Collateral; (c) any diminution in the value of the Collateral; or (d) any act or default of any carrier, warehouseman, bailee, or other Person. Borrower bears all risk of loss, damage or
destruction of the Collateral. 
 9.6    No Waiver; Remedies Cumulative. Failure by
Collateral Agent or any Lender, at any time or times, to require strict performance by Borrower of any provision of this Agreement or any other Loan Document shall not waive, affect, or diminish any right of Collateral Agent or any Lender thereafter
to demand strict performance and compliance herewith or therewith. No waiver hereunder shall be effective unless signed by Collateral Agent and the Required Lenders and then is only effective for the specific instance and purpose for which it is
given. The rights and remedies of Collateral Agent and the Lenders under this Agreement and the other Loan Documents are cumulative. Collateral Agent and the Lenders have all rights and remedies provided under the Code, any applicable law, by law,
or in equity. The exercise by Collateral Agent or any Lender of one right or remedy is not an election, and Collateral 

  
 22 

 
Agent’s or any Lender’s waiver of any Event of Default is not a continuing waiver. Collateral Agent’s or any Lender’s delay in exercising any remedy is not a waiver, election,
or acquiescence. 
 9.7    Demand Waiver. Borrower waives, to the fullest extent permitted
by law, demand, notice of default or dishonor, notice of payment and nonpayment, notice of any default, nonpayment at maturity, release, compromise, settlement, extension, or renewal of accounts, documents, instruments, chattel paper, and guarantees
held by Collateral Agent or any Lender on which Borrower or any Subsidiary is liable. 
  

	10.	 NOTICES 

All notices, consents, requests, approvals, demands, or other communication by any party to this Agreement or any other Loan Document must be
in writing and shall be deemed to have been validly served, given, or delivered: (a) upon the earlier of actual receipt and three (3) Business Days after deposit in the U.S. mail, first class, registered or certified mail return receipt
requested, with proper postage prepaid; (b) upon transmission, when sent by facsimile transmission; (c) one (1) Business Day after deposit with a reputable overnight courier with all charges prepaid; or (d) when delivered, if hand
delivered by messenger, all of which shall be addressed to the party to be notified and sent to the address, facsimile number, or email address indicated below. Any of Collateral Agent, Lender or Borrower may change its mailing address or facsimile
number by giving the other party written notice thereof in accordance with the terms of this Section 10. 
  

			
	             If to Borrower:
	 	 BIONANO GENOMICS, INC.

		 	 9540 Towne Centre Drive

		 	 Suite 100

		 	 San Diego, CA 92121

		 	 Attn: Michael Ward

		 	 Email: mward@bionanogenomics.com

		 	 with a copy (which shall

		 	 not constitute notice) to:
                    

		 	
                       
                                     

		 	 Cooley LLP

		 	 James Pennington

		 	 4401 Eastgate Mall

		 	 San Diego, CA 92121-1909

		 	 Attn: James Pennington

		 	 Email: jpennington@cooley.com

		
	 If to Collateral Agent:
	 	 INNOVATUS LIFE SCIENCES

		 	 LENDING FUND I, LP

		 	 777 Third Avenue, 25th Floor

		 	 New York, NY 10017

		 	 Attn: Claes Ekstrom

		 	 Email: cekstrom@innovatuscp.com

		
	 with a copy to:
	 	 EAST WEST BANK

		 	 2350 Mission College Blvd.

		 	 Ste. 988

		 	 Santa Clara, CA 95054

		 	 Attn: James Tai

		 	 Email: James.Tai@eastwestbank.com

		
	 with a copy (which shall
	 	
	 not constitute notice) to:
	 	 Greenberg Traurig, LLP

		
		 	 One International Place

		 	 Boston, MA 02110

  
 23 

			
		 	 Attn: Abdullah Malik

		 	 Fax: (617) 897-0983

		 	 Email: malikab@gtlaw.com

  

	11.	 CHOICE OF LAW, VENUE AND JURY TRIAL WAIVER 

11.1    Waiver of Jury Trial. EACH OF BORROWER, COLLATERAL AGENT AND LENDERS UNCONDITIONALLY
WAIVES ANY AND ALL RIGHT TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION BASED UPON OR ARISING OUT OF THIS AGREEMENT, ANY OF THE OTHER LOAN DOCUMENTS, ANY OF THE INDEBTEDNESS SECURED HEREBY, ANY DEALINGS AMONG BORROWER, COLLATERAL AGENT AND/OR
LENDERS RELATING TO THE SUBJECT MATTER OF THIS TRANSACTION OR ANY RELATED TRANSACTIONS, AND/OR THE RELATIONSHIP THAT IS BEING ESTABLISHED AMONG BORROWER, COLLATERAL AGENT AND/OR LENDERS. THE SCOPE OF THIS WAIVER IS INTENDED TO BE ALL ENCOMPASSING OF
ANY AND ALL DISPUTES THAT MAY BE FILED IN ANY COURT. THIS WAIVER IS IRREVOCABLE. THIS WAIVER MAY NOT BE MODIFIED EITHER ORALLY OR IN WRITING. THE WAIVER ALSO SHALL APPLY TO ANY SUBSEQUENT AMENDMENTS, RENEWALS, SUPPLEMENTS OR MODIFICATIONS TO THIS
AGREEMENT, ANY OTHER LOAN DOCUMENTS, OR TO ANY OTHER DOCUMENTS OR AGREEMENTS RELATING TO THIS TRANSACTION OR ANY RELATED TRANSACTION. THIS AGREEMENT MAY BE FILED AS A WRITTEN CONSENT TO A TRIAL BY THE COURT. 

11.2    Governing Law and Jurisdiction. 

(a)    THIS AGREEMENT, THE OTHER LOAN DOCUMENTS (EXCLUDING THOSE LOAN DOCUMENTS THAT BY THEIR OWN TERMS ARE
EXPRESSLY GOVERNED BY THE LAWS OF ANOTHER JURISDICTION) AND THE RIGHTS AND OBLIGATIONS OF THE PARTIES HEREUNDER AND THEREUNDER SHALL IN ALL RESPECTS BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH, THE INTERNAL LAWS OF THE STATE OF NEW YORK (WITHOUT
REGARD TO THE CONFLICT OF LAWS PRINCIPLES THAT WOULD RESULT IN THE APPLICATION OF ANY LAWS OTHER THAN THE LAWS OF THE STATE OF NEW YORK), INCLUDING ALL MATTERS OF CONSTRUCTION, VALIDITY AND PERFORMANCE, REGARDLESS OF THE LOCATION OF THE COLLATERAL,
PROVIDED, HOWEVER, THAT IF THE LAWS OF ANY JURISDICTION OTHER THAN NEW YORK SHALL GOVERN IN REGARD TO THE VALIDITY, PERFECTION OR EFFECT OF PERFECTION OF ANY LIEN OR IN REGARD TO PROCEDURAL MATTERS AFFECTING ENFORCEMENT OF ANY LIENS IN COLLATERAL,
SUCH LAWS OF SUCH OTHER JURISDICTIONS SHALL CONTINUE TO APPLY TO THAT EXTENT. 
 (b)    Submission to
Jurisdiction. Any legal action or proceeding with respect to the Loan Documents shall be brought exclusively in the courts of the State of New York located in the City of New York, Borough of Manhattan, or of the United States of America for the
Southern District of New York and, by execution and delivery of this Agreement, Borrower hereby accepts for itself and in respect of its Property, generally and unconditionally, the jurisdiction of the aforesaid courts. Notwithstanding the
foregoing, Collateral Agent and Lenders shall have the right to bring any action or proceeding against Borrower (or any property of Borrower) in the court of any other jurisdiction Collateral Agent or Lenders deem necessary or appropriate in order
to realize on the Collateral or other security for the Obligations. The parties hereto hereby irrevocably waive any objection, including any objection to the laying of venue or based on the grounds of forum non conveniens, that any of them may now
or hereafter have to the bringing of any such action or proceeding in such jurisdictions. 

(c)    Service of Process. Borrower irrevocably waives personal service of any and all legal
process, summons, notices and other documents and other service of process of any kind and consents to such service in any suit, action or proceeding brought in the United States of America with respect to or otherwise arising out of or in
connection with any Loan Document by any means permitted by applicable requirements of law, including by the mailing thereof (by registered or certified mail, postage prepaid) to the address of Borrower specified herein (and shall be effective when
such mailing shall be effective, as provided therein). Borrower agrees that a final judgment in any such action or proceeding shall be conclusive and may be enforced in other jurisdictions by suit on the judgment or in any other manner provided by
law. 

  
 24 

(d)    Non-exclusive Jurisdiction. Nothing contained in this
Section 11.2 shall affect the right of Collateral Agent or Lenders to serve process in any other manner permitted by applicable requirements of law or commence legal proceedings or otherwise proceed against Borrower in any other jurisdiction.

  

	12.	 GENERAL PROVISIONS 

12.1    Successors and Assigns. This Agreement binds and is for the benefit of the successors
and permitted assigns of each party. Borrower may not transfer, pledge or assign this Agreement or any rights or obligations under it without Collateral Agent’s prior written consent (which may be granted or withheld in Collateral Agent’s
discretion, subject to Section 12.5). The Lenders have the right, without the consent of or notice to Borrower, to sell, transfer, assign, pledge, negotiate, or grant participation in1 all or any part of, or any interest in, the Lenders’
obligations, rights, and benefits under this Agreement and the other Loan Documents. 

12.2    Indemnification. Borrower agrees to indemnify, defend and hold Collateral Agent and
the Lenders and their respective directors, officers, employees, consultants, agents, attorneys, or any other Person affiliated with or representing Collateral Agent or the Lenders (each, an “Indemnified Person”) harmless against:
(a) all obligations, demands, claims, and liabilities (collectively, “Claims”) asserted by any other party in connection with; related to; following; or arising from, out of or under, the transactions contemplated by the Loan
Documents; and (b) all losses or Lenders’ Expenses incurred, or paid by Indemnified Person in connection with; related to; following; or arising from, out of or under, the transactions contemplated by the Loan Documents between Collateral
Agent, and/or the Lenders and Borrower (including reasonable attorneys’ fees and expenses), except for Claims and/or losses directly caused by such Indemnified Person’s gross negligence or willful misconduct. Borrower hereby further
indemnifies, defends and holds each Indemnified Person harmless from and against any and all liabilities, obligations, losses, damages, penalties, actions, judgments, suits, claims, costs, expenses and disbursements of any kind or nature whatsoever
(including the fees and disbursements of counsel for such Indemnified Person) in connection with any investigative, response, remedial, administrative or judicial matter or proceeding, whether or not such Indemnified Person shall be designated a
party thereto and including any such proceeding initiated by or on behalf of Borrower, and the reasonable expenses of investigation by engineers, environmental consultants and similar technical personnel and any commission, fee or compensation
claimed by any broker (other than any broker retained by Collateral Agent or Lenders) asserting any right to payment for the transactions contemplated hereby which may be imposed on, incurred by or asserted against such Indemnified Person as a
result of or in connection with the transactions contemplated hereby and the use or intended use of the proceeds of the loan proceeds except for liabilities, obligations, losses, damages, penalties, actions, judgments, suits, claims, costs, expenses
and disbursements directly caused by such Indemnified Person’s gross negligence or willful misconduct. 

12.3    Severability of Provisions. Each provision of this Agreement is severable from every
other provision in determining the enforceability of any provision. 
 12.4    Correction of
Loan Documents. Collateral Agent may correct patent errors and fill in any blanks in this Agreement and the other Loan Documents consistent with the agreement of the parties. 

12.5    Amendments in Writing; Integration. 

(a)    No amendment, modification, termination or waiver of any provision of this Agreement or any other
Loan Document, no approval or consent thereunder, or any consent to any departure by Borrower or any of 

  
 25 

 
its Subsidiaries therefrom, shall in any event be effective unless the same shall be in writing and signed by Borrower, Collateral Agent and the Required Lenders provided that: 

(i)    no such amendment, waiver or other modification that would have the effect of increasing or
reducing a Lender’s Commitment Amount or Commitment Percentage shall be effective as to such Lender without such Lender’s written consent; 

(ii)    no such amendment, waiver or modification that would affect the rights and duties of Collateral
Agent shall be effective without Collateral Agent’s written consent or signature; and 

(iii)    no such amendment, waiver or other modification shall, unless signed by all the Lenders directly
affected thereby, (A) reduce the principal of, rate of interest on or any fees with respect to any Credit Extension or forgive any principal, interest (other than default interest) or fees (other than late charges) with respect to any Credit
Extension (B) postpone the date fixed for, or waive, any payment of principal of any Credit Extension or of interest on any Credit Extension (other than default interest) or any fees provided for hereunder (other than late charges or for any
termination of any commitment); (C) change the definition of the term “Required Lenders” or the percentage of Lenders which shall be required for the Lenders to take any action hereunder; (D) release all or substantially all of any
material portion of the Collateral, authorize Borrower to sell or otherwise dispose of all or substantially all or any material portion of the Collateral or release any Guarantor of all or any portion of the Obligations or its guaranty obligations
with respect thereto, except, in each case with respect to this clause (D), as otherwise may be expressly permitted under this Agreement or the other Loan Documents (including in connection with any disposition permitted hereunder); (E) amend, waive
or otherwise modify this Section 12.5 or the definitions of the terms used in this Section 12.5 insofar as the definitions affect the substance of this Section 12.5; (F) consent to the assignment, delegation or other transfer by
Borrower of any of its rights and obligations under any Loan Document or release Borrower of its payment obligations under any Loan Document, except, in each case with respect to this clause (F), pursuant to a merger or consolidation permitted
pursuant to this Agreement; (G) amend any of the provisions of Section 9.4 or amend any of the definitions of Pro Rata Share, Commitment Amount, Commitment Percentage or that provide for the Lenders to receive their Pro Rata Shares of any
fees, payments, setoffs or proceeds of Collateral hereunder; (H) subordinate the Liens granted in favor of Collateral Agent securing the Obligations; or (I) amend any of the provisions of Section 12.5. It is hereby understood and
agreed that all Lenders shall be deemed directly affected by an amendment, waiver or other modification of the type described in the preceding clauses (C), (D), (E), (F), (G) and (H) of the immediately preceding sentence. 

(b)    Other than as expressly provided for in Section 12.5(a)(i)-(iii), Collateral Agent may, if
requested by the Required Lenders, from time to time designate covenants in this Agreement less restrictive by notification to a representative of Borrower. 

(c)    This Agreement and the Loan Documents represent the entire agreement about this subject matter and
supersede prior negotiations or agreements with respect to such subject matter. All prior agreements, understandings, representations, warranties, and negotiations between the parties about the subject matter of this Agreement and the Loan Documents
merge into this Agreement and the Loan Documents. 
 12.6    Counterparts. This Agreement
may be executed in any number of counterparts and by different parties on separate counterparts, each of which, when executed and delivered, is an original, and all taken together, constitute one Agreement. 

12.7    Survival. All covenants, representations and warranties made in this Agreement
continue in full force and effect until this Agreement has terminated pursuant to its terms and all Obligations (other than inchoate indemnity obligations and any other obligations which, by their terms, are to survive the termination of this
Agreement) have been satisfied. The obligation of Borrower in Section 12.2 to indemnify each Lender and Collateral Agent, as well as the confidentiality provisions in Section 12.8 below, shall survive until the statute of limitations with
respect to such claim or cause of action shall have run. 
 12.8    Confidentiality. In
handling any confidential information of Borrower, the Lenders and Collateral Agent shall exercise the same degree of care that it exercises for their own proprietary information, but disclosure of information may be made: (a) subject to the
terms and conditions of this Agreement, to the Lenders’ and Collateral 

  
 26 

 
Agent’s Subsidiaries or Affiliates; (b) to prospective transferees (other than those identified in (a) above) or purchasers of any interest in any Credit Extension (provided,
however, the Lenders and Collateral Agent shall, except upon the occurrence and during the continuance of an Event of Default, obtain such prospective transferee’s or purchaser’s agreement to the terms of this provision or to similar
confidentiality terms); (c) as required by law, regulation, subpoena, or other order; (d) to Lenders’ or Collateral Agent’s regulators or as otherwise required in connection with an examination or audit; (e) as Collateral Agent
reasonably considers appropriate in exercising remedies under the Loan Documents; and (f) to third party service providers of the Lenders and/or Collateral Agent so long as such service providers have executed a confidentiality agreement or
have agreed to similar confidentiality terms with the Lenders and Collateral Agent with terms no less restrictive than those contained herein. Confidential information does not include information that either: (i) is in the public domain or in
the Lenders’ and/or Collateral Agent’s possession when disclosed to the Lenders and/or Collateral Agent, or becomes part of the public domain after disclosure to the Lenders and/or Collateral Agent at no fault of the Lenders or the
Collateral Agent; or (ii) is disclosed to the Lenders and/or Collateral Agent by a third party, if the Lenders and/or Collateral Agent does not know that the third party is prohibited from disclosing the information. Collateral Agent and the
Lenders may use confidential information for any purpose, so long as the identity of Borrower is not disclosed and the use is not for competing with the business of Borrower, including, without limitation, for the development of client databases,
reporting purposes, and market analysis. The provisions of the immediately preceding sentence shall survive the termination of this Agreement. The agreements provided under this Section 12.8 supersede all prior agreements, understanding,
representations, warranties, and negotiations between the parties about the subject matter of this Section 12.8. 

12.9    Right of Set Off. Borrower hereby grants to Collateral Agent and to each Lender, a
lien, security interest and right of set off as security for all Obligations to Collateral Agent and each Lender hereunder, whether now existing or hereafter arising upon and against all deposits, credits, collateral and property, now or hereafter
in the possession, custody, safekeeping or control of Collateral Agent or the Lenders or any entity under the control of Collateral Agent or the Lenders (including a Collateral Agent affiliate) or in transit to any of them. At any time after the
occurrence and during the continuance of an Event of Default, without demand or notice, Collateral Agent or the Lenders may set off the same or any part thereof and apply the same to any liability or obligation of Borrower even though unmatured and
regardless of the adequacy of any other collateral securing the Obligations. ANY AND ALL RIGHTS TO REQUIRE COLLATERAL AGENT TO EXERCISE ITS RIGHTS OR REMEDIES WITH RESPECT TO ANY OTHER COLLATERAL WHICH SECURES THE OBLIGATIONS, PRIOR TO EXERCISING
ITS RIGHT OF SETOFF WITH RESPECT TO SUCH DEPOSITS, CREDITS OR OTHER PROPERTY OF BORROWER ARE HEREBY KNOWINGLY, VOLUNTARILY AND IRREVOCABLY WAIVED BY BORROWER. 

12.10    Cooperation of Borrower. If necessary, Borrower agrees to (i) execute any
documents reasonably required to effectuate and acknowledge each assignment of a Commitment or Credit Extension to an assignee in accordance with Section 12.1, (ii) make Borrower’s management available upon reasonable advance notice to
meet with Collateral Agent and prospective participants and assignees of Commitments (which meetings shall be conducted no more often than twice every twelve months unless an Event of Default has occurred and is continuing), and (iii) assist
Collateral Agent or the Lenders in the preparation of information relating to the financial affairs of Borrower as any prospective participant or assignee of a Commitment or Credit Extension reasonably may request. Subject to the provisions of
Section 12.8, Borrower authorizes each Lender to disclose to any prospective participant or assignee of a Commitment, any and all information in such Lender’s possession concerning Borrower and its financial affairs which has been
delivered to such Lender by or on behalf of Borrower pursuant to this Agreement, or which has been delivered to such Lender by or on behalf of Borrower in connection with such Lender’s credit evaluation of Borrower prior to entering into this
Agreement. 
 12.11    Public Announcement. Borrower hereby agrees that Collateral Agent
and each Lender may make a public announcement of the transactions contemplated by this Agreement, and may publicize the same in marketing 

  
 27 

 
materials, newspapers and other publications, and otherwise, and in connection therewith may use Borrower’s name, tradenames and logos. 

12.12    Collateral Agent and Lender Agreement. Collateral Agent and each Lender hereby
agree to the terms and conditions set forth on Annex I attached hereto. Borrower acknowledges and agrees to the terms and conditions set forth on Annex I attached hereto. 

12.13    Intercreditor Agreement. The parties (a) consent to the subordination of Liens
provided for in the Intercreditor Agreement and (b) agree that they will be bound by, and will take no actions contrary to, the provisions of the Intercreditor Agreement. 

 

	13.	 DEFINITIONS 

As used in this Agreement, the following terms have the following meanings: 

“Account” is any “account” as defined in the Code with such additions to such term as may hereafter
be made, and includes, without limitation, all accounts receivable and other sums owing to Borrower. 
 “Account
Debtor” is any “account debtor” as defined in the Code with such additions to such term as may hereafter be made under the Code. 

“Advance” or “Advances” means a cash advance or cash advances under the Revolving Line. 

“Affiliate” of any Person is a Person that owns or controls directly or indirectly the Person, any Person
that controls or is controlled by or is under common control with the Person, and each of that Person’s senior executive officers, directors, partners if such Person is a partnership and, for any Person that is a limited liability company, that
Person’s managers and members. 
 “Aggregate Equity Value” of Borrower on any given day is the sum of
(i) the closing price of Borrower’s Common Stock on Nasdaq Stock Market LLC on such day (or the then last trading day on the Nasdaq Stock Market LLC, if such day is not a trading day) multiplied by the then outstanding number of shares of
common stock of Borrower, (ii) if warrants to purchase Common Stock of Borrower (currently traded under the symbol BNGOW) are then traded on Nasdaq Stock Market LLC, the closing price on Nasdaq Stock Market LLC on such day (or the then last
trading day on the Nasdaq Stock Market LLC, if such day is not a trading day) of one such warrant multiplied by the then outstanding number of such warrants and (iii) the aggregate Stock Option Values of all then issued and outstanding In Money
Stock Options. 
 “Amortization Date” is the earlier of (i) the date of an Event of Default occurring
(the “Early Amortization Date”), and (ii) the thirty sixth (36th) Payment Date following the Effective Date. 

“Anti-Terrorism Laws” are any laws relating to terrorism or money laundering, including without limitation
Executive Order No. 13224 (effective September 24, 2001), the USA PATRIOT Act, the laws comprising or implementing the Bank Secrecy Act, and the laws administered by OFAC. 

“Bank” is defined in the preamble to this Agreement. 

“Blocked Person” is any Person: (a) listed in the annex to, or is otherwise subject to the provisions
of, Executive Order No. 13224, (b) a Person owned or controlled by, or acting for or on behalf of, any Person that is listed in the annex to, or is otherwise subject to the provisions of, Executive Order No. 13224, (c) a Person with which
any Lender is prohibited from dealing or otherwise engaging in any transaction by any Anti-Terrorism Law, (d) a Person that commits, threatens or conspires to commit or supports “terrorism” as defined in Executive Order
No. 13224, or (e) a Person that is named a “specially designated national” or “blocked person” on the most current list published by OFAC or other similar list. 

“Borrower’s Books” are Borrower’s or any of its Subsidiaries’ books and records including
ledgers, federal, 

  
 28 

 
and state tax returns, records regarding Borrower’s or its Subsidiaries’ assets or liabilities, the Collateral, business operations or financial condition, and all computer programs or
storage or any equipment containing such information. 
 “Borrowing Base” means an amount equal to eighty
percent (80.00%) of Eligible Accounts, as determined by Bank with reference to the most recent Borrowing Base Certificate delivered by Borrower; provided that Bank may, with prior notice to Borrower, change the advance rate in Bank’s reasonable
discretion based upon the results of Collateral audits; provided, further, that Borrowing Base shall be no greater than One Million Five Hundred Thousand Dollars ($1,500,000.00), if on the Funding Date of the Advance, the Debt To Equity Ratio (the
calculation of which must be acceptable to Bank) is equal to or greater than 38.75%. 
 “Borrowing Base
Certificate” is that certain certificate in substantially the form attached hereto as Exhibit D. 

“Business Day” is any day that is not a Saturday, Sunday or a day on which Collateral Agent is closed. 

“Cash Burn” is the cash used by Borrower in its operations and in investing activities. 

“Cash Equivalents” are (a) marketable direct obligations issued or unconditionally guaranteed by the
United States or any agency or any State thereof having maturities of not more than one (1) year from the date of acquisition; (b) commercial paper maturing no more than one (1) year after its creation and having the highest rating
from either Standard & Poor’s Ratings Group or Moody’s Investors Service, Inc.; and (c) certificates of deposit maturing no more than one (1) year after issue provided that the account in which any such certificate of
deposit is maintained is subject to a Control Agreement in favor of Collateral Agent. 
 “Code” is the
Uniform Commercial Code, as the same may, from time to time, be enacted and in effect in the State of New York; provided, that, to the extent that the Code is used to define any term herein or in any Loan Document and such term is defined
differently in different Articles or Divisions of the Code, the definition of such term contained in Article or Division 9 shall govern; provided further, that in the event that, by reason of mandatory provisions of law, any or all of the
attachment, perfection, or priority of, or remedies with respect to, Collateral Agent’s Lien on any Collateral is governed by the Uniform Commercial Code in effect in a jurisdiction other than the State of New York, the term
“Code” shall mean the Uniform Commercial Code as enacted and in effect in such other jurisdiction solely for purposes of the provisions thereof relating to such attachment, perfection, priority, or remedies and for purposes of
definitions relating to such provisions. 
 “Collateral” is any and all properties, rights and assets of
Borrower described on Exhibit A. 
 “Collateral Account” is any Deposit Account, Securities Account,
or Commodity Account, or any other bank account maintained by Borrower or any Subsidiary at any time. 
 “Commitment
Amount” is set forth in Schedule 1.1, as amended from time to time. 
 “Commitment
Percentage” is set forth in Schedule 1.1, as amended from time to time. 
 “Commitments”
means, collectively, the Revolving Line Commitments and the Term Loan Commitments. 
 “Commodity Account”
is any “commodity account” as defined in the Code with such additions to such term as may hereafter be made under the Code. 

“Compliance Certificate” is that certain certificate in substantially the form attached hereto as Exhibit
C. 
 “Contingent Obligation” is, for any Person, any direct or indirect liability, contingent or not,
of that Person for (a) any indebtedness, lease, dividend, letter of credit or other obligation of another Person such as an obligation directly or indirectly guaranteed, endorsed, co-made, discounted or
sold with recourse by that Person, or for which that Person is directly or indirectly liable; (b) any obligations for undrawn letters of credit for the account of that Person; and (c) all obligations from any interest rate, currency or
commodity swap agreement, interest rate cap or 

  
 29 

 
collar agreement, or other agreement or arrangement designated to protect a Person against fluctuation in interest rates, currency exchange rates or commodity prices; but “Contingent
Obligation” does not include endorsements in the ordinary course of business. The amount of a Contingent Obligation is the stated or determined amount of the primary obligation for which the Contingent Obligation is made or, if not
determinable, the maximum reasonably anticipated liability for it determined by the Person in good faith; but the amount may not exceed the maximum of the obligations under any guarantee or other support arrangement. 

“Control Agreement” is any control agreement entered into among the depository institution at which Borrower
or any of its Subsidiaries maintains a Deposit Account or the securities intermediary or commodity intermediary at which Borrower or any of its Subsidiaries maintains a Securities Account or a Commodity Account, Borrower and such Subsidiary, and
Collateral Agent pursuant to which Collateral Agent, for the benefit of the Lenders, obtains “control” (within the meaning of the Code) over such Deposit Account, Securities Account, or Commodity Account. 

“Copyrights” are any and all copyright rights, copyright applications, copyright registrations and like
protections in each work of authorship and derivative work thereof, whether published or unpublished and whether or not the same also constitutes a trade secret. 

“Credit Extension” is each Advance, Term Loan or any other extension of credit by any Lender to or for the
benefit of Borrower hereunder. 
 “Debt To Equity Ratio” is at any given time the ratio of aggregate
outstanding Indebtedness of Borrower (including, without limitation, the Indebtedness outstanding under this Agreement and the aggregate amount of all Credit Extensions then requested by Borrower hereunder but not as yet funded by Lenders) at such
time to the Aggregate Equity Value of Borrower at such time, expressed as a percentage. 
 “Deposit
Account” is any “deposit account” as defined in the Code with such additions to such term as may hereafter be made. 

“Disbursement Letter” is that certain form attached hereto as EXHIBIT
B-2. 
 “Domestic Subsidiary” means any Subsidiary which is not
a Foreign Subsidiary. 
 “DOJ” means the U.S. Department of Justice or any successor thereto or any other
comparable Governmental Authority. 
 “Dollars,” “dollars” and “$” each mean lawful
money of the United States. 
 “Eligible Accounts” means those Accounts that arise in the ordinary course
of Borrower’s business that comply with all of Borrower’s representations and warranties set forth in Section 5.2; provided, that Bank may, in its reasonable discretion, change the standards of eligibility immediately by giving
Borrower a written notice of the effectiveness of any such change. Unless otherwise agreed to by Bank, Eligible Accounts shall not include the following: 

(a)    Accounts that the Account Debtor has failed to pay in full within ninety (90) days of invoice
date; 
 (b)    Uninsured Accounts with respect to which the Account Debtor does not have its principal
place of business in the United States; 
 (c)    Credit balances over ninety (90) days; 

(d)    Accounts with respect to an Account Debtor, twenty-five percent (25%) of whose Accounts the Account
Debtor has failed to pay within ninety (90) days of invoice date, except as approved in writing by Bank; 

  
 30 

 (e)    Accounts with respect to an Account Debtor,
including Subsidiaries and Affiliates, whose total obligations to Borrower exceed twenty-five percent (25%) of all Accounts, to the extent such obligations exceed the aforementioned percentage, except as approved in writing by Bank; 

(f)    Accounts with respect to which the goods have not been shipped or delivered, or the services have
not been rendered, to the Account Debtor; 
 (g)    Accounts consisting of non-trade claims, i.e., freight claims, insurance claims, warranty claims, claims against government, etc.; 

(h)    Accounts arising from cash sales or from collect on delivery sales of inventory; 

(i)    Accrued finance charges on Account; 

(j)    Accounts which consists of progress billings; 

(k)    Accounts with respect to which the Account Debtor is the United States or any department, agency,
or instrumentality of the United States, except for (i) Accounts of the United States, or (ii) Accounts with the United States Department of Veterans Affairs (and related hospitals), if in each case Borrower has assigned its payment rights
to Bank and the assignment has been acknowledged under the Assignment of Claims Act of 1940 (31 U.S.C, 3727); 

(l)    Accounts with respect to which Borrower is liable to the Account Debtor for goods sold or services
rendered by the Account Debtor to Borrower, but only to the extent of any amounts owing to the Account Debtor against amounts owed to Borrower; 

(m)    Accounts with respect to which goods are placed on consignment, guaranteed sale, sale or return,
sale on approval, bill and hold, demo or promotional, or other terms by reason of which the payment by the Account Debtor may be conditional; 

(n)    Accounts with respect to which the Account Debtor is an officer, employee, agent or Affiliate of
Borrower; 
 (o)    Accounts that have not yet been billed to the Account Debtor or that relate to
deposits (such as good faith deposits) or other property of the Account Debtor held by Borrower for the performance of services or delivery of goods which Borrower has not yet performed or delivered; 

(p)    Accounts with respect to which the Account Debtor disputes liability or makes any claim with
respect thereto as to which Bank believes, in its sole reasonable discretion, that there may be a basis for dispute (but only to the extent of the amount subject to such dispute or claim), or is subject to any Insolvency Proceeding, has filed for
bankruptcy protection, is or becomes Insolvent, or goes out of business; 
 (q)    Accounts the
collection of which Bank reasonably determines after inquiry and consultation with Borrower to be doubtful; and 

(r)    Retentions and hold-backs. 

“Equipment” is all “equipment” as defined in the Code with such additions to such term as may
hereafter be made, and includes without limitation all machinery, fixtures, goods, vehicles (including motor vehicles and trailers), and any interest in any of the foregoing. 

“ERISA” is the Employee Retirement Income Security Act of 1974, as amended, and its regulations. 

“Exigent Circumstance” means any event or circumstance that, in the reasonable judgment of Collateral Agent,
imminently threatens the ability of Collateral Agent to realize upon all or any material portion of the Collateral, 

  
 31 

 
such as, without limitation, fraudulent removal, concealment, or abscondment thereof, destruction or material waste thereof, or failure of Borrower or any of its Subsidiaries after reasonable
demand to maintain or reinstate adequate casualty insurance coverage, or which, in the judgment of Collateral Agent, could reasonably be expected to result in a material diminution in value of the Collateral. 

“Existing Indebtedness” is the indebtedness of Borrower to MidCap Financial Trust in the aggregate principal
outstanding amount as of the Effective Date of approximately Ten Million Eight Hundred Sixty Thousand Eight Hundred Thirty-Seven and 44/100 Dollars ($10,860,837.44) pursuant to that certain Credit and Security Agreement, dated June 29, 2018,
entered into by and between MidCap Financial Trust and Borrower. 
 “FDA” means the U.S. Food and Drug
Administration or any successor thereto or any other comparable Governmental Authority. 
 “Final Fee” is a
payment (in addition to and not a substitution for the regular monthly payments of principal plus accrued interest or any other fee payable hereunder) due on the earliest to occur of (a) the Maturity Date, or (b) the acceleration of any
Term Loan, or (c) the prepayment of the Term Loan pursuant to Section 2.2(c) or (d), in each case equal to Three and Seventy-Five Hundredths percent (3.75%) multiplied by the aggregate amount of the Term Loans funded, payable to
Lenders in accordance with their respective Pro Rata Shares. 
 “Foreign Currency” means lawful money of a
country other than the United States. 
 “Foreign Subsidiary” is a Subsidiary that is not an entity
organized under the laws of the United States or any state thereof. 
 “Funding Date” is any date on which
the Credit Extension is made to or on account of Borrower which shall be a Business Day. 
 “GAAP” is
generally accepted accounting principles set forth in the opinions and pronouncements of the Accounting Principles Board of the American Institute of Certified Public Accountants and statements and pronouncements of the Financial Accounting
Standards Board or in such other statements by such other Person as may be approved by a significant segment of the accounting profession in the United States, which are applicable to the circumstances as of the date of determination. 

“General Intangibles” are all “general intangibles” as defined in the Code in effect on the date
hereof with such additions to such term as may hereafter be made, and includes without limitation, all copyright rights, copyright applications, copyright registrations and like protections in each work of authorship and derivative work, whether
published or unpublished, any patents, trademarks, service marks and, to the extent permitted under applicable law, any applications therefor, whether registered or not, any trade secret rights, including any rights to unpatented inventions, payment
intangibles, royalties, contract rights, goodwill, franchise agreements, purchase orders, customer lists, route lists, telephone numbers, domain names, claims, income and other tax refunds, security and other deposits, options to purchase or sell
real or personal property, rights in all litigation presently or hereafter pending (whether in contract, tort or otherwise), insurance policies (including without limitation key man, property damage, and business interruption insurance), payments of
insurance and rights to payment of any kind. 
 “Governmental Approval” is any consent, authorization,
approval, order, license, franchise, permit, certificate, accreditation, registration, filing or notice, of, issued by, from or to, or other act by or in respect of, any Governmental Authority. 

“Governmental Authority” is any nation or government, any state or other political subdivision thereof, any
agency, authority, instrumentality, regulatory body (including, without limitation, the FDA and any state board of pharmacy or state pharmacy licensing authority), court, central bank or other entity exercising executive, legislative, judicial,
taxing, regulatory or administrative functions of or pertaining to government, any securities exchange and any self-regulatory organization. 

“Guarantor” is any Person providing a Guaranty in favor of Collateral Agent for the benefit of the Lenders.

  
 32 

 “Guaranty” is any guarantee of all or any part of the
Obligations, as the same may from time to time be amended, restated, modified or otherwise supplemented. 
 “In
Money Stock Option” is an option to purchase shares of Borrower’s Common Stock at a strike price per share that is less than the then last closing price of one share of Borrower’s Common Stock on the Nasdaq Stock Market LLC. 

“Indebtedness” is (a) indebtedness for borrowed money or the deferred price of property or services,
such as reimbursement and other obligations for surety bonds and letters of credit, (b) obligations evidenced by notes, bonds, debentures or similar instruments, (c) capital lease obligations, and (d) Contingent Obligations. 

“Insolvency Proceeding” is any proceeding by or against any Person under the United States Bankruptcy Code,
or any other bankruptcy or insolvency law, including assignments for the benefit of creditors, compositions or proceedings seeking reorganization, arrangement, or other relief. 

“Insolvent” means not Solvent. 

“Intellectual Property” means all of Borrower’s or any of its Subsidiaries’ right, title and
interest in and to the following: 
 (a)    its Copyrights, Trademarks and Patents; 

(b)    any and all trade secrets and trade secret rights, including, without limitation, any rights to
unpatented inventions, know-how, operating manuals; 

(c)    any and all source code; 

(d)    any and all design rights which may be available to Borrower; 

(e)    any and all claims for damages by way of past, present and future infringement of any of the
foregoing, with the right, but not the obligation, to sue for and collect such damages for said use or infringement of the Intellectual Property rights identified above; 

(f)    all amendments, renewals and extensions of any of the Copyrights, Trademarks or Patents; and 

(g)    all licenses, sublicenses or other contracts under which Borrower or any Subsidiary is granted
rights by third parties in any Intellectual Property asset. 
 “Intercreditor Agreement” means that certain
Intercreditor Agreement, as modified, amended and or restated from time to time in the sole discretion of Collateral Agent, by and between the Bank and Collateral Agent. 

“Inventory” is all “inventory” as defined in the Code in effect on the date hereof with such
additions to such term as may hereafter be made under the Code, and includes without limitation all merchandise, raw materials, parts, supplies, packing and shipping materials, work in process and finished products, including without limitation such
inventory as is temporarily out of any Person’s custody or possession or in transit and including any returned goods and any documents of title representing any of the above. 

“Investment” is any beneficial ownership interest in any Person (including stock, partnership interest or
other securities), and any loan, advance or capital contribution to any Person. 
 “IP Security Agreement”
is that certain Intellectual Property Security Agreement executed and delivered by Borrower to Collateral Agent and dated as of the date of the first Credit Extension made under this Agreement, as may be amended, restated, or otherwise modified or
supplemented from time to time. 

  
 33 

 “Key Person” is each of Borrower’s (i) President
and Chief Executive Officer, who is Erik Holmlin as of the Effective Date and (ii) Chief Financial Officer, who is Mike Ward as of the Effective Date. 

“Knowledge” means to the “best of” Borrower’s knowledge, or with a similar qualification,
knowledge or awareness means the actual knowledge, after reasonable investigation, of the Responsible Officers. 

“Lender” is any one of the Lenders. 

“Lenders” are the Persons identified on Schedule 1.1 hereto and each assignee that becomes a party to
this Agreement pursuant to Section 12.1. 
 “Lenders’ Expenses” are all audit fees and expenses,
costs, and expenses (including reasonable and documented attorneys’ fees and expenses (provided, however, neither any Lender nor the Collateral Agent will be obligated to provide detailed or itemized invoices for such fees and expenses), as
well as appraisal fees, fees incurred on account of lien searches, inspection fees, and filing fees) for preparing, amending, negotiating, administering, defending and enforcing the Loan Documents (including, without limitation, those incurred in
connection with appeals or Insolvency Proceedings) or otherwise incurred by Collateral Agent and/or the Lenders in connection with the Loan Documents. 

“Lien” is a claim, mortgage, deed of trust, levy, charge, pledge, security interest, or other encumbrance of
any kind, whether voluntarily incurred or arising by operation of law or otherwise against any property. 
 “Loan
Documents” are, collectively, this Agreement, the IP Security Agreement, the Intercreditor Agreement, each Secured Promissory Note, each Warrant, the Perfection Certificate(s), each Control Agreement, each Compliance Certificate, each Loan
Payment Request Form, each Disbursement Letter, any subordination agreements, any note, or notes or guaranties executed by Borrower or any other Person, and any other present or future agreement entered into by Borrower, any Guarantor or any other
Person for the benefit of the Lenders and Collateral Agent in connection with this Agreement; all as amended, restated, or otherwise modified or supplemented from time to time. 

“Loan Payment Request Form” is that certain form attached hereto as EXHIBIT
B-1. 
 “Management Plan” is Borrower’s projected revenue
attached hereto as Annex X. 
 “Material Adverse Change” is (a) a material adverse change in
the business, operations or condition (financial or otherwise) of Borrower or any Subsidiary, when taken as a whole; (b) a material impairment of the prospect of repayment of any portion of the Obligations, or (c) a material adverse effect
on the Collateral. 
 “Material Agreement” is any license, agreement or other contractual arrangement with
a Person or Governmental Authority whereby Borrower or any of its Subsidiaries is reasonably likely to be required to transfer, either in-kind or in cash, prior to the Maturity Date, assets or property valued
(book or market) at more than Two Hundred Fifty Thousand Dollars ($250,000.00) in the aggregate or any license, agreement or other contractual arrangement conveying rights in or to any intellectual property necessary to make, use or sell any
Inventory, products or services of Borrower or any Subsidiary. 
 “Maturity Date” is the earlier of
(i) March 1, 2024 and (ii) twenty-four (24) months following the Early Amortization Date, if triggered. 

“Obligations” are all of Borrower’s obligations to pay when due any debts, principal, interest,
Lenders’ Expenses, the Prepayment Fee, the Final Fee, and other amounts Borrower owes the Lenders now or later, in connection with, related to, following, or arising from, out of or under, this Agreement or, the other Loan Documents (other than
the Warrant), or otherwise, including, without limitation, all obligations relating to letters of credit (including reimbursement obligations for drawn and undrawn letters of credit), cash management services, and foreign exchange contracts, if any,
and including interest accruing after Insolvency Proceedings begin (whether or not allowed) and debts, liabilities, or obligations of Borrower assigned to the Lenders and/or Collateral Agent, and the performance of Borrower’s duties under the
Loan Documents (other than the Warrant). 

  
 34 

 “OFAC” is the U.S. Department of Treasury Office of Foreign
Assets Control. 
 “OFAC Lists” are, collectively, the Specially Designated Nationals and Blocked Persons
List maintained by OFAC pursuant to Executive Order No. 13224, 66 Fed. Reg. 49079 (Sept. 25, 2001) and/or any other list of terrorists or other restricted Persons maintained pursuant to any of the rules and regulations of OFAC or pursuant to
any other applicable Executive Orders. 
 “Operating Documents” are, for any Person, such Person’s
formation documents, as certified by the Secretary of State (or equivalent agency) of such Person’s jurisdiction of organization on a date that is no earlier than thirty (30) days prior to the Effective Date, and, (a) if such Person
is a corporation, its bylaws in current form, (b) if such Person is a limited liability company, its limited liability company agreement (or similar agreement), and (c) if such Person is a partnership, its partnership agreement (or similar
agreement), each of the foregoing with all current amendments or modifications thereto. 
 “Patents” means
all patents, patent applications and like protections including without limitation improvements, divisions, continuations, renewals, reissues, re-examination certificates, utility models, extensions and continuations-in-part of the same. 

“Payment Date” is the first (1st) calendar day of each calendar month, commencing on April 1, 2019. 

“Permitted Indebtedness” is: 

(a)    Borrower’s Indebtedness to the Lenders and Collateral Agent under this Agreement and the other
Loan Documents; 
 (b)    Indebtedness existing on the Effective Date and disclosed on the Perfection
Certificate(s); 
 (c)    Subordinated Debt; 

(d)    unsecured Indebtedness to trade creditors and Indebtedness in connection with credit cards incurred
in the ordinary course of business; 
 (e)    Indebtedness consisting of capitalized lease obligations
and purchase money Indebtedness, in each case incurred by Borrower or any of its Subsidiaries to finance the acquisition, repair, improvement or construction of fixed or capital assets of such Person, provided that (i) the aggregate outstanding
principal amount of all such Indebtedness does not exceed Fifty Thousand Dollars ($50,000.00) at any time and (ii) the principal amount of such Indebtedness does not exceed the lower of the cost or fair market value of the property so acquired
or built or of such repairs or improvements financed with such Indebtedness (each measured at the time of such acquisition, repair, improvement or construction is made); 

(f)    Indebtedness incurred as a result of endorsing negotiable instruments received in the ordinary
course of Borrower’s business; 
 (g)    extensions, refinancings, modifications, amendments and
restatements of any items of Permitted Indebtedness (a) through (e) above, provided that the principal amount thereof is not increased or the terms thereof are not modified to impose materially more burdensome terms upon Borrower, or its
Subsidiary, as the case may be; and 
 (h)    any other unsecured Indebtedness in an amount not to
exceed One Hundred Fifty Thousand Dollars ($150,000.00) in the aggregate at any time outstanding. 
 “Permitted
Investments” are: 
 (a)    Investments disclosed on the Perfection Certificate(s) and existing
on the Effective Date; 

  
 35 

 (b)    (i) Investments consisting of cash and Cash
Equivalents, and (ii) any Investments permitted by Borrower’s investment policy, as amended from time to time, provided that such investment policy (and any such amendment thereto) has been approved in writing by Collateral Agent; 

(c)    Investments consisting of the endorsement of negotiable instruments for deposit or collection or
similar transactions in the ordinary course of Borrower; 
 (d)    Investments consisting of Deposit
Accounts in which Collateral Agent has a perfected security interest; 
 (e)    Investments in
connection with Transfers permitted by Section 7.1; 
 (f)    Investments consisting of
(i) travel advances and employee relocation loans and other employee loans and advances in the ordinary course of business, and (ii) loans to employees, officers or directors relating to the purchase of equity securities of Borrower or its
Subsidiaries pursuant to employee stock purchase plans or agreements approved by Borrower’s board of directors, not to exceed Fifty Thousand Dollars ($50,000.00) in the aggregate for (i) and (ii) in any fiscal year; 

(g)    Investments (including debt obligations) received in connection with the bankruptcy or
reorganization of customers or suppliers and in settlement of delinquent obligations of, and other disputes with, customers or suppliers arising in the ordinary course of business; 

(h)    Investments consisting of notes receivable of, or prepaid royalties and other credit extensions, to
customers and suppliers who are not Affiliates, in the ordinary course of business; provided that this paragraph (h) shall not apply to Investments of Borrower in any Subsidiary; 

(i)    Investments in Subsidiaries, not to exceed Fifty Thousand Dollars ($50,000.00) per fiscal year;

 (j)    Investments in joint ventures or strategic alliances in the ordinary course of Borrower’s
business consisting of the non-exclusive licensing of technology, the development of technology or the providing of technical support, provided that any such cash Investments by Borrower do not exceed Two
Hundred Fifty Thousand Dollars ($250,000.00) in the aggregate in any fiscal year; and 
 (k)    any
other Investments in an amount not to exceed Two Hundred Fifty Thousand Dollars ($250,000.00) in the aggregate in any fiscal year. 

“Permitted Licenses” are (A) licenses of
over-the-counter software that is commercially available to the public and (B) non-exclusive licenses for the use of the
Intellectual Property of Borrower or any of its Subsidiaries entered into in the ordinary course of business, provided, that, with respect to each such license described in clause (B), the license constitutes an
arm’s-length transaction, the terms of which, on their face, do not provide for a sale or assignment of any Intellectual Property and do not restrict the ability of Borrower or any of its Subsidiaries, as
applicable, to pledge, grant a security interest in or lien on, or assign or otherwise Transfer any Intellectual Property. 

“Permitted Liens” are: 

(a)    Liens existing on the Effective Date and disclosed on the Perfection Certificates or arising under
this Agreement and the other Loan Documents; 
 (b)    Liens for taxes, fees, assessments or other
government charges or levies, either (i) not due and payable or (ii) being contested in good faith and for which Borrower maintains adequate reserves on its books, provided that no notice of any such Lien has been filed or recorded under
the Internal Revenue Code of 1986, as amended, and the Treasury Regulations adopted thereunder; 

  
 36 

 (c)    liens securing Indebtedness permitted under
clause (e) of the definition of “Permitted Indebtedness,” provided that (i) such liens exist prior to the acquisition of, or attach substantially simultaneous with, or within twenty (20) days after the, acquisition, lease,
repair, improvement or construction of, such property financed or leased by such Indebtedness and (ii) such liens do not extend to any property of Borrower other than the property (and proceeds thereof) acquired, leased or built, or the
improvements or repairs, financed by such Indebtedness; 
 (d)    Liens of carriers, warehousemen,
suppliers, or other Persons that are possessory in nature arising in the ordinary course of business so long as such Liens attach only to Inventory, securing liabilities in the aggregate amount not to exceed Fifty Thousand Dollars ($50,000.00), and
which are not delinquent or remain payable without penalty or which are being contested in good faith and by appropriate proceedings which proceedings have the effect of preventing the forfeiture or sale of the property subject thereto; 

(e)    Liens to secure payment of workers’ compensation, employment insurance, old age pensions,
social security and other like obligations incurred in the ordinary course of business (other than Liens imposed by ERISA); 

(f)    Liens incurred in the extension, renewal or refinancing of the indebtedness secured by Liens
described in (a) through (c), but any extension, renewal or replacement Lien must be limited to the property encumbered by the existing Lien and the principal amount of the indebtedness may not increase; 

(g)    leases or subleases of real property granted in the ordinary course of Borrower’s business
(or, if referring to another Person, in the ordinary course of such Person’s business), and leases, subleases, non-exclusive licenses or sublicenses of personal property (other than Intellectual Property)
granted in the ordinary course of Borrower’s business (or, if referring to another Person, in the ordinary course of such Person’s business), if the leases, subleases, licenses and sublicenses do not prohibit granting Collateral Agent or
any Lender a security interest therein; 
 (h)    banker’s liens, rights of setoff and Liens in
favor of financial institutions incurred in the ordinary course of business arising in connection with Borrower’s deposit accounts or securities accounts held at such institutions solely to secure payment of fees and similar costs and expenses
and provided such accounts are maintained in compliance with Section 6.6 hereof; 
 (i)    Liens
arising from judgments, decrees or attachments in circumstances not constituting an Event of Default under Section 8.4 or 8.7; and 

(j)    Permitted Licenses. 

“Person” is any individual, sole proprietorship, partnership, limited liability company, joint venture,
company, trust, unincorporated organization, association, corporation, institution, public benefit corporation, firm, joint stock company, estate, entity or government agency. 

“Prepayment Fee” is, with respect to any Term Loan subject to prepayment prior to the Maturity Date, whether
by mandatory or voluntary prepayment, acceleration or otherwise, an additional fee payable to the Lenders in amount equal to: 

(i)    for a prepayment made pursuant to Section 2.2(c) on or after the Funding Date of the Term
Loan through and including the first anniversary of the Funding Date of the Term Loan, three percent (3.00%) of the principal amount of the Term Loan prepaid; 

(ii)    for a prepayment made after the date which is the first anniversary of the Funding Date of the
Term Loan through and including the date which is the second anniversary of the Funding Date of the Term Loan, two percent (2.00%) of the principal amount of the Term Loan prepaid; 

  
 37 

 (iii)    for a prepayment made after the date which is
the second anniversary of the Funding Date of the Term Loan through and including the date which is the third anniversary of the Funding Date of the Term Loan, one percent (1.00%) of the principal amount of the Term Loan prepaid; and 

(iv)    for a prepayment made after the date which is the third anniversary of the Funding Date of the
Term Loan and prior to the Maturity Date, zero percent (0.00%) of the principal amount of the Term Loan prepaid. 
 For the purposes of
clarification, no voluntary prepayment of a Term Loan may be made prior to the first anniversary of the Effective Date. 

“Prime Rate” means the variable rate of interest, per annum, most recently announced by Bank, as its
“prime rate,” whether or not such announced rate is the lowest rate available from Bank. 
 “Pro Rata
Share” is, as of any date of determination, with respect to each Lender, a percentage (expressed as a decimal, rounded to the ninth decimal place) determined by dividing the outstanding principal amount of the Term Loan held by such Lender
by the aggregate outstanding principal amount of the Term Loan. 
 “Prohibited Territory” is any country
jurisdiction listed by the OFAC as to which transactions between a United States Person and that territory are prohibited. 

“Property” means any interest in any kind of property or asset, whether real, personal or mixed, and whether
tangible or intangible. 
 “Registered Organization” is any “registered organization” as defined
in the Code with such additions to such term as may hereafter be made under the Code. 
 “Registration”
means any registration, authorization, approval, license, permit, clearance, certificate, and exemption issued or allowed by the FDA or state pharmacy licensing authorities (including, without limitation, new drug applications, abbreviated new drug
applications, biologics license applications, investigational new drug applications, over-the-counter drug monograph, device
pre-market approval applications, device pre-market notifications, investigational device exemptions, product recertifications, manufacturing approvals, registrations
and authorizations, CE Marks, pricing and reimbursement approvals, labeling approvals or their foreign equivalent, controlled substance registrations, and wholesale distributor permits). 

“Regulatory Action” means an administrative, regulatory, or judicial enforcement action, proceeding,
investigation or inspection, FDA Form 483 notice of inspectional observation, warning letter, untitled letter, other notice of violation letter, recall, seizure, Section 305 notice or other similar written communication, injunction or consent
decree, issued by the FDA or a federal or state court. 
 “Related Persons” means, with respect to any
Person, each Affiliate of such Person and each director, officer, employee, agent, trustee, representative, attorney, accountant and each insurance, environmental, legal, financial and other advisor and other consultants and agents of or to such
Person or any of its Affiliates. 
 “Required Lenders” means (i) for so long as all of the Persons
that are Lenders on the Effective Date (each an “Original Lender”) have not assigned or transferred any of their interests in the Term Loan, Lenders holding one hundred percent (100%) of the aggregate outstanding principal balance
of the Term Loan, or (ii) at any time from and after any Original Lender has assigned or transferred any interest in its Term Loan, Lenders holding at least fifty one percent (51%) of the aggregate outstanding principal balance of the Term
Loan. 
 “Requirement of Law” is as to any Person, the organizational or governing documents of such
Person, and any law (statutory or common), treaty, rule or regulation or determination of an arbitrator or a court or other Governmental Authority, in each case applicable to or binding upon such Person or any of its property or to which such Person
or any of its property is subject. 

  
 38 

 “Responsible Officer” is any of the President, Chief
Executive Officer, or Chief Financial Officer of Borrower acting alone. 
 “Revolving Facility Fee” is a
fee due on the Effective Date equal to Seventy-Five Hundredths percent (0.75%) of the Revolving Line; payable solely for the account of Bank. 

“Revolving Line” means a Credit Extension by Bank of up to Five Million Dollars ($5,000,000.00). 

“Revolving Line Commitments” is, for any Lender, the obligation of such Lender to make Advances, up to the
principal amount shown on Schedule 1.1; it being agreed and understood that neither INNOVATUS LIFE SCIENCES LENDING FUND I, LP nor any of its Affiliates has any Revolving Line Commitment. 

“Secured Promissory Note” is defined in Section 2.6. 

“Secured Promissory Note Record” is a record maintained by each Lender with respect to the outstanding
Obligations owed by Borrower to Lender and credits made thereto. 
 “Securities Account” is any
“securities account” as defined in the Code with such additions to such term as may hereafter be made under the Code. 

“Shares” is (x) one hundred percent (100.00%) of the stock, units or other evidence of ownership held by
Borrower or its Subsidiaries of any Subsidiary which is organized under the laws of the United States, and (y) sixty-five percent (65.00%) of the stock, units or other evidence of ownership held by Borrower or its Subsidiaries of any Subsidiary
which is not organized under the laws of the United States. 
 “Solvent” is, with respect to any Person:
the fair salable value of such Person’s consolidated assets (including goodwill minus disposition costs) exceeds the fair value of such Person’s liabilities; such Person is not left with unreasonably small capital after the transactions in
this Agreement; and such Person is able to pay its debts (including trade debts) as they mature in the ordinary course (without taking into account any forbearance and extensions related thereto). 

“Stock Option Value” of any In Money Stock Option is the number of shares of Common Stock of Borrower for
which such In Money Stock Option can be exercised multiplied by the difference between the last closing price per share of Common Stock of Borrower on the Nasdaq Stock Market LLC and the strike per share of Borrower’s Common Stock for such In
Money Stock Option. 
 “Subordinated Debt” is indebtedness incurred by Borrower or any of its Subsidiaries
subordinated to all Indebtedness of Borrower and/or its Subsidiaries to the Lenders (pursuant to a subordination, intercreditor, or other similar agreement in form and substance satisfactory to Collateral Agent and the Lenders entered into between
Collateral Agent, Borrower, and/or any of its Subsidiaries, and the other creditor), on terms acceptable to Collateral Agent and the Lenders. 

“Subsidiary” is, with respect to any Person, any Person of which more than fifty percent (50%) of the voting
stock or other equity interests (in the case of Persons other than corporations) is owned or controlled, directly or indirectly, by such Person or through one or more intermediaries. Unless otherwise specified, references herein to a Subsidiary
means a Subsidiary of Borrower. 
 “Term A-1 Draw Period” is the
period commencing on the Effective Date and ending on the earlier of (i) March 31, 2019 and (ii) the occurrence of the Event of Default. 

“Term A-1 Loan” is defined in Section 2.2(a)(i) hereof. 

“Term A-2 Draw Period” is the period commencing on the later of
(i) Effective Date and (ii) the first date on which Debt to Equity Ratio for each of the last five consecutive trading days on the Nasdaq Stock Market LLC (based on the closing price of Borrower’s Common Stock on the Nasdaq Stock
Market LLC on each such day) was 

  
 39 

 
less than 38.75%, and ending on the earlier of (i) December 31, 2019 and (ii) the occurrence of the Event of Default. 

“Term A-2 Loan” is defined in Section 2.2(a)(ii) hereof. 

“Term B Draw Period” is the period commencing on the achievement of the Term B Milestone and ending on the
earlier of (i) January 31, 2020 and (ii) the occurrence of an Event of Default; provided, however, that the Term B Draw Period shall not commence if Borrower does not achieve the Term B Milestone and/or on January 31, 2020, an
Event of Default has occurred and is continuing. 
 “Term B Loan” is defined in Section 2.2(a)(iii)
hereof. 
 “Term B Milestone” means, as of the Funding Date of the Term B Loan, (a) TTM Revenue of
Borrower of greater than Thirteen Million Dollars ($13,000,000), (b) TTM Gross Margin of Borrower of at least forty percent (40%) and (c) Debt To Equity Ratio of less than 38.75%; in each case, subject to delivery of evidence of the same, in
form and content satisfactory, to Collateral Agent and the Lenders. 
 “Term Loan” is defined in
Section 2.2(a)(iii) hereof. 
 “Term Loan Basic Rate” is with respect to Term Loan, the floating per
annum rate of interest (based on a year of three hundred sixty five (365) days) equal to the sum of (a) the greater of (i) Five and one-half percent (5.50%) and (ii) Prime Rate, subject to
Section 2.5(g), and (b) Four and seventy-five hundredths percent (4.75%). 
 “Term Loan
Commitment” is, for any Lender, the obligation of such Lender to make the Term Loan, up to the principal amount shown on Schedule 1.1. “Term Loan Commitments” means the aggregate amount of such commitments of all
Lenders. 
 “Term Loan Facility Fee” is a fee due on the Effective Date equal to one and twenty-five
hundredths percent (1.25%) of the total funded Term A-1 Loan; an additional one and twenty-five hundredths percent (1.25%) of the total funded Term A-2 Loan, if and when
funded; and an additional one and twenty-five hundredths percent (1.25%) of the total funded Term B Loan, if and when funded; in each case, payable to Collateral Agent for the ratable benefit of the Lenders according to their Term Loan Commitments.

 “Trademarks” means any trademark and servicemark rights, whether registered or not, applications to
register and registrations of the same and like protections, and the entire goodwill of the business of Borrower and each of its Subsidiaries connected with and symbolized by such trademarks. 

“TTM Gross Margin” means trailing twelve (12) months’ gross margin, determined in accordance with
GAAP, as of any date of determination, excluding any one-time charge to cost of goods sold. 

“TTM Revenue” means trailing twelve (12) months’ revenue, determined in accordance with GAAP, as of
any date of determination. 
 “Warrant” means any of that certain Warrant to Purchase Stock dated the
Effective Date issued by Borrower in favor of each Lender or such Lender’s Affiliates or any other warrant entered into in connection with the Term Loan, all as may be amended, restated, or otherwise modified or supplemented from time to time.

 [Balance of Page Intentionally Left Blank] 

  
 40 

 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to
be executed as of the Effective Date. 
 BORROWER: 

BIONANO GENOMICS, INC. 
  

					
	 By
	 	 /s/ Robert Erik Holmlin

	 Name:
	 	 Robert Erik Holmlin

	 Title:
	 	 Chief Executive Officer

	
	COLLATERAL AGENT AND LENDER:
	
	INNOVATUS LIFE SCIENCES LENDING FUND I, LP
	
	 By: Innovatus Life Sciences GP, LP

	 Its: General Partner

			
		 	 By
	 	 /s/ Andrew Dym

		 	 Name:
	 	 Andrew Dym

		 	 Title:
	 	 Authorized Signatory

	
	EAST WEST BANK:
	
	 EAST WEST BANK

		
	 By
	 	 /s/ James Tai

	 Name:
	 	 James Tai

	 Title:
	 	 Managing Director/Head of Life Sciences

 SCHEDULE 1.1 

Lenders and Commitments 

Term A-1 Loans 

 

									
	 Lender
	  	Term A-1 Loan Commitment	 	 	Commitment Percentage	 
	 INNOVATUS LIFE SCIENCES LENDING FUND I, LP
	  	$	17,500,000.00	 	 	 	100.00	% 
		  	  
	  
	 	 			
	 TOTAL
	  	$	17,500,000.00	 	 	 	100.00	% 
		  	  
	  
	 	 			
	
	Term A-2 Loans	 
	
	 Lender
	  	Term A-2 Loan Commitment	 	 	Commitment Percentage	 
	 INNOVATUS LIFE SCIENCES LENDING FUND I, LP
	  	$	2,500,000.00	 	 	 	100.00	% 
		  	  
	  
	 	 			
	 TOTAL
	  	$	2,500,000.00	 	 	 	100.00	% 
		  	  
	  
	 	 			
	
	Term B Loans	 
	
	 Lender
	  	Term B Loan Commitment	 	 	Commitment Percentage	 
	 INNOVATUS LIFE SCIENCES LENDING FUND I, LP
	  	$	5,000,000.0	 	 	 	100.00	% 
		  	  
	  
	 	 			
	 TOTAL
	  	$	5,000,000.00	 	 	 	100.00	% 
		  	  
	  
	 	 			
	
	Aggregate (All Term Loans)	 
	
	 Lender
	  	Term Loan Commitment	 	 	Commitment Percentage	 
	 INNOVATUS LIFE SCIENCES LENDING FUND I, LP
	  	$	25,000,000.00	 	 	 	100.00	% 
		  	  
	  
	 	 			
	 TOTAL
	  	$	25,000,000.00	 	 	 	100.00	% 
		  	  
	  
	 	 			
	
	Revolving Line	 
	
	 Lender
	  	Revolving Line Commitment	 	 	Commitment Percentage	 
	 EAST WEST BANK
	  	$	5,000,000.00	 	 	 	100.00	% 
		  	  
	  
	 	 			
	 TOTAL
	  	$	5,000,000.00	 	 	 	100.00	% 
		  	  
	  
	 	 			

 EXHIBIT A 

Description of Collateral 

The Collateral consists of all of Borrower’s right, title and interest in and to the following property: 

All goods, Accounts (including health-care receivables), Equipment, Inventory, contract rights or
rights to payment of money, leases, license agreements, franchise agreements, General Intangibles (including Intellectual Property), commercial tort claims, documents, instruments (including any promissory notes), chattel paper (whether tangible or
electronic), cash, deposit accounts and other Collateral Accounts, all certificates of deposit, fixtures, letters of credit rights (whether or not the letter of credit is evidenced by a writing), securities, and all other investment property,
supporting obligations, and financial assets, whether now owned or hereafter acquired, wherever located; and 
 All Borrower’s Books
relating to the foregoing, and any and all claims, rights and interests in any of the above and all substitutions for, additions, attachments, accessories, accessions and improvements to and replacements, products, proceeds and insurance proceeds of
any or all of the foregoing. 

 EXHIBIT B-1 

Loan Payment Request Form 
  

			
	 Fax To:             
	  	Date:                     

  

LOAN PAYMENT: 

BIONANO GENOMICS, INC. 

From Account
#                                         
                                         
     To Account 

#                       
                                         
                                         
            
 (Deposit Account
#)                                         
                                         
           (Loan Account #) 
 Principal
$                                         
                                         
             and/or Interest 

$                       
                                         
                                         
            
 Authorized
Signature:                                       
                                      Phone Number:
                                         
                    
 Print Name/Title:
                                         
              
      

 

LOAN ADVANCE: 

Complete Outgoing Wire Request section below if all or a portion of the funds from this loan advance are for an outgoing wire. 

From Account
#                                         
                                       
    To Account 

#                       
                                         
                                         
        
 (Loan Account
#)                                         
                                         
       (Deposit Account #) 
 Amount of Advance
$                                         
                    

All Borrower’s representations and warranties in the Loan and Security Agreement are true, correct and complete in all
material respects on the date of the request for an advance; provided, however, that such materiality qualifier shall not be applicable to any representations and warranties that already are qualified or modified by materiality in the text thereof;
and provided, further that those representations and warranties expressly referring to a specific date shall be true, accurate and complete in all material respects as of such date: 

Authorized Signature:
                                         
                                    Phone Number:
                                         
                    

Print Name/Title:
                                         
           

 

OUTGOING WIRE REQUEST: 

Complete only if all or a portion of funds from the loan advance above is to be wired. 

Beneficiary Name:
                                         
                        

                          
                                         
             Amount of Wire: $                       
                                         
                                         
              
 Beneficiary Bank:
                                         
                         

                          
                                         
             Account Number:                         
                                         
                                         
              
 City and State:
                                         
                          

Beneficiary Bank Transit (ABA) #:
                                        
              Beneficiary Bank Code (Swift, Sort, Chip, etc.):
                                      

(For International Wire Only) 

Intermediary Bank:                   
                                         
                       Transit (ABA) #:             
                                         
                                

For Further Credit to:                 
                                         
                                         
                                         
                                         
             

Special Instruction:                   
                                         
                                         
                                         
                                         
               
 By signing below, I (we) acknowledge and agree
that my (our) funds transfer request shall be processed in accordance with and subject to the terms and conditions set forth in the agreements(s) covering funds transfer service(s), which agreements(s) were previously received and executed by me
(us). 
 Authorized Signature:
                                         
                                2nd
Signature (if required): 
  

                       
                                         
                         

Print Name/Title:
                                         
                                        Print
Name/Title:  
  

                       
                                         
                                         

Telephone #:
                                        
                         Telephone #:
                                        

      

 EXHIBIT B-2 

Form of Disbursement Letter 

[see attached] 

 DISBURSEMENT LETTER 

[DATE] 
 The
undersigned, being the duly elected and acting                      of BIONANO GENOMICS, INC., a Delaware corporation (“Borrower”),
does hereby certify to INNOVATUS LIFE SCIENCES LENDING FUND I, LP (“Innovatus” and “Lender”), as collateral agent (the “Collateral Agent”) in connection with that certain Loan and Security
Agreement dated as of [DATE], by and among Borrower, Collateral Agent and the Lenders from time to time party thereto (the “Loan Agreement”; with other capitalized terms used below having the meanings ascribed thereto in the Loan
Agreement) that: 
 1.    The representations and warranties made by Borrower in Section 5 of the Loan Agreement
and in the other Loan Documents are true and correct in all material respects as of the date hereof. 
 2.    No event
or condition has occurred that would constitute an Event of Default under the Loan Agreement or any other Loan Document. 

3.    Borrower is in compliance with the covenants and requirements contained in Sections 4, 6 and 7 of the Loan
Agreement. 
 4.    All conditions referred to in Section 3 of the Loan Agreement to the making of the Credit
Extension to be made on or about the date hereof have been satisfied or waived by Collateral Agent. 
 5.    No Material
Adverse Change has occurred. 
 6.    The undersigned is a Responsible Officer. 

[Balance of Page Intentionally Left Blank] 

 7.    The proceeds of the Term [A-1][A-2][B] Loan shall be disbursed as follows: 
  

					
	 Disbursement from Innovatus:
	  			
	 Loan Amount
	  	$	             	 
	 Plus:
	  			
	 —Deposit Received
	  	$	             	 
	 Less:
	  			
	 —Facility Fee
	  	($	             	) 
	 —Existing Debt Payoff to be remitted to MidCap Financial Trust per the Payoff Letter dated
March [    ], 2019
	  	($	             	) 
	 [—Interim Interest
	  	($	             	)] 
	 —Lender’s Legal Fees (Greenberg Traurig, LLP)
	  	($	             	)* 
	 —Lender’s IP Due Diligence Fees (Leason Ellis LLP)
	  	($	             	) 
	 —Lender’s Technology Due Diligence Fees (Equitas Life Sciences, LLC)
	  	($	             	) 
	 —Lender’s Management Background Check Fees (Exiger)
	  	($	             	) 
	 —Lender’s Expert Calls (Coleman Research Group)
	  	($	             	) 
	 —Lender’s Expert Calls (AlphaSights)
	  	($	             	) 
	 —Lender’s T&E
	  	($	             	) 
	 Net Proceeds due from Innovatus:
	  	$	             	 
	 TOTAL
TERM [A-1][A-2][B] LOAN NET PROCEEDS FROM INNOVATUS
	  	$	             	 

 8.    The [initial][Term Loan][Term A-1
Loan][Term A-2 Loan][Term B Loan] shall amortize in accordance with the Loan Interest Rate And Payment Of Principal schedule attached as Annex Y (as amended or restated from time to time) to the Loan
Agreement. 
 9.    The aggregate net proceeds of the Term Loans shall be transferred to the Designated Deposit Account
as follows: 
  

							
		 	 Account Name:
	  	 [BIONANO GENOMICS, INC.]
	  	
				
		 	 Bank Name:
	  	  
	  	
				
		 	 Bank Address:
	  	  
	  	
				
		 		  	  
	  	
				
		 	 Account Number:
	  	  
	  	
				
		 	 ABA Number:
	  	  
	  	

 [Balance of Page Intentionally Left Blank] 

 
  

	*	 Legal fees and costs are through the Effective Date. Post-closing legal fees and costs, payable after the
Effective Date, to be invoiced and paid post-closing. 

 Dated as of the date first set forth above. 

 

			
	BORROWER:
	
	 BIONANO GENOMICS, INC.

		
	 By
	 	  

	 Name:
	 	  

	 Title:
	 	  

	
	COLLATERAL AGENT AND LENDER:
	
	 INNOVATUS LIFE SCIENCES LENDING FUND I, LP

		
	 By:
	 	 Innovatus Life Sciences GP, LP

	 Its:
	 	 General Partner

		
	 By
	 	  

	 Name:
	 	  

	 Title:
	 	  

 EXHIBIT C 

Compliance Certificate 
  

			
	 TO:
	  	 INNOVATUS LIFE SCIENCES LENDING FUND I, LP, as Collateral Agent and Lender

EAST WEST BANK, as Lender

		
	 FROM:
	  	 BIONANO GENOMICS, INC., as Borrower

 The undersigned authorized officer (“Officer”) of BIONANO GENOMICS, INC.
(“Borrower”), hereby certifies that in accordance with the terms and conditions of the Loan and Security Agreement dated as of [DATE], by and among Borrower, Collateral Agent, and the Lenders from time to time party thereto (the
“Loan Agreement;” capitalized terms used but not otherwise defined herein shall have the meanings given them in the Loan Agreement), 

(a)    Borrower is in complete compliance for the period ending
                     with all required covenants except as noted below; 

(b)    There are no Defaults or Events of Default, except as noted below; 

(c)    Except as noted below, all representations and warranties of Borrower stated in the Loan Documents are true and
correct in all material respects on this date and for the period described in (a), above; provided, however, that such materiality qualifier shall not be applicable to any representations and warranties that already are qualified or modified by
materiality in the text thereof; and provided, further that those representations and warranties expressly referring to a specific date shall be true, accurate and complete in all material respects as of such date. 

(d)    Borrower, and each of Borrower’s Subsidiaries, has timely filed all required tax returns and reports,
Borrower, and each of Borrower’s Subsidiaries, has timely paid all foreign, federal, state, and local taxes, assessments, deposits and contributions owed by Borrower, or Subsidiary, except as otherwise permitted pursuant to the terms of
Section 5.8 of the Loan Agreement; 
 (e)    No Liens have been levied or claims made against Borrower or any of
its Subsidiaries relating to unpaid employee payroll or benefits of which Borrower has not previously provided written notification to Collateral Agent and the Lenders. 

Attached are the required documents, if any, supporting our certification(s). The Officer, on behalf of Borrower, further certifies that the
attached financial statements are prepared in accordance with Generally Accepted Accounting Principles (GAAP) and are consistently applied from one period to the next except as explained in an accompanying letter or footnotes and except, in the case
of unaudited financial statements, for the absence of footnotes and subject to year-end audit adjustments as to the interim financial statements. 

Please indicate compliance status since the last Compliance Certificate by circling Yes, No, or N/A under “Complies” column. 

 

													
	 	  	Reporting Covenant	  	Requirement	    	Actual	 	 	 	Complies	 	 
	1)	  	Financial statements	  	Monthly within 30 days and quarterly within 45 days	    		 	Yes	 	No	 	N/A
							
	2)	  	Annual (CPA Audited) statements	  	Within 120 days after FYE	    		 	Yes	 	No	 	N/A
							
	3)	  	Annual Financial Projections/Budget (prepared on a monthly basis)	  	Annually (within earlier 10 days of approval or 45 days of FYE), and when revised (no later than 7 days of approval)	    		 	Yes	 	No	 	N/A
							
	4)	  	8-K, 10-K and 10-Q Filings	  	If applicable, within 5 days of filing	    		 	Yes	 	No	 	N/A

													
							
	5)	  	Month-end account statements	  	Monthly within 30 days	    		 	Yes	 	No	 	N/A
							
	6)	  	Compliance Certificate	  	Monthly within 30 days	    		 	Yes	 	No	 	N/A
							
	7)	  	IP Report	  	When required	    		 	Yes	 	No	 	N/A
							
	8)	  	Total amount of Borrower’s cash and cash equivalents at the last day of the measurement period	  		    	$            	 	Yes	 	No	 	N/A
							
	9)	  	Total amount of Borrower’s Subsidiaries’ cash and cash equivalents at the last day of the measurement period	  		    	$            	 	Yes	 	No	 	N/A
							
	10)	  	Loan confirmation submitted to the fund administrator for Innovatus Life Sciences Lending Fund I, LP (see Exhibit C-2 to the Loan Agreement)	  		    		 	Yes	 	No	 	N/A
							
	11)	  	Perfection Certificate	  	Quarterly within 45 days	    		 	Yes	 	No	 	N/A
							
	12)	  	Borrowing Base Certificate	  	Monthly within 30 days	    		 	Yes	 	No	 	N/A
							
	13)	  	A/R & A/P agings	  	If applicable	    		 	Yes	 	No	 	N/A
					
	 	  	Financial Covenant	  	Requirement	    	Actual	 	Complies
	1)	  	Minimum TTM Revenue	  	FQs ending in 2019, 85% of Management Plan, FQs thereafter, 75% of Management Plan	    	        %	 	Yes	 	No	 	N/A
							
	2)	  	Minimum Liquidity	  	Greater of $3,000,0000 or trailing 3 months cash burn less capacity under the Revolving Line; provided, however, must not be less than Two Million Dollars ($2,000,000.00)	    	$            	 	Yes	 	No	 	N/A

 Negative Covenant Compliance 
  

									
	 	  	Negative Covenant	  	Complies
	1)	  	Dispositions (§ 7.1)	  	Yes	  	No	  	N/A
					
	2)	  	Changes in Business, Management, Ownership, or Business Locations (§ 7.2)	  	Yes	  	No	  	N/A
					
	3)	  	Mergers or Acquisitions (§ 7.3)	  	Yes	  	No	  	N/A
					
	4)	  	Indebtedness (§ 7.4)	  	Yes	  	No	  	N/A
					
	5)	  	Encumbrance (§ 7.5)	  	Yes	  	No	  	N/A
					
	6)	  	Maintenance of Collateral Accounts (§ 7.6)	  	Yes	  	No	  	N/A
					
	7)	  	Restricted Payments (§ 7.7)	  	Yes	  	No	  	N/A

									
	 8)
	  	Investments (§ 7.8)	  	Yes	  	No	  	N/A
					
	 9)
	  	Transactions with Affiliates (§ 7.9)	  	Yes	  	No	  	N/A
					
	 10)
	  	Subordinated Debt (§ 7.10)	  	Yes	  	No	  	N/A
					
	 11)
	  	Compliance (§ 7.11)	  	Yes	  	No	  	N/A
					
	 12)
	  	Compliance with Anti-Terrorism Laws (§ 7.12)	  	Yes	  	No	  	N/A
					
	 13)
	  	Material Agreements (§ 7.13)	  	Yes	  	No	  	N/A

 Deposit and Securities Accounts 

(Please list all accounts; attach separate sheet if additional space needed) 

 

													
	 	  	Institution Name	  	Account Number	  	New Account?	 	 Account Control Agreement in

place?

	1)	  		  		  	Yes	  	No	 	        Yes        	    	No
	2)	  		  		  	Yes	  	No	 	Yes	    	No
	3)	  		  		  	Yes	  	No	 	Yes	    	No
	4)	  		  		  	Yes	  	No	 	Yes	    	No

 Other Matters 
  

							
	1)	    	Have there been any changes in any Key Person since the last Compliance Certificate?	  	Yes	  	No
				
	2)	    	Have there been any transfers/sales/disposals/retirement of Collateral or IP prohibited by the Loan Agreement?	  	Yes	  	No
				
	3)	    	Have there been any new or pending claims or causes of action against Borrower that involve more than Two Hundred Fifty Thousand Dollars ($250,000.00)?	  	Yes	  	No
				
	4)	    	Have there been any amendments of or other changes to the capitalization table of Borrower and to the Operating Documents of Borrower or any of its Subsidiaries? If yes, provide copies of any such amendments or changes with this
Compliance Certificate.	  	Yes	  	No
				
	5)	    	Has Borrower or any Subsidiary entered into or amended any Material Agreement? If yes, please explain and provide a copy of the Material Agreement(s) and/or amendment(s).	  	Yes	  	No
				
	6)	    	Has Borrower provided the Collateral Agent with all notices required to be delivered under Sections 6.2(a) and 6.2(b) of the Loan Agreement?	  	Yes	  	No
				
	7)	    	Have there been any material updates to the contents of the Perfection Certificate last delivered? If yes, please explain.	  	Yes	  	No

 Exceptions 

Please explain any exceptions with respect to the certification above: (If no exceptions exist, state “No exceptions.” Attach
separate sheet if additional space needed.) 
  

			
	 BIONANO GENOMICS, INC.

		
	By:	 	
                  
                       

	Name:	 	
                  
                       

	Title:	 	
                  
                       

		
	Date:	 	
                  
                       

  

					
	 	  	COLLATERAL AGENT USE ONLY
			
		  	Received by:                                   
                                    	 	Date:                     
			
		  	Verified by:                                   
                                      	 	Date:                     
		
		  	Compliance Status:        Yes        No

 Exhibit C-2 

Loan Confirmation 
 In
accordance with the loan documents, Innovatus Life Sciences Lending Fund I, LP and Innovatus Life Sciences Offshore Fund I, LP (collectively, the “Funds”), managed by Innovatus Capital Partners, LLC, please complete the information below
on a quarterly basis and sign and date this confirmation. Please then send directly to the Funds administrator, SS&C Technologies Inc., the following information related to the Funds’ total investment in Bionano Genomics, Inc.: 

 

	 	1)	 Please provide the following information as it relates to the Funds (Include: Date, Loan Description,
Principal Outstanding): Please see table below 

  

									
	Date – For the Quarter Ended	  	Loan Description	 	  	Principal Outstanding	 
		  				  			
		  				  			
	 Total
	  
	  			

 Please sign, date, and email a copy of your response to SS&C Technologies at
innovatuscp.pe@sscinc.com and copy kbergen@innovatuscp.com no later than 30 days after quarter end. 
 CONFIRMATION: 

 

			
	Signature:	 	  

	Print Name:	 	  

	Title:	 	  

	Date:	 	  

	Phone:	 	  

 EXHIBIT D 

BORROWING BASE CERTIFICATE 

Form to be provided by Bank upon the completion of successful and satisfactory (to Bank) collateral audit of Borrower by Bank 

 EXHIBIT E 

Form of Secured Promissory Note 

[see attached] 

 SECURED PROMISSORY NOTE 

(Term [A-1][A-2][B] Loan) 

 

			
	 $            
	  	Dated: [DATE]

 FOR VALUE RECEIVED, the undersigned, BIONANO GENOMICS, INC., a Delaware corporation
(“Borrower”) HEREBY PROMISES TO PAY to the order of [INNOVATUS LIFE SCIENCES LENDING FUND I, LP][EAST WEST BANK] (“Lender”) the principal amount of
[                    ] MILLION DOLLARS ($            ) or such lesser amount as shall
equal the outstanding principal balance of the Term [A-1][A-2][B] Loan made to Borrower by Lender, plus interest on the aggregate unpaid principal amount of such Term [A-1][A-2][B] Loan, at the rates and in accordance with the terms of the Loan and Security Agreement dated [DATE] by and among Borrower, Lender, INNOVATUS LIFE
SCIENCES LENDING FUND I, LP, as Collateral Agent, and the other Lenders from time to time party thereto (as amended, restated, supplemented or otherwise modified from time to time, the “Loan Agreement”). If not sooner paid, the
entire principal amount and all accrued and unpaid interest hereunder shall be due and payable on the Maturity Date as set forth in the Loan Agreement. Any capitalized term not otherwise defined herein shall have the meaning attributed to such term
in the Loan Agreement. 
 Principal, interest and all other amounts due with respect to the Term [A-1][A-2][B] Loan, are payable in lawful money of the United States of America to Lender as set forth in the Loan Agreement and this Secured Promissory Note (this “Note”). The
principal amount of this Note and the interest rate applicable thereto, and all payments made with respect thereto, shall be recorded by Lender and, prior to any transfer hereof, endorsed on the grid attached hereto which is part of this Note. 

The Loan Agreement, among other things, (a) provides for the making of a secured Term [A-1][A-2][B] Loan by Lender to Borrower, and (b) contains provisions for acceleration of the maturity hereof upon the happening of certain stated events. 

This Note may not be prepaid except as set forth in Section 2.2 (c) and Section 2.2(d) of the Loan Agreement. 

This Note and the obligation of Borrower to repay the unpaid principal amount of the Term [A-1][A-2][B] Loan, interest on the Term [A-1][A-2][B] Loan and all other amounts due Lender under the Loan
Agreement is secured under the Loan Agreement. 
 Presentment for payment, demand, notice of protest and all other demands and notices of
any kind in connection with the execution, delivery, performance and enforcement of this Note are hereby waived. 
 Borrower shall pay all
reasonable fees and expenses, including, without limitation, reasonable attorneys’ fees and costs, incurred by Lender in the enforcement or attempt to enforce any of Borrower’s obligations hereunder not performed when due. 

This Note shall be governed by, and construed and interpreted in accordance with, the internal laws of the State of New York. 

The ownership of an interest in this Note shall be registered on a record of ownership maintained by Lender or its agent. Notwithstanding
anything else in this Note to the contrary, the right to the principal of, and stated interest on, this Note may be transferred only if the transfer is registered on such record of ownership and the transferee is identified as the owner of an
interest in the obligation. Borrower shall be entitled to treat the registered holder of this Note (as recorded on such record of ownership) as the owner in fact thereof for all purposes and shall not be bound to recognize any equitable or other
claim to or interest in this Note on the part of any other person or entity. 
 [Balance of Page Intentionally Left Blank] 

 IN WITNESS WHEREOF, Borrower has caused this Note to be duly executed by one of its officers
thereunto duly authorized on the date hereof. 
  

			
	BORROWER:
	
	 BIONANO GENOMICS, INC.

		
	 By
	 	
                  
               

	 Name:
	 	
                  
               

	 Title:
	 	
                  
               

 SECURED PROMISSORY NOTE 

(Revolving Line) 
  

			
	$5,000,000.00	 	Dated: [DATE]

 FOR VALUE RECEIVED, the undersigned, BIONANO GENOMICS, INC., a Delaware corporation
(“Borrower”) HEREBY PROMISES TO PAY to the order of EAST WEST BANK (“Lender”) the principal amount of FIVE MILLION DOLLARS ($5,000,000.00) or such lesser amount as shall equal the outstanding principal balance of
the Revolving Line made to Borrower by Lender, plus interest on the aggregate unpaid principal amount of such Revolving Line, at the rates and in accordance with the terms of the Loan and Security Agreement dated [DATE] by and among Borrower,
Lender, INNOVATUS LIFE SCIENCES LENDING FUND I, LP, as Collateral Agent, and the other Lenders from time to time party thereto (as amended, restated, supplemented or otherwise modified from time to time, the “Loan Agreement”). If
not sooner paid, the entire principal amount and all accrued and unpaid interest hereunder shall be due and payable on the Maturity Date as set forth in the Loan Agreement. Any capitalized term not otherwise defined herein shall have the meaning
attributed to such term in the Loan Agreement. 
 Principal, interest and all other amounts due with respect to the Revolving Line, are
payable in lawful money of the United States of America to Lender as set forth in the Loan Agreement and this Secured Promissory Note (this “Note”). The principal amount of this Note and the interest rate applicable thereto, and all
payments made with respect thereto, shall be recorded by Lender and, prior to any transfer hereof, endorsed on the grid attached hereto which is part of this Note. 

The Loan Agreement, among other things, (a) provides for the making of secured Advances by Lender to Borrower, and (b) contains
provisions for acceleration of the maturity hereof upon the happening of certain stated events. 
 This Note may not be prepaid except as
set forth in Section 2.2 (c) and Section 2.2(d) of the Loan Agreement. 
 This Note and the obligation of Borrower to
repay the unpaid principal amount of the Revolving Line, interest on the Revolving Line and all other amounts due Lender under the Loan Agreement is secured under the Loan Agreement. 

Presentment for payment, demand, notice of protest and all other demands and notices of any kind in connection with the execution, delivery,
performance and enforcement of this Note are hereby waived. 
 Borrower shall pay all reasonable fees and expenses, including, without
limitation, reasonable attorneys’ fees and costs, incurred by Lender in the enforcement or attempt to enforce any of Borrower’s obligations hereunder not performed when due. 

This Note shall be governed by, and construed and interpreted in accordance with, the internal laws of the State of New York. 

The ownership of an interest in this Note shall be registered on a record of ownership maintained by Lender or its agent. Notwithstanding
anything else in this Note to the contrary, the right to the principal of, and stated interest on, this Note may be transferred only if the transfer is registered on such record of ownership and the transferee is identified as the owner of an
interest in the obligation. Borrower shall be entitled to treat the registered holder of this Note (as recorded on such record of ownership) as the owner in fact thereof for all purposes and shall not be bound to recognize any equitable or other
claim to or interest in this Note on the part of any other person or entity. 
 [Balance of Page Intentionally Left Blank] 

 IN WITNESS WHEREOF, Borrower has caused this Note to be duly executed by one of its officers
thereunto duly authorized on the date hereof. 
  

			
	BORROWER:
	
	 BIONANO GENOMICS, INC.

		
	 By
	 	
                  
                       

	 Name:
	 	
                  
                       

	 Title:
	 	
                  
                       

 CORPORATE BORROWING CERTIFICATE 

 

					
	 BORROWER:
	  	BIONANO GENOMICS, INC., a Delaware corporation	  	DATE: [DATE]
		
	 LENDERS:
	  	INNOVATUS LIFE SCIENCES LENDING FUND I, LP, as Collateral Agent and Lender
		  	EAST WEST BANK, as Lender

 I hereby certify as follows, as of the date set forth above: 

1.    I am the Secretary, Assistant Secretary or other officer of Borrower. My title is as set forth below. 

2.    Borrower’s exact legal name is set forth above. Borrower is a corporation existing under the laws of the State
of Delaware. 
 3.    Attached hereto as Exhibit A and Exhibit B,
respectively, are true, correct and complete copies of (i) Borrower’s Articles/Certificate of Incorporation (including amendments), as filed with the Secretary of State of the state in which Borrower is incorporated as set forth in
paragraph 2 above; and (ii) Borrower’s bylaws. Neither such Articles/Certificate of Incorporation nor such bylaws have been amended, annulled, rescinded, revoked or supplemented, and such Articles/Certificate of Incorporation and such
bylaws remain in full force and effect as of the date hereof. 
 4.    The following resolutions were duly and validly
adopted by Borrower’s Board of Directors at a duly held meeting of such directors (or pursuant to a unanimous written consent or other authorized corporate action). Such resolutions are in full force and effect as of the date hereof and have
not been in any way modified, repealed, rescinded, amended or revoked, and the Lenders may rely on them until each Lender receives written notice of revocation from Borrower. 

[Balance of Page Intentionally Left Blank] 

 RESOLVED, that any one of the
following officers or employees of Borrower, whose names, titles and signatures are below, may act on behalf of Borrower: 
  

							
	 Name
	 	 Title
	 	 Signature
	 	 Authorized to

Add or Remove

    Signatories    

				
	  
	 	  
	 	  
	 	☐
				
	  
	 	  
	 	  
	 	☐
				
	  
	 	  
	 	  
	 	☐
				
	  
	 	  
	 	  
	 	☐

 RESOLVED FURTHER, that any one of the persons
designated above with a checked box beside his or her name may, from time to time, add or remove any individuals to and from the above list of persons authorized to act on behalf of Borrower. 

RESOLVED FURTHER, that such individuals may, on behalf of
Borrower: 
 Borrow Money. Borrow money from the Lenders. 

Execute Loan Documents. Execute any loan documents any Lender requires. 

Grant Security. Grant Collateral Agent a security interest in any of Borrower’s assets. 

Negotiate Items. Negotiate or discount all drafts, trade acceptances, promissory notes, or other indebtedness in which
Borrower has an interest and receive cash or otherwise use the proceeds. 
 [Issue Warrants. Issue warrants for
Borrower’s capital stock.] 
 Further Acts. Designate other individuals to request advances, pay fees and costs
and execute other documents or agreements (including documents or agreement that waive Borrower’s right to a jury trial) they believe to be necessary to effectuate such resolutions. 

RESOLVED FURTHER, that all acts authorized by the above
resolutions and any prior acts relating thereto are ratified. 
 [Balance of Page Intentionally Left Blank] 

 5.    The persons listed above are Borrower’s officers or employees
with their titles and signatures shown next to their names. 
  

			
	 By:
	 	
                  
                       

	 Name:
	 	
                  
                       

	 Title:
	 	
                  
                       

  

	***	 If the Secretary, Assistant Secretary or other certifying officer executing above is designated by the
resolutions set forth in paragraph 4 as one of the authorized signing officers, this Certificate must also be signed by a second authorized officer or director of Borrower. 

I, the
                                     of Borrower, hereby
certify as to paragraphs 1 through 5 above, as 
     [print title] 

of the date set forth above. 
  

			
	 By:
	 	
                  
                       

	 Name:
	 	
                  
                       

	 Title:
	 	
                  
                       

  

[Signature Page to Corporate Borrowing Certificate] 

 EXHIBIT A 

Articles/Certificate of Incorporation (including amendments) 

[see attached] 

 EXHIBIT B 

Bylaws 
 [see
attached] 

 ANNEX I 

Collateral Agent and Lender Terms 

1.    Appointment of Collateral Agent. 

(a)    Each Lender hereby appoints INNOVATUS LIFE SCIENCES LENDING FUND I, LP (together with any successor Collateral Agent
pursuant to Section 7 of this Annex I) as Collateral Agent under the Loan Documents and authorizes Collateral Agent to (i) execute and deliver the Loan Documents and accept delivery thereof on its behalf from Borrower, (ii) take such
action on its behalf and to exercise all rights, powers and remedies and perform the duties as are expressly delegated to Collateral Agent under such Loan Documents and (iii) exercise such powers as are reasonably incidental thereto. 

(b)    Without limiting the generality of clause (a) above, Collateral Agent shall have the sole and exclusive right
and authority (to the exclusion of the Lenders), and is hereby authorized, to (i) act as the disbursing and collecting agent for the Lenders with respect to all payments and collections arising in connection with the Loan Documents (including
in any other bankruptcy, insolvency or similar proceeding), and each Person making any payment in connection with any Loan Document to any Lender is hereby authorized to make such payment to Collateral Agent, (ii) file and prove claims and file
other documents necessary or desirable to allow the claims of Collateral Agent and Lenders with respect to any Obligation in any bankruptcy, insolvency or similar proceeding (but not to vote, consent or otherwise act on behalf of such Lender), (iii)
act as collateral agent for Collateral Agent and each Lender for purposes of the perfection of all Liens created by the Loan Documents and all other purposes stated therein, (iv) manage, supervise and otherwise deal with the Collateral,
(v) take such other action as is necessary or desirable to maintain the perfection and priority of the Liens created or purported to be created by the Loan Documents, (vi) except as may be otherwise specified in any Loan Document, exercise
all remedies given to Collateral Agent and the other Lenders with respect to the Borrower and/or the Collateral, whether under the Loan Documents, applicable Requirements of Law or otherwise and (vii) execute any amendment, consent or waiver
under the Loan Documents on behalf of any Lender that has consented in writing to such amendment, consent or waiver; provided, however, that Collateral Agent hereby appoints, authorizes and directs each Lender to act as collateral sub-agent for Collateral Agent and the Lenders for purposes of the perfection of all Liens with respect to the Collateral, including any Deposit Account maintained by Borrower with, and cash and Cash Equivalents
held by, such Lender, and may further authorize and direct the Lenders to take further actions as collateral sub-agents for purposes of enforcing such Liens or otherwise to transfer the Collateral subject
thereto to Collateral Agent, and each Lender hereby agrees to take such further actions to the extent, and only to the extent, so authorized and directed. Collateral Agent may, upon any term or condition it specifies, delegate or exercise any of its
rights, powers and remedies under, and delegate or perform any of its duties or any other action with respect to, any Loan Document by or through any trustee, co-agent, employee,
attorney-in-fact and any other Person (including any Lender). Any such Person shall benefit from this Annex I to the extent provided by Collateral Agent. 

(c)    Under the Loan Documents, Collateral Agent (i) is acting solely on behalf of the Lenders, with duties that are
entirely administrative in nature, notwithstanding the use of the defined term “Collateral Agent”, the terms “agent”, “Collateral Agent” and “collateral agent” and similar terms in any Loan Document to refer
to Collateral Agent, which terms are used for title purposes only, (ii) is not assuming any obligation under any Loan Document other than as expressly set forth therein or any role as agent, fiduciary or trustee of or for any Lender or any
other Person and (iii) shall have no implied functions, responsibilities, duties, obligations or other liabilities under any Loan Document, and each Lender, by accepting the benefits of the Loan Documents, hereby waives and agrees not to assert
any claim against Collateral Agent based on the roles, duties and legal relationships expressly disclaimed in clauses (i) through (iii) above. Except as expressly set forth in the Loan Documents, Collateral Agent shall not have any duty to
disclose, and shall not be liable for failure to disclose, any information relating to Borrower or any of its Subsidiaries that is communicated to or obtained by any other Lender or any of its Affiliates in any capacity. 

2.    Binding Effect; Use of Discretion; E-Systems. 

(a)    Each Lender, by accepting the benefits of the Loan Documents, agrees that (i) any action taken by Collateral
Agent or Required Lenders (or, if expressly required in any Loan Document, a greater proportion of the Lenders) in accordance with the provisions of the Loan Documents, (ii) any action taken by Collateral Agent in

 
reliance upon the instructions of Required Lenders (or, where so required, such greater proportion) and (iii) the exercise by Collateral Agent or Required Lenders (or, where so required,
such greater proportion) of the powers set forth herein or therein, together with such other powers as are reasonably incidental thereto, shall be authorized and binding upon all of Lenders. 

(b)    If Collateral Agent shall request instructions from Required Lenders or all affected Lenders with respect to any
act or action (including failure to act) in connection with any Loan Document, then Collateral Agent shall be entitled to refrain from such act or taking such action unless and until Collateral Agent shall have received instructions from Required
Lenders or all affected Lenders, as the case may be, and Collateral Agent shall not incur liability to any Person by reason of so refraining. Collateral Agent shall be fully justified in failing or refusing to take any action under any Loan Document
(i) if such action would, in the opinion of Collateral Agent, be contrary to any Requirement of Law or any Loan Document, (ii) if such action would, in the opinion of Collateral Agent, expose Collateral Agent to any potential liability
under any Requirement of Law or (iii) if Collateral Agent shall not first be indemnified to its satisfaction against any and all liability and expense which may be incurred by it by reason of taking or continuing to take any such action.
Without limiting the foregoing, no Lender shall have any right of action whatsoever against Collateral Agent as a result of Collateral Agent acting or refraining from acting under any Loan Document in accordance with the instructions of Required
Lenders or all affected Lenders, as applicable. 
 (c)    Collateral Agent is hereby authorized by Borrower and each
Lender to establish procedures (and to amend such procedures from time to time) to facilitate administration and servicing of the Term Loan and other matters incidental thereto. Without limiting the generality of the foregoing, Collateral Agent is
hereby authorized to establish procedures to make available or deliver, or to accept, notices, documents (including, without limitation, borrowing base certificates) and similar items on, by posting to or submitting and/or completion, on E-Systems. Borrower and each Lender acknowledges and agrees that the use of transmissions via an E-System or electronic mail is not necessarily secure and that there are risks
associated with such use, including risks of interception, disclosure and abuse, and Borrower and each Lender assumes and accepts such risks by hereby authorizing the transmission via E-Systems or electronic
mail. Each “e-signature” on any such posting shall be deemed sufficient to satisfy any requirement for a “signature”, and each such posting shall be deemed sufficient to satisfy any
requirement for a “writing”, in each case including pursuant to any Loan Document, any applicable provision of any Code, the federal Uniform Electronic Transactions Act, the Electronic Signatures in Global and National Commerce Act and any
substantive or procedural Requirement of Law governing such subject matter. All uses of an E-System shall be governed by and subject to, in addition to this Section, the separate terms, conditions and privacy
policy posted or referenced in such E-System (or such terms, conditions and privacy policy as may be updated from time to time, including on such E-System) and related
contractual obligations executed by Collateral Agent, Borrower and/or Lenders in connection with the use of such E-System. ALL E-SYSTEMS AND ELECTRONIC TRANSMISSIONS
SHALL BE PROVIDED “AS IS” AND “AS AVAILABLE”. NO REPRESENTATION OR WARRANTY OF ANY KIND IS MADE BY AGENT, ANY LENDER OR ANY OF THEIR RELATED PERSONS IN CONNECTION WITH ANY E-SYSTEMS. 

3.    Collateral Agent’s Reliance, Etc. Collateral Agent may, without incurring any liability
hereunder, (a) consult with any of its Related Persons and, whether or not selected by it, any other advisors, accountants and other experts (including advisors to, and accountants and experts engaged by, Borrower) and (b) rely and act
upon any document and information (including those transmitted by electronic transmission) and any telephone message or conversation, in each case believed by it to be genuine and transmitted, signed or otherwise authenticated by the appropriate
parties. None of Collateral Agent and its Related Persons shall be liable for any action taken or omitted to be taken by any of them under or in connection with any Loan Document, and each Lender and Borrower hereby waives and shall not assert (and
Borrower shall cause its Subsidiaries to waive and agree not to assert) any right, claim or cause of action based thereon, except to the extent of liabilities resulting from the gross negligence or willful misconduct of Collateral Agent or, as the
case may be, such Related Person (each as determined in a final, non-appealable judgment of a court of competent jurisdiction) in connection with the duties of Collateral Agent expressly set forth herein. Without limiting the foregoing, Collateral
Agent: (i) shall not be responsible or otherwise incur liability for any action or omission taken in reliance upon the instructions of the Required Lenders or for the actions or omissions of any of its Related Persons, except to the extent that
a court of competent jurisdiction determines in a final non-appealable judgment that Collateral Agent acted with gross negligence or willful misconduct in the selection of such Related Person; (ii) shall
not be responsible to any Lender or other Person for the due execution, legality, 

 
validity, enforceability, effectiveness, genuineness, sufficiency or value of, or the attachment, perfection or priority of any Lien created or purported to be created under or in connection
with, any Loan Document; (iii) makes no warranty or representation, and shall not be responsible, to any Lender or other Person for any statement, document, information, representation or warranty made or furnished by or on behalf of Borrower
or any Related Person of Borrower in connection with any Loan Document or any transaction contemplated therein or any other document or information with respect to Borrower, whether or not transmitted or (except for documents expressly required
under any Loan Document to be transmitted to the Lenders) omitted to be transmitted by Collateral Agent, including as to completeness, accuracy, scope or adequacy thereof, or for the scope, nature or results of any due diligence performed by
Collateral Agent in connection with the Loan Documents; and (iv) shall not have any duty to ascertain or to inquire as to the performance or observance of any provision of any Loan Document, whether any condition set forth in any Loan Document
is satisfied or waived, as to the financial condition of Borrower or as to the existence or continuation or possible occurrence or continuation of any Event of Default, and shall not be deemed to have notice or Knowledge of such occurrence or
continuation unless it has received a notice from Borrower or any Lender describing such Event of Default that is clearly labeled “notice of default” (in which case Collateral Agent shall promptly give notice of such receipt to all
Lenders, provided that Collateral Agent shall not be liable to any Lender for any failure to do so, except to the extent that such failure is attributable to Collateral Agent’s gross negligence or willful misconduct as determined by a
final non-appealable judgment of a court of competent jurisdiction); and, for each of the items set forth in clauses (i) through (iv) above, each Lender and Borrower hereby waives and agrees not to assert
(and Borrower shall cause its Subsidiaries to waive and agree not to assert) any right, claim or cause of action it might have against Collateral Agent based thereon. 

4.    Collateral Agent Individually. Collateral Agent and its Affiliates may make loans and other extensions
of credit to, acquire stock and stock equivalents of, engage in any kind of business with, Borrower or any Affiliate of Borrower as though it were not acting as Collateral Agent and may receive separate fees and other payments therefor. To the
extent Collateral Agent or any of its Affiliates makes the Term Loan or otherwise becomes a Lender hereunder, it shall have and may exercise the same rights and powers hereunder and shall be subject to the same obligations and liabilities as any
other Lender and the terms “Lender”, “Required Lender” and any similar terms shall, except where otherwise expressly provided in any Loan Document, include, without limitation, Collateral Agent or such Affiliate, as the case may
be, in its individual capacity as Lender, or as one of the Required Lenders. 
 5.    Lender Credit Decision;
Collateral Agent Report. Each Lender acknowledges that it shall, independently and without reliance upon Collateral Agent, any Lender or any of their Related Persons or upon any document solely or in part because such document was transmitted by
Collateral Agent or any of its Related Persons, conduct its own independent investigation of the financial condition and affairs of Borrower and make and continue to make its own credit decisions in connection with entering into, and taking or not
taking any action under, any Loan Document or with respect to any transaction contemplated in any Loan Document, in each case based on such documents and information as it shall deem appropriate. Except for documents expressly required by any Loan
Document to be transmitted by Collateral Agent to the Lenders, Collateral Agent shall not have any duty or responsibility to provide any Lender with any credit or other information concerning the business, prospects, operations, Property, financial
and other condition or creditworthiness of Borrower or any Affiliate of Borrower that may come in to the possession of Collateral Agent or any of its Related Persons. Each Lender agrees that is shall not rely on any field examination, audit or other
report provided by Collateral Agent or its Related Persons (a “Collateral Agent Report”). Each Lender further acknowledges that any Collateral Agent Report (a) is provided to the Lenders solely as a courtesy, without
consideration, and based upon the understanding that such Lender will not rely on such Collateral Agent Report, (b) was prepared by Collateral Agent or its Related Persons based upon information provided by Borrower solely for Collateral
Agent’s own internal use, and (c) may not be complete and may not reflect all information and findings obtained by Collateral Agent or its Related Persons regarding the operations and condition of Borrower. Neither Collateral Agent nor any
of its Related Persons makes any representations or warranties of any kind with respect to (i) any existing or proposed financing, (ii) the accuracy or completeness of the information contained in any Collateral Agent Report or in any
related documentation, (iii) the scope or adequacy of Collateral Agent’s and its Related Persons’ due diligence, or the presence or absence of any errors or omissions contained in any Collateral Agent Report or in any related
documentation, and (iv) any work performed by Collateral Agent or Collateral Agent’s Related Persons in connection with or using any Collateral Agent Report or any related documentation. Neither Collateral Agent nor any of its Related
Persons shall have any duties or obligations in connection with or as a result of any Lender receiving a copy of any Collateral Agent Report. Without limiting the generality of the forgoing, neither Collateral Agent nor any of its Related Persons
shall have any responsibility for the 

 
accuracy or completeness of any Collateral Agent Report, or the appropriateness of any Collateral Agent Report for any Lender’s purposes, and shall have no duty or responsibility to correct
or update any Collateral Agent Report or disclose to any Lender any other information not embodied in any Collateral Agent Report, including any supplemental information obtained after the date of any Collateral Agent Report. Each Lender releases,
and agrees that it will not assert, any claim against Collateral Agent or its Related Persons that in any way relates to any Collateral Agent Report or arises out of any Lender having access to any Collateral Agent Report or any discussion of its
contents, and agrees to indemnify and hold harmless Collateral Agent and its Related Persons from all claims, liabilities and expenses relating to a breach by any Lender arising out of such Lender’s access to any Collateral Agent Report or any
discussion of its contents. 
 6.    Indemnification. Each Lender agrees to reimburse Collateral Agent and
each of its Related Persons (to the extent not reimbursed by Borrower as required under the Loan Documents) promptly upon demand for its Pro Rata Share of any
out-of-pocket costs and expenses (including, without limitation, fees, charges and disbursements of financial, legal and other advisors and any taxes or insurance paid
in the name of, or on behalf of, Borrower) incurred by Collateral Agent or any of its Related Persons in connection with the preparation, syndication, execution, delivery, administration, modification, amendment, consent, waiver or enforcement of,
or the taking of any other action (whether through negotiations, through any work-out, bankruptcy, restructuring or other legal or other proceeding (including, without limitation, preparation for and/or
response to any subpoena or request for document production relating thereto) or otherwise) in respect of, or legal advice with respect to, its rights or responsibilities under, any Loan Document. Each Lender further agrees to indemnify Collateral
Agent and each of its Related Persons (to the extent not reimbursed by Borrower as required under the Loan Documents), ratably according to its Pro Rata Share, from and against any and all liabilities, obligations, losses, damages, penalties,
actions, judgments, suits, costs, expenses or disbursements of any kind or nature whatsoever (including, to the extent not indemnified by the applicable Lender, taxes, interests and penalties imposed for not properly withholding or backup
withholding on payments made to or for the account of any Lender) that may be imposed on, incurred by, or asserted against Collateral Agent or any of its Related Persons in any matter relating to or arising out of, in connection with or as a result
of any Loan Document or any other act, event or transaction related, contemplated in or attendant to any such document, or, in each case, any action taken or omitted to be taken by Collateral Agent or any of its Related Persons under or with respect
to the foregoing; provided that no Lender shall be liable to Collateral Agent or any of its Related Persons under this Section 6 of this Annex I to the extent such liability has resulted from the gross negligence or willful misconduct of
Collateral Agent or, as the case may be, such Related Person, as determined by a final non-appealable judgment of a court of competent jurisdiction. To the extent required by any applicable Requirement of Law,
Collateral Agent may withhold from any payment to any Lender under a Loan Document an amount equal to any applicable withholding tax. If the Internal Revenue Service or any other Governmental Authority asserts a claim that Collateral Agent did not
properly withhold tax from amounts paid to or for the account of any Lender for any reason, or if Collateral Agent reasonably determines that it was required to withhold taxes from a prior payment to or for the account of any Lender but failed to do
so, such Lender shall promptly indemnify Collateral Agent fully for all amounts paid, directly or indirectly, by Collateral Agent as tax or otherwise, including penalties and interest, and together with all expenses incurred by Collateral Agent.
Collateral Agent may offset against any payment to any Lender under a Loan Document, any applicable withholding tax that was required to be withheld from any prior payment to such Lender but which was not so withheld, as well as any other amounts
for which Collateral Agent is entitled to indemnification from such Lender under the immediately preceding sentence of this Section 6 of this Annex I. 

7.    Successor Collateral Agent. Collateral Agent may resign at any time by delivering notice of such
resignation to the Lenders and Borrower, effective on the date set forth in such notice or, if no such date is set forth therein, upon the date such notice shall be effective, in accordance with the terms of this Section 7 of this Annex I. If
Collateral Agent delivers any such notice, the Required Lenders shall have the right to appoint a successor Collateral Agent. If, after 30 days after the date of the retiring Collateral Agent’s notice of resignation, no successor Collateral
Agent has been appointed by the Required Lenders that has accepted such appointment, then the retiring Collateral Agent may, on behalf of the Lenders, appoint a successor Collateral Agent from among the Lenders. Effective immediately upon its
resignation, (a) the retiring Collateral Agent shall be discharged from its duties and obligations under the Loan Documents, (b) the Lenders shall assume and perform all of the duties of Collateral Agent until a successor Collateral Agent
shall have accepted a valid appointment hereunder, (c) the retiring Collateral Agent and its Related Persons shall no longer have the benefit of any provision of any Loan Document other than with respect to any actions taken or omitted to be
taken while such retiring Collateral Agent was, or because such Collateral Agent had been, validly acting as Collateral Agent under the Loan Documents, and (d) subject to its rights under Section

 
2(b) of this Annex I, the retiring Collateral Agent shall take such action as may be reasonably necessary to assign to the successor Collateral Agent its rights as Collateral Agent under the Loan
Documents. Effective immediately upon its acceptance of a valid appointment as Collateral Agent, a successor Collateral Agent shall succeed to, and become vested with, all the rights, powers, privileges and duties of the retiring Collateral Agent
under the Loan Documents. 
 8.    Release of Collateral. Each Lender hereby consents to the release and
hereby directs Collateral Agent to release (or in the case of clause (b)(ii) below, release or subordinate) the following: 

(a)    any Guarantor or Subsidiary “co-borrower” if all of the stock of
such Subsidiary owned by Borrower is sold or transferred in a transaction permitted under the Loan Documents (including pursuant to a valid waiver or consent), to the extent that, after giving effect to such transaction, such Subsidiary would not be
required to guaranty any Obligations pursuant to any Loan Document; and 
 (b)    any Lien held by Collateral Agent for
the benefit of itself and the Lenders against (i) any Collateral that is sold or otherwise disposed of by Borrower in a transaction permitted by the Loan Documents (including pursuant to a valid waiver or consent), (ii) any Collateral subject
to a Lien that is expressly permitted under clause (c) of the definition of the term “Permitted Lien” and (iii) all of the Collateral and Borrower, upon (A) termination of all of the Commitments, (B) payment in full in
cash of all of the Obligations that Collateral Agent has theretofore been notified in writing by the holder of such Obligation are then due and payable, and (C) to the extent requested by Collateral Agent, receipt by Collateral Agent and
Lenders of liability releases from Borrower in form and substance acceptable to Collateral Agent (the satisfaction of the conditions in this clause (iii), the “Termination Date”). 

9.    Setoff and Sharing of Payments. In addition to any rights now or hereafter granted under any
applicable requirement of law and not by way of limitation of any such rights, upon the occurrence and during the continuance of any Event of Default and subject to Section 10(d) of this Annex I, each Lender is hereby authorized at any time or
from time to time upon the direction of Collateral Agent, without notice to Borrower or any other Person, any such notice being hereby expressly waived, to setoff and to appropriate and to apply any and all balances held by it at any of its offices
for the account of Borrower (regardless of whether such balances are then due to Borrower) and any other properties or assets at any time held or owing by that Lender or that holder to or for the credit or for the account of Borrower against and on
account of any of the Obligations that are not paid when due. Any Lender exercising a right of setoff or otherwise receiving any payment on account of the Obligations in excess of its Pro Rata Share thereof shall purchase for cash (and the other
Lenders or holders shall sell) such participations in each such other Lender’s or holder’s Pro Rata Share of the Obligations as would be necessary to cause such Lender to share the amount so offset or otherwise received with each other
Lender or holder in accordance with their respective Pro Rata Shares of the Obligations. Borrower agrees, to the fullest extent permitted by law, that (a) any Lender may exercise its right to offset with respect to amounts in excess of its Pro
Rata Share of the Obligations and may purchase participations in accordance with the preceding sentence and (b) any Lender so purchasing a participation in the Term Loan made or other Obligations held by other Lenders or holders may exercise
all rights of offset, bankers’ lien, counterclaim or similar rights with respect to such participation as fully as if such Lender or holder were a direct holder of the Term Loan and the other Obligations in the amount of such participation.
Notwithstanding the foregoing, if all or any portion of the offset amount or payment otherwise received is thereafter recovered from the Lender that has exercised the right of offset, the purchase of participations by that Lender shall be rescinded
and the purchase price restored without interest. 
 10.    Advances; Payments; Non-Funding Lenders; Actions in Concert. 
 (a)    Advances; Payments. If
Collateral Agent receives any payment with respect to the Term Loan for the account of Lenders on or prior to 2:00 p.m. (New York time) on any Business Day, Collateral Agent shall pay to each applicable Lender such Lender’s Pro Rata Share of
such payment on such Business Day. If Collateral Agent receives any payment with respect to the Term Loan for the account of Lenders after 2:00 p.m. (New York time) on any Business Day, Collateral Agent shall pay to each applicable Lender such
Lender’s Pro Rata Share of such payment on the next Business Day. 
 (b)    Return of Payments. 

 (i)    If Collateral Agent pays an amount to a Lender under this
Agreement in the belief or expectation that a related payment has been or will be received by Collateral Agent from Borrower and such related payment is not received by Collateral Agent, then Collateral Agent will be entitled to recover such amount
(including interest accruing on such amount at the rate otherwise applicable to such Obligation) from such Lender on demand without setoff, counterclaim or deduction of any kind. 

(ii)    If Collateral Agent determines at any time that any amount received by Collateral Agent under any Loan Document
must be returned to Borrower or paid to any other Person pursuant to any insolvency law or otherwise, then, notwithstanding any other term or condition of any Loan Document, Collateral Agent will not be required to distribute any portion thereof to
any Lender. In addition, each Lender will repay to Collateral Agent on demand any portion of such amount that Collateral Agent has distributed to such Lender, together with interest at such rate, if any, as Collateral Agent is required to pay to
Borrower or such other Person, without setoff, counterclaim or deduction of any kind and Collateral Agent will be entitled to set off against future distributions to such Lender any such amounts (with interest) that are not repaid on demand. 

(c)    Non-Funding Lenders. 

(i)    Unless Collateral Agent shall have received notice from a Lender prior to the date of any Term Loan
that such Lender will not make available to Collateral Agent such Lender’s Pro Rata Share of such Term Loan, Collateral Agent may assume that such Lender will make such amount available to it on the date of such Term Loan in accordance with
Section 2(b) of this Annex I, and Collateral Agent may (but shall not be obligated to), in reliance upon such assumption, make available a corresponding amount for the account of Borrower on such date. If and to the extent that such Lender
shall not have made such amount available to Collateral Agent, such Lender and Borrower severally agree to repay to Collateral Agent forthwith on demand such corresponding amount together with interest thereon, for each day from the day such amount
is made available to Borrower until the day such amount is repaid to Collateral Agent, at a rate per annum equal to the interest rate applicable to the Obligation that would have been created when Collateral Agent made available such amount to
Borrower had such Lender made a corresponding payment available. If such Lender shall repay such corresponding amount to Collateral Agent, the amount so repaid shall constitute such Lender’s portion of such Term Loan for purposes of this
Agreement. 
 (ii)    To the extent that any Lender has failed to fund any Term Loan or any other payments required to
be made by it under the Loan Documents after any such Term Loan is required to be made or such payment is due (a “Non-Funding Lender”), Collateral Agent shall be entitled to set off the
funding short-fall against that Non-Funding Lender’s Pro Rata Share of all payments received from Borrower. The failure of any Non-Funding Lender to make any
Term Loan or any payment required by it hereunder shall not relieve any other Lender (each such other Lender, an “Other Lender”) of its obligations to make such Term Loan, but neither any Other Lender nor Collateral Agent shall be
responsible for the failure of any Non-Funding Lender to make such Term Loan or make any other payment required hereunder. Notwithstanding anything set forth herein to the contrary, a Non-Funding Lender shall not have any voting or consent rights under or with respect to any Loan Document or constitute a “Lender” (or be included in the calculation of “Required Lender”
hereunder) for any voting or consent rights under or with respect to any Loan Document. At Borrower’s request, Collateral Agent or a Person reasonably acceptable to Collateral Agent shall have the right with Collateral Agent’s consent and
in Collateral Agent’s sole discretion (but Collateral Agent or any such Person shall have no obligation) to purchase from any Non-Funding Lender, and each Lender agrees that if it becomes a Non-Funding Lender it shall, at Collateral Agent’s request, sell and assign to Collateral Agent or such Person, all of the Term Loan Commitment (if any), and all of the outstanding Term Loan of that Non-Funding Lender for an amount equal to the aggregate outstanding principal balance of the Term Loan held by such Non-Funding Lender and all accrued interest with respect
thereto through the date of sale, such purchase and sale to be consummated pursuant to an executed assignment agreement in form and substance reasonably satisfactory to, and acknowledged by, Collateral Agent. 

(d)    Actions in Concert. Anything in this Agreement to the contrary notwithstanding, each Lender hereby agrees
with each other Lender that no Lender shall take any action to protect or enforce its rights arising out of any Loan Document (including exercising any rights of setoff) without first obtaining the prior written consent of Collateral Agent or
Required Lenders, it being the intent of Lenders that any such action to protect or enforce rights under any Loan Document shall be taken in concert and at the direction or with the consent of Collateral Agent or Required Lenders. 

 ANNEX X 

MANAGEMENT PLAN 
 PLEASE
SEE ATTACHED 

 ANNEX Y 

LOAN INTEREST RATE AND PAYMENT OF PRINCIPAL 

(Term Loan) 
 PLEASE SEE
ATTACHED 
 WHICH WILL BE UPDATED ON THE DATE OF THE FUNDING OF THE TERM A-1 LOAN 

																																																					
	 	 	 	 	 	 	 	 	 	 	 	Beginning	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	Tranche	 	 	Ending	 
	 	 	Beginning	 	 	Ending	 	 	Payment	 	 	Loan	 	 	Prime	 	 	Interest	 	 	Interest	 	 	PIK	 	 	Cash	 	 	Principal	 	 	Total	 	 	A2/ B	 	 	Loan	 
	 Month
	 	Date	 	 	Date	 	 	Date	 	 	Balance	 	 	Rate	 	 	Rate	 	 	Earned	 	 	Interest	 	 	Interest	 	 	Amortization	 	 	Payment	 	 	Funding	 	 	Balance	 
	—  	 	 	3/14/19	 	 	 	3/31/19	 	 				 	$	17,500,000.00	 	 	 	5.50	% 	 	 	10.25	% 	 	$	88,458.90	 	 	$	25,890.41	 	 	 	—  	 	 	 	—  	 	 	 	—  	 	 	 	—  	 	 	$	17,525,890.41	 
	1	 	 	4/1/19	 	 	 	4/30/19	 	 	 	5/1/19	 	 	$	17,525,890.41	 	 	 	5.50	% 	 	 	10.25	% 	 	$	147,649.62	 	 	$	43,214.52	 	 	$	104,435.10	 	 	 	—  	 	 	$	104,435.10	 	 	 	—  	 	 	$	17,569,104.94	 
	2	 	 	5/1/19	 	 	 	5/31/19	 	 	 	6/1/19	 	 	$	17,569,104.94	 	 	 	5.50	% 	 	 	10.25	% 	 	$	152,947.48	 	 	$	44,765.12	 	 	$	108,182.37	 	 	 	—  	 	 	$	108,182.37	 	 	 	—  	 	 	$	17,613,870.05	 
	3	 	 	6/1/19	 	 	 	6/30/19	 	 	 	7/1/19	 	 	$	17,613,870.05	 	 	 	5.50	% 	 	 	10.25	% 	 	$	148,390.82	 	 	$	43,431.46	 	 	$	104,959.36	 	 	 	—  	 	 	$	104,959.36	 	 	 	—  	 	 	$	17,657,301.51	 
	4	 	 	7/1/19	 	 	 	7/31/19	 	 	 	8/1/19	 	 	$	17,657,301.51	 	 	 	5.50	% 	 	 	10.25	% 	 	$	153,715.28	 	 	$	44,989.84	 	 	$	108,725.44	 	 	 	—  	 	 	$	108,725.44	 	 	 	—  	 	 	$	17,702,291.35	 
	5	 	 	8/1/19	 	 	 	8/31/19	 	 	 	9/1/19	 	 	$	17,702,291.35	 	 	 	5.50	% 	 	 	10.25	% 	 	$	154,106.93	 	 	$	45,104.47	 	 	$	109,002.47	 	 	 	—  	 	 	$	109,002.47	 	 	 	—  	 	 	$	17,747,395.82	 
	6	 	 	9/1/19	 	 	 	9/30/19	 	 	 	10/1/19	 	 	$	17,747,395.82	 	 	 	5.50	% 	 	 	10.25	% 	 	$	149,515.73	 	 	$	43,760.70	 	 	$	105,755.03	 	 	 	—  	 	 	$	105,755.03	 	 	 	—  	 	 	$	17,791,156.52	 
	7	 	 	10/1/19	 	 	 	10/31/19	 	 	 	11/1/19	 	 	$	17,791,156.52	 	 	 	5.50	% 	 	 	10.25	% 	 	$	154,880.55	 	 	$	45,330.89	 	 	$	109,549.66	 	 	 	—  	 	 	$	109,549.66	 	 	 	—  	 	 	$	17,836,487.41	 
	8	 	 	11/1/19	 	 	 	11/30/19	 	 	 	12/1/19	 	 	$	17,836,487.41	 	 	 	5.50	% 	 	 	10.25	% 	 	$	150,266.30	 	 	$	43,980.38	 	 	$	106,285.92	 	 	 	—  	 	 	$	106,285.92	 	 	 	—  	 	 	$	17,880,467.79	 
	9	 	 	12/1/19	 	 	 	12/31/19	 	 	 	1/1/20	 	 	$	17,880,467.79	 	 	 	5.50	% 	 	 	10.25	% 	 	$	155,658.04	 	 	$	45,558.45	 	 	$	110,099.59	 	 	 	—  	 	 	$	110,099.59	 	 	 	—  	 	 	$	17,926,026.24	 
	10	 	 	1/1/20	 	 	 	1/31/20	 	 	 	2/1/20	 	 	$	17,926,026.24	 	 	 	5.50	% 	 	 	10.25	% 	 	$	156,054.65	 	 	$	45,674.53	 	 	$	110,380.12	 	 	 	—  	 	 	$	110,380.12	 	 	 	—  	 	 	$	17,971,700.78	 
	11	 	 	2/1/20	 	 	 	2/29/20	 	 	 	3/1/20	 	 	$	17,971,700.78	 	 	 	5.50	% 	 	 	10.25	% 	 	$	146,358.58	 	 	$	42,836.66	 	 	$	103,521.92	 	 	 	—  	 	 	$	103,521.92	 	 	 	—  	 	 	$	18,014,537.43	 
	12	 	 	3/1/20	 	 	 	3/31/20	 	 	 	4/1/20	 	 	$	18,014,537.43	 	 	 	5.50	% 	 	 	10.25	% 	 	$	156,825.19	 	 	$	45,900.05	 	 	$	110,925.13	 	 	 	—  	 	 	$	110,925.13	 	 	 	—  	 	 	$	18,060,437.49	 
	13	 	 	4/1/20	 	 	 	4/30/20	 	 	 	5/1/20	 	 	$	18,060,437.49	 	 	 	5.50	% 	 	 	10.25	% 	 	$	152,153.00	 	 	$	44,532.59	 	 	$	107,620.42	 	 	 	—  	 	 	$	107,620.42	 	 	 	—  	 	 	$	18,104,970.07	 
	14	 	 	5/1/20	 	 	 	5/31/20	 	 	 	6/1/20	 	 	$	18,104,970.07	 	 	 	5.50	% 	 	 	10.25	% 	 	$	157,612.44	 	 	$	46,130.47	 	 	$	111,481.97	 	 	 	—  	 	 	$	111,481.97	 	 	 	—  	 	 	$	18,151,100.54	 
	15	 	 	6/1/20	 	 	 	6/30/20	 	 	 	7/1/20	 	 	$	18,151,100.54	 	 	 	5.50	% 	 	 	10.25	% 	 	$	152,916.81	 	 	$	44,756.14	 	 	$	108,160.67	 	 	 	—  	 	 	$	108,160.67	 	 	 	—  	 	 	$	18,195,856.68	 
	16	 	 	7/1/20	 	 	 	7/31/20	 	 	 	8/1/20	 	 	$	18,195,856.68	 	 	 	5.50	% 	 	 	10.25	% 	 	$	158,403.66	 	 	$	46,362.05	 	 	$	112,041.61	 	 	 	—  	 	 	$	112,041.61	 	 	 	—  	 	 	$	18,242,218.73	 
	17	 	 	8/1/20	 	 	 	8/31/20	 	 	 	9/1/20	 	 	$	18,242,218.73	 	 	 	5.50	% 	 	 	10.25	% 	 	$	158,807.26	 	 	$	46,480.17	 	 	$	112,327.09	 	 	 	—  	 	 	$	112,327.09	 	 	 	—  	 	 	$	18,288,698.90	 
	18	 	 	9/1/20	 	 	 	9/30/20	 	 	 	10/1/20	 	 	$	18,288,698.90	 	 	 	5.50	% 	 	 	10.25	% 	 	$	154,076.02	 	 	$	45,095.42	 	 	$	108,980.60	 	 	 	—  	 	 	$	108,980.60	 	 	 	—  	 	 	$	18,333,794.32	 
	19	 	 	10/1/20	 	 	 	10/31/20	 	 	 	11/1/20	 	 	$	18,333,794.32	 	 	 	5.50	% 	 	 	10.25	% 	 	$	159,604.47	 	 	$	46,713.50	 	 	$	112,890.97	 	 	 	—  	 	 	$	112,890.97	 	 	 	—  	 	 	$	18,380,507.83	 
	20	 	 	11/1/20	 	 	 	11/30/20	 	 	 	12/1/20	 	 	$	18,380,507.83	 	 	 	5.50	% 	 	 	10.25	% 	 	$	154,849.48	 	 	$	45,321.80	 	 	$	109,527.68	 	 	 	—  	 	 	$	109,527.68	 	 	 	—  	 	 	$	18,425,829.63	 
	21	 	 	12/1/20	 	 	 	12/31/20	 	 	 	1/1/21	 	 	$	18,425,829.63	 	 	 	5.50	% 	 	 	10.25	% 	 	$	160,405.68	 	 	$	46,948.00	 	 	$	113,457.68	 	 	 	—  	 	 	$	113,457.68	 	 	 	—  	 	 	$	18,472,777.63	 
	22	 	 	1/1/21	 	 	 	1/31/21	 	 	 	2/1/21	 	 	$	18,472,777.63	 	 	 	5.50	% 	 	 	10.25	% 	 	$	160,814.39	 	 	$	47,067.63	 	 	$	113,746.76	 	 	 	—  	 	 	$	113,746.76	 	 	 	—  	 	 	$	18,519,845.26	 
	23	 	 	2/1/21	 	 	 	2/28/21	 	 	 	3/1/21	 	 	$	18,519,845.26	 	 	 	5.50	% 	 	 	10.25	% 	 	$	145,621.80	 	 	$	42,621.01	 	 	$	103,000.78	 	 	 	—  	 	 	$	103,000.78	 	 	 	—  	 	 	$	18,562,466.27	 
	24	 	 	3/1/21	 	 	 	3/31/21	 	 	 	4/1/21	 	 	$	18,562,466.27	 	 	 	5.50	% 	 	 	10.25	% 	 	$	161,595.17	 	 	$	47,296.15	 	 	$	114,299.02	 	 	 	—  	 	 	$	114,299.02	 	 	 	—  	 	 	$	18,609,762.42	 
	25	 	 	4/1/21	 	 	 	4/30/21	 	 	 	5/1/21	 	 	$	18,609,762.42	 	 	 	5.50	% 	 	 	10.25	% 	 	$	156,780.88	 	 	 	—  	 	 	$	156,780.88	 	 	 	—  	 	 	$	156,780.88	 	 	 	—  	 	 	$	18,609,762.42	 
	26	 	 	5/1/21	 	 	 	5/31/21	 	 	 	6/1/21	 	 	$	18,609,762.42	 	 	 	5.50	% 	 	 	10.25	% 	 	$	162,006.90	 	 	 	—  	 	 	$	162,006.90	 	 	 	—  	 	 	$	162,006.90	 	 	 	—  	 	 	$	18,609,762.42	 
	27	 	 	6/1/21	 	 	 	6/30/21	 	 	 	7/1/21	 	 	$	18,609,762.42	 	 	 	5.50	% 	 	 	10.25	% 	 	$	156,780.88	 	 	 	—  	 	 	$	156,780.88	 	 	 	—  	 	 	$	156,780.88	 	 	 	—  	 	 	$	18,609,762.42	 
	28	 	 	7/1/21	 	 	 	7/31/21	 	 	 	8/1/21	 	 	$	18,609,762.42	 	 	 	5.50	% 	 	 	10.25	% 	 	$	162,006.90	 	 	 	—  	 	 	$	162,006.90	 	 	 	—  	 	 	$	162,006.90	 	 	 	—  	 	 	$	18,609,762.42	 
	29	 	 	8/1/21	 	 	 	8/31/21	 	 	 	9/1/21	 	 	$	18,609,762.42	 	 	 	5.50	% 	 	 	10.25	% 	 	$	162,006.90	 	 	 	—  	 	 	$	162,006.90	 	 	 	—  	 	 	$	162,006.90	 	 	 	—  	 	 	$	18,609,762.42	 
	30	 	 	9/1/21	 	 	 	9/30/21	 	 	 	10/1/21	 	 	$	18,609,762.42	 	 	 	5.50	% 	 	 	10.25	% 	 	$	156,780.88	 	 	 	—  	 	 	$	156,780.88	 	 	 	—  	 	 	$	156,780.88	 	 	 	—  	 	 	$	18,609,762.42	 
	31	 	 	10/1/21	 	 	 	10/31/21	 	 	 	11/1/21	 	 	$	18,609,762.42	 	 	 	5.50	% 	 	 	10.25	% 	 	$	162,006.90	 	 	 	—  	 	 	$	162,006.90	 	 	 	—  	 	 	$	162,006.90	 	 	 	—  	 	 	$	18,609,762.42	 
	32	 	 	11/1/21	 	 	 	11/30/21	 	 	 	12/1/21	 	 	$	18,609,762.42	 	 	 	5.50	% 	 	 	10.25	% 	 	$	156,780.88	 	 	 	—  	 	 	$	156,780.88	 	 	 	—  	 	 	$	156,780.88	 	 	 	—  	 	 	$	18,609,762.42	 
	33	 	 	12/1/21	 	 	 	12/31/21	 	 	 	1/1/22	 	 	$	18,609,762.42	 	 	 	5.50	% 	 	 	10.25	% 	 	$	162,006.90	 	 	 	—  	 	 	$	162,006.90	 	 	 	—  	 	 	$	162,006.90	 	 	 	—  	 	 	$	18,609,762.42	 
	34	 	 	1/1/22	 	 	 	1/31/22	 	 	 	2/1/22	 	 	$	18,609,762.42	 	 	 	5.50	% 	 	 	10.25	% 	 	$	162,006.90	 	 	 	—  	 	 	$	162,006.90	 	 	 	—  	 	 	$	162,006.90	 	 	 	—  	 	 	$	18,609,762.42	 
	35	 	 	2/1/22	 	 	 	2/28/22	 	 	 	3/1/22	 	 	$	18,609,762.42	 	 	 	5.50	% 	 	 	10.25	% 	 	$	146,328.82	 	 	 	—  	 	 	$	146,328.82	 	 	 	—  	 	 	$	146,328.82	 	 	 	—  	 	 	$	18,609,762.42	 
	36	 	 	3/1/22	 	 	 	3/31/22	 	 	 	4/1/22	 	 	$	18,609,762.42	 	 	 	5.50	% 	 	 	10.25	% 	 	$	162,006.90	 	 	 	—  	 	 	$	162,006.90	 	 	 	—  	 	 	$	162,006.90	 	 	 	—  	 	 	$	18,609,762.42	 
	37	 	 	4/1/22	 	 	 	4/30/22	 	 	 	5/1/22	 	 	$	18,609,762.42	 	 	 	5.50	% 	 	 	10.25	% 	 	$	156,780.88	 	 	 	—  	 	 	$	156,780.88	 	 	$	775,406.77	 	 	$	932,187.64	 	 	 	—  	 	 	$	17,834,355.65	 
	38	 	 	5/1/22	 	 	 	5/31/22	 	 	 	6/1/22	 	 	$	17,834,355.65	 	 	 	5.50	% 	 	 	10.25	% 	 	$	155,256.62	 	 	 	—  	 	 	$	155,256.62	 	 	$	775,406.77	 	 	$	930,663.38	 	 	 	—  	 	 	$	17,058,948.88	 
	39	 	 	6/1/22	 	 	 	6/30/22	 	 	 	7/1/22	 	 	$	17,058,948.88	 	 	 	5.50	% 	 	 	10.25	% 	 	$	143,715.80	 	 	 	—  	 	 	$	143,715.80	 	 	$	775,406.77	 	 	$	919,122.57	 	 	 	—  	 	 	$	16,283,542.12	 
	40	 	 	7/1/22	 	 	 	7/31/22	 	 	 	8/1/22	 	 	$	16,283,542.12	 	 	 	5.50	% 	 	 	10.25	% 	 	$	141,756.04	 	 	 	—  	 	 	$	141,756.04	 	 	$	775,406.77	 	 	$	917,162.81	 	 	 	—  	 	 	$	15,508,135.35	 
	41	 	 	8/1/22	 	 	 	8/31/22	 	 	 	9/1/22	 	 	$	15,508,135.35	 	 	 	5.50	% 	 	 	10.25	% 	 	$	135,005.75	 	 	 	—  	 	 	$	135,005.75	 	 	$	775,406.77	 	 	$	910,412.52	 	 	 	—  	 	 	$	14,732,728.58	 
	42	 	 	9/1/22	 	 	 	9/30/22	 	 	 	10/1/22	 	 	$	14,732,728.58	 	 	 	5.50	% 	 	 	10.25	% 	 	$	124,118.19	 	 	 	—  	 	 	$	124,118.19	 	 	$	775,406.77	 	 	$	899,524.96	 	 	 	—  	 	 	$	13,957,321.81	 
	43	 	 	10/1/22	 	 	 	10/31/22	 	 	 	11/1/22	 	 	$	13,957,321.81	 	 	 	5.50	% 	 	 	10.25	% 	 	$	121,505.18	 	 	 	—  	 	 	$	121,505.18	 	 	$	775,406.77	 	 	$	896,911.95	 	 	 	—  	 	 	$	13,181,915.05	 
	44	 	 	11/1/22	 	 	 	11/30/22	 	 	 	12/1/22	 	 	$	13,181,915.05	 	 	 	5.50	% 	 	 	10.25	% 	 	$	111,053.12	 	 	 	—  	 	 	$	111,053.12	 	 	$	775,406.77	 	 	$	886,459.89	 	 	 	—  	 	 	$	12,406,508.28	 
	45	 	 	12/1/22	 	 	 	12/31/22	 	 	 	1/1/23	 	 	$	12,406,508.28	 	 	 	5.50	% 	 	 	10.25	% 	 	$	108,004.60	 	 	 	—  	 	 	$	108,004.60	 	 	$	775,406.77	 	 	$	883,411.37	 	 	 	—  	 	 	$	11,631,101.51	 
	46	 	 	1/1/23	 	 	 	1/31/23	 	 	 	2/1/23	 	 	$	11,631,101.51	 	 	 	5.50	% 	 	 	10.25	% 	 	$	101,254.32	 	 	 	—  	 	 	$	101,254.32	 	 	$	775,406.77	 	 	$	876,661.08	 	 	 	—  	 	 	$	10,855,694.74	 
	47	 	 	2/1/23	 	 	 	2/28/23	 	 	 	3/1/23	 	 	$	10,855,694.74	 	 	 	5.50	% 	 	 	10.25	% 	 	$	85,358.48	 	 	 	—  	 	 	$	85,358.48	 	 	$	775,406.77	 	 	$	860,765.24	 	 	 	—  	 	 	$	10,080,287.98	 
	48	 	 	3/1/23	 	 	 	3/31/23	 	 	 	4/1/23	 	 	$	10,080,287.98	 	 	 	5.50	% 	 	 	10.25	% 	 	$	87,753.74	 	 	 	—  	 	 	$	87,753.74	 	 	$	775,406.77	 	 	$	863,160.51	 	 	 	—  	 	 	$	9,304,881.21	 
	49	 	 	4/1/23	 	 	 	4/30/23	 	 	 	5/1/23	 	 	$	9,304,881.21	 	 	 	5.50	% 	 	 	10.25	% 	 	$	78,390.44	 	 	 	—  	 	 	$	78,390.44	 	 	$	775,406.77	 	 	$	853,797.20	 	 	 	—  	 	 	$	8,529,474.44	 
	50	 	 	5/1/23	 	 	 	5/31/23	 	 	 	6/1/23	 	 	$	8,529,474.44	 	 	 	5.50	% 	 	 	10.25	% 	 	$	74,253.16	 	 	 	—  	 	 	$	74,253.16	 	 	$	775,406.77	 	 	$	849,659.93	 	 	 	—  	 	 	$	7,754,067.67	 
	51	 	 	6/1/23	 	 	 	6/30/23	 	 	 	7/1/23	 	 	$	7,754,067.67	 	 	 	5.50	% 	 	 	10.25	% 	 	$	65,325.36	 	 	 	—  	 	 	$	65,325.36	 	 	$	775,406.77	 	 	$	840,732.13	 	 	 	—  	 	 	$	6,978,660.91	 
	52	 	 	7/1/23	 	 	 	7/31/23	 	 	 	8/1/23	 	 	$	6,978,660.91	 	 	 	5.50	% 	 	 	10.25	% 	 	$	60,752.59	 	 	 	—  	 	 	$	60,752.59	 	 	$	775,406.77	 	 	$	836,159.36	 	 	 	—  	 	 	$	6,203,254.14	 
	53	 	 	8/1/23	 	 	 	8/31/23	 	 	 	9/1/23	 	 	$	6,203,254.14	 	 	 	5.50	% 	 	 	10.25	% 	 	$	54,002.30	 	 	 	—  	 	 	$	54,002.30	 	 	$	775,406.77	 	 	$	829,409.07	 	 	 	—  	 	 	$	5,427,847.37	 
	54	 	 	9/1/23	 	 	 	9/30/23	 	 	 	10/1/23	 	 	$	5,427,847.37	 	 	 	5.50	% 	 	 	10.25	% 	 	$	45,727.76	 	 	 	—  	 	 	$	45,727.76	 	 	$	775,406.77	 	 	$	821,134.52	 	 	 	—  	 	 	$	4,652,440.60	 
	55	 	 	10/1/23	 	 	 	10/31/23	 	 	 	11/1/23	 	 	$	4,652,440.60	 	 	 	5.50	% 	 	 	10.25	% 	 	$	40,501.73	 	 	 	—  	 	 	$	40,501.73	 	 	$	775,406.77	 	 	$	815,908.49	 	 	 	—  	 	 	$	3,877,033.84	 
	56	 	 	11/1/23	 	 	 	11/30/23	 	 	 	12/1/23	 	 	$	3,877,033.84	 	 	 	5.50	% 	 	 	10.25	% 	 	$	32,662.68	 	 	 	—  	 	 	$	32,662.68	 	 	$	775,406.77	 	 	$	808,069.45	 	 	 	—  	 	 	$	3,101,627.07	 
	57	 	 	12/1/23	 	 	 	12/31/23	 	 	 	1/1/24	 	 	$	3,101,627.07	 	 	 	5.50	% 	 	 	10.25	% 	 	$	27,001.15	 	 	 	—  	 	 	$	27,001.15	 	 	$	775,406.77	 	 	$	802,407.92	 	 	 	—  	 	 	$	2,326,220.30	 
	58	 	 	1/1/24	 	 	 	1/31/24	 	 	 	2/1/24	 	 	$	2,326,220.30	 	 	 	5.50	% 	 	 	10.25	% 	 	$	20,250.86	 	 	 	—  	 	 	$	20,250.86	 	 	$	775,406.77	 	 	$	795,657.63	 	 	 	—  	 	 	$	1,550,813.53	 
	59	 	 	2/1/24	 	 	 	2/29/24	 	 	 	3/1/24	 	 	$	1,550,813.53	 	 	 	5.50	% 	 	 	10.25	% 	 	$	12,629.57	 	 	 	—  	 	 	$	12,629.57	 	 	$	775,406.77	 	 	$	788,036.34	 	 	 	—  	 	 	$	775,406.77	 
	60	 	 	3/1/24	 	 	 	3/14/24	 	 	 	3/14/24	 	 	$	775,406.77	 	 	 	5.50	% 	 	 	10.25	% 	 	$	3,048.52	 	 	 	—  	 	 	$	3,048.52	 	 	$	775,406.77	 	 	$	778,455.28	 	 	 	—  	 	 	($	0.00	)

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00293-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00293-of-00352.parquet"}]]